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A B S T R A C T
Background
Endocrine therapy removes the influence of oestrogen on breast cancer cells and so hormonal treatments such as tamoxifen, megestrol
acetate and medroxyprogesterone acetate have been in use for many years for advanced breast cancer. Aromatase inhibitors (AIs) in-
hibit oestrogen synthesis in the peripheral tissues and have a similar tumour-regressing effect to other endocrine treatments. Aminog-
lutethimide was the first AI in clinical use and now the third generation AIs, anastrozole, exemestane and letrozole, are in current use.
Randomised trial evidence on response rates and side effects of these drugs is still limited.
Objectives
To compare AIs to other endocrine therapy in the treatment of advanced breast cancer in postmenopausal women.
Search methods
For this update, the Cochrane Breast Cancer Group Specialised Register and the Cochrane Central Register of Controlled Trials
(CENTRAL) and relevant conference proceedings were searched (to 30 June 2008).
Selection criteria
Randomised controlled trials in postmenopausal women comparing the effects of any AI versus other endocrine therapy, no endocrine
therapy, or a different AI in the treatment of advanced (metastatic) breast cancer. Non-English language publications, comparisons of
the same AI at different doses, AIs used as neoadjuvant treatment, or outcomes not related to tumour response were excluded.
Data collection and analysis
Data from published trials were extracted independently by two review authors and cross-checked by a third. Hazard ratios (HR) were
derived for analysis of time-to-event outcomes (overall and progression-free survival). Odds ratios (OR) were derived for objective
response, clinical benefit, and toxicity.
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Main results
Thirty-seven trials were identified, 31 of which were included in the main analysis of any AI versus any other treatment (11,403
women). No trials were excluded due to inadequate allocation concealment. The pooled estimate showed a significant survival benefit
for treatment with an AI over other endocrine therapies (HR 0.90, 95% CI 0.84 to 0.97). A subgroup analysis of the three commonly
prescribed AIs (anastrozole, exemestane, letrozole) also showed a similar survival benefit (HR 0.88, 95% CI 0.80 to 0.96). There were
very limited data to compare one AI with a different AI, but these suggested an advantage for letrozole over anastrozole.
AIs have a different toxicity profile to other endocrine therapies. For those currently prescribed, and for all AIs combined, they had
similar levels of hot flushes and arthralgia; increased risks of rash, nausea, diarrhoea and vomiting; but a 71% decreased risk of vaginal
bleeding and 47% decrease in thromboembolic events compared with other endocrine therapies.
Authors’ conclusions
In women with advanced (metastatic) breast cancer, aromatase inhibitors including those in current clinical use show a survival benefit
when compared to other endocrine therapy.
P L A I N L A N G U A G E S U M M A R Y
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Advanced (or metastatic) breast cancer is cancer that has spread beyond the breast and regional lymph node areas. Breast cancer
can progress to metastatic disease despite the person undergoing a range of therapies given after initial treatment, such as surgery,
chemotherapy or radiation therapy. Metastatic breast cancer is treatable but it is not curable. Most breast cancer is sensitive to the
female hormone oestrogen. Sensitive cancer cells need oestrogen to stay alive and removal of oestrogen from the body, or stopping any
circulating oestrogen getting to the cancer cells, is very effective treatment for hormone-sensitive breast cancers. Endocrine (hormonal)
therapy removes the influence of oestrogen on breast cancer cells. Hormonal treatments for advanced breast cancer include tamoxifen,
the progestins megestrol acetate and medroxyprogesterone acetate, and aromatase inhibitors (AIs). AIs reduce the body’s ability to make
(synthesise) oestrogen and have tumour-regressing effects. The AIs in current clinical use include anastrozole, exemestane, and letrozole.
The aim of this systematic review was to compare AIs to other endocrine therapy in the treatment of advanced (metastatic) breast
cancer. A systematic search was conducted which identified 37 controlled trials in which over 14,000 women were randomised to
treatment groups. Treatment with an AI improved survival for women with metastatic disease by 10%. The overall benefits on disease-
free survival and response of the tumour were however unclear based on the studies included in this review. Trials using AIs as first-line
and second-line therapy reported benefits of therapy that varied with the different AIs and measures of effectiveness. We were unable
to identify specific subgroups of women who may benefit from AI use.
Toxicity (negative side effects) was not well reported in the trials. Where it was reported, there was variation as to the method used for
reporting, the type of toxicities reported, as well as the criteria used to assess toxicity. Nevertheless, toxicity data were available for 26
of the 32 trials where an AI was compared with a non-AI. AIs had similar levels of arthritic pain (arthralgia) and hot flushes (especially
when compared to tamoxifen); increased risks of rash, diarrhoea, nausea and vomiting; but decreased risk of vaginal bleeding and blood
clotting (thromboembolic) events compared with other endocrine therapies. Limited quality of life (QOL) data were provided and, as
such, no conclusions can be drawn by this review as to the effect on QOL related to an AI versus a non-AI. This is due to the differences
between participants and the side-effect profiles of the agents used, different methods of drug application (injection versus tablets), and
use of four different QOL instruments at several different timepoints, some which provided results of responders versus non-responders
rather than by treatment group. Some QOL measures were based on clinician-reported rather than patient-reported symptoms.
B A C K G R O U N D
Description of the condition
Breast cancer is the most common cause of cancer and cancer
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mortality in women worldwide (Ferlay 2000). Metastatic breast
cancer occurs when the cancer has spread beyond the breast and
regional node areas. Breast cancer canprogress tometastatic disease
despite a range of adjuvant systemic therapies. Once breast cancer
is metastatic it is no longer curable, but it is treatable. The aim
of any further treatment is to improve the individual’s quality and
length of life.
Description of the intervention
Endocrine (hormonal) therapy removes the influence of oestro-
gen on breast cancer cells, preventing the cancer cells from grow-
ing and spreading. It has been shown to improve survival in early
breast cancer EBCTCG 2005. Hormone dependency of breast
cancer was first demonstrated in the 19th century by a Glasgow
surgeon, Thomas Beatson, who achieved temporary regression of
metastatic disease by oophorectomy (Beatson 1896). Other early
methods of therapy consisted of adrenalectomy and hypophysec-
tomy. These procedures have largely been superseded by effective
hormonal treatments. Most endocrine therapies either block the
binding of oestrogen to its receptor, for example tamoxifen, or re-
duce serum and tumour concentrations of oestrogen, for example
aromatase inhibitors (AIs). A positive initial response to endocrine
treatment is a good indication for use of second and even third-
line endocrine therapy, until the disease becomes hormone resis-
tant (Roseman 1997). The most important predictor of response
to hormone therapy is the oestrogen receptor (ER) status of the
original tumour.
How the intervention might work
Currently, the most widely-used endocrine therapy for treat-
ment of hormone-sensitivemetastatic disease is tamoxifen (Howell
1997). Tamoxifen is an oral, non-steroidal competitive ER antag-
onist. Tamoxifen, however, also has an agonist effect and although
patients may relapse and develop acquired resistance to tamoxifen,
this does not mean that they will not respond to other endocrine
therapy.
Other endocrine therapies used in this setting are fulvestrant,
megestrol acetate (MA), andmedroxyprogesterone acetate (MPA).
Fulvestrant is an ER antagonist that both downregulates and de-
grades the ER and reduces progesterone receptor content but, un-
like tamoxifen, does not have an agonist effect. It can be used as a
treatment for tamoxifen-resistant advanced disease or after failure
of treatment with an AI, so is an alternative second choice to an
AI. MPA and MA are oral progestogens which have been shown
to have significant antitumour activity after failure of other en-
docrine therapies in postmenopausal patients.
In postmenopausal women, oestrogen is no longer produced in
the ovaries but androgens (mainly from the adrenal glands) are
converted to oestrogens in peripheral tissue by the enzyme aro-
matase (Miller 1996a). Aromatase inhibitors (AIs) are a class of
compounds that act systemically to inhibit oestrogen synthesis
in tissues. AIs are of two types, reversible and irreversible; both
types of inhibitors compete with normal substrates for binding on
the enzyme. The non-competitive inhibitors (which are steroidal)
leave the enzyme permanently inactivated (Ibrahim 1995).
AIs are classified as either first, second or third generation (Table
1). Aminoglutethimide (AG) was the first AI and although ef-
fective it was poorly tolerated. This was supplanted by 4-hy-
droxy androstenedione (formestane), which was better tolerated.
Third generation AIs fall into two principal categories of (a)
non-steroidal, reversible triazole derivatives (anastrozole, fadro-
zole, letrozole, vorozole) and (b) steroidal, irreversible inhibitors
(exemestane). The most widely used AIs are currently anastrozole,
exemestane, and letrozole.
Why it is important to do this review
AIs have a different toxicity profile to other endocrine therapies,
although some side effects that mimic menopausal symptoms due
to depletion of oestrogen are the same, such as hot flushes and
sweating. Adverse events particular to AIs include stomach upsets
(nausea, vomiting, diarrhoea), rash, and arthralgia. In particular,
AG is poorly tolerated and can cause drowsiness, fever, and inhi-
bition of cortisol synthesis. Formestane, although generally well
tolerated as a treatment, results in a local reaction around the in-
jection site. Of the other endocrine therapies, tamoxifen can cause
endometrial changes including vaginal bleeding and increased risk
of thromboembolic events. Side effects with progestogens are usu-
ally mild but may include hot flushes, night sweats, nausea and
indigestion, fluid retention, weight gain, and headaches as well
as an increased risk of thromboembolism. Fulvestrant can have
similar oestrogen deprivation side effects, injection site reactions,
vomiting and diarrhoea.
AIs are now increasingly being used in the treatment of early
breast cancer, which may have an impact on their use in advanced
(metastatic) disease.
O B J E C T I V E S
This systematic review aimed to compare AIs to other endocrine
therapy in the treatment of advanced (metastatic) breast cancer in
postmenopausal women.
M E T H O D S
Criteria for considering studies for this review
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Types of studies
Only randomised controlled trials in the following populations
were included.
Types of participants
a) Included:
• postmenopausal women with advanced (stage 3) or
metastatic (stage 4) breast cancer either at diagnosis or upon
relapse;
• oestrogen receptor (ER) positive or status unknown.
b) Excluded:
• local recurrence only;
• with no restrictions on metastatic site or age of the women;
• inclusion not limited to use of an AI as first-line therapy.
Types of interventions
• Any AI versus any other endocrine treatment
• Any AI versus no endocrine treatment
• Any AI plus other endocrine treatment versus other
endocrine treatment alone
• Direct comparison between different AIs
Types of outcome measures
Outcome measures were defined a priori as follows.
Primary outcomes
Overall survival (defined as time from date of randomisation to
date of death from any cause)
Secondary outcomes
1. Progression-free survival (defined as time from date of
randomisation to disease progression), also known as time to
progression
2. Clinical response rate, comprising objective response (those
women with either complete or partial shrinkage of the tumour)
and clinical benefit (objective response plus stable disease for
more than 24 weeks)*
3. Treatment toxicity (particularly AI related)
4. Quality of life (QOL), where available and comparable
5. Dropout rate
6. Time to treatment end (stopped or changed due to toxicity)
* International Union Against Cancer (UICC) guidelines were
used for evaluation of these criteria (Hayward 1977).
Subgroup analyses
The following subgroup analyses were considered:
• first-line therapy (where the AI was given as initial therapy
for advanced disease);
• second-line therapy (where the advanced disease had already
been treated with a different AI or another endocrine therapy);
• ER positive versus ER unknown;
• according to site of distant metastases and differential
treatment effect.
Search methods for identification of studies
Only English language publications were included.
Electronic searches
1. The Cochrane Breast Cancer Group Specialised Register.
For the first published version of this review (Gibson 2007), the
Cochrane Breast Cancer Group Specialised Register was searched
(December 2004, 30 September 2005). For this update, addi-
tional searches were conducted (30 June 2008). Details of the
search strategy used by the group for the identification of stud-
ies and the procedure used to code references are outlined in
the group’s module (www.mrw.interscience.wiley.com/cochrane/
clabout/articles/BREASTCA/frame.html). Studies coded as “ad-
vanced” and “endocrine therapy” were extracted for consideration.
2. The Cochrane Central Register of Controlled Trials (CEN-
TRAL) (The Cochrane Library 2008, Issue 2). See Appendix 1.
Searching other resources
Reference sections of each published paper were searched for ad-
ditional studies. Conference proceedings were also searched but
abstracts, apart from one, were not included. The one that was
included (Schmid 2001) had no corresponding publication but
there was adequate information in the abstract for the trial to be
included.
Data collection and analysis
Selection of studies
Two authors (CLD, LJG) assessed all trials identified through the
search strategy and independently decided on eligibility; any dif-
ferences were resolved by discussion and confirmed by a third au-
thor (DJL). Final confirmation of inclusion was made by two au-
thors (LJG, DJL). Any exclusions have been justified and docu-
mented in the table Characteristics of excluded studies.
Data from unpublished trials are not included in the review but
these are included in the table of ongoing trials. For these, informa-
tion was obtained from the trial protocol or other available source.
Authors were approached for missing or additional information
however only two replies were received out of six contacted.
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Data extraction and management
Two review authors (CLD, LJG) extracted data independently us-
ing data extraction forms designed for this purpose. Data extracted
included details of treatment arms and patient numbers, base-
line patient characteristics, tumour response rates, time to pro-
gression, median survival, and median follow up. Data on toxicity
and quality of life were extracted at a later date. The authors were
not blinded to the source of the document for article selection or
data extraction. A third author (DJL) assessed the data collected
to ensure consistency and accuracy. Any differences were resolved
by discussion. Data on study quality were extracted as described
in ’Assessment of the methodological quality’. Hazard ratios and
their associated variances were extracted for all measures available.
If a hazard ratio and confidence interval were not reported, these
values were calculated (Parmar 1995). Of the report authors (n
= 8) who were contacted for supplementary information on the
primary endpoints, only two replied (and the data were not avail-
able). For the updated review, data extraction was performed in-
dependently by two of the review authors (CLD, DJL).
Assessment of risk of bias in included studies
Two review authors (LJG, CLD) independently assessed the qual-
ity of all trials deemed eligible and discrepancies were resolved by
discussion. The quality of each trial was assessed based on reports
in the publication regarding:
• quality of allocation concealment;
• comparability between the baseline characteristics of the
treatment arms;
• inclusion of all randomised participants in the analysis;
• details of dropouts.
Randomisationwas assessed by grading the allocation concealment
(for example blinded, stratified) as: A = adequate, B = unclear, C
= inadequate (see Characteristics of included studies). It was not
possible to accurately assess the quality of randomisation in all trials
due to lack of information in the published articles. Any imbalance
between treatment arms, both in numbers and characteristics, was
taken into account in the grading.
Intention-to-treat statements: analyses that were stated to be by
intention to treat and included all randomised patients for the pri-
mary endpoint. However, it is common practice to report response
variables, that is clinical benefit and objective response, only on
’assessable’ patients. We have reported these outcomes on both
assessable and randomised patients.
Description of the eligibility and exclusion criteria: all trials de-
scribed in detail the patient characteristics of those patients eligible
for the trial. The table ’Characteristics of included studies’ includes
information on the balance of baseline characteristics, details of
patients excluded after randomisation, definitions of the outcome
measures, duration of follow up, and median length of follow up.
Measures of treatment effect
The most complete dataset feasible was assembled. Data were,
however, only available for the following endpoints: overall sur-
vival, progression-free survival, clinical benefit, objective response,
and toxicity.
Overall and progression-free survival were analysed using time-
to-event methods and for this the hazard ratio (HR) is the most
appropriate statistic. If a HR and corresponding confidence in-
tervals (CI) were not reported, these values were calculated indi-
rectly using median time to event (progression or survival) and
the number of events extracted from the published Kaplan-Meier
curves, following the method of Parmar 1995. A weighted aver-
age of survival duration across trials was then calculated. Ratios of
treatment effects for time to event were reported so that HRs less
than 1.0 favoured the AI regimen.
Response rates were obtained from the tables of best response
presented for each trial. Response has been analysed based on
assessable (not randomised) patients as most of the trials included
in this review only reported responses in this way. As a sensitivity
analysis, we also analysed results by intention to treat (ITT); there
was no difference. Response rates were analysed as dichotomous
variables (for example objective response compared complete or
partial response versus stable disease or no response). An odds ratio
(OR) and its associated 95% CI were calculated for each trial and
a pooled OR derived. Ratios of treatment effects on response were
reported so that ORs less than 1.0 favoured the AI regimen. In
this case, the ’event’ is in effect ’not getting an objective reponse’
or ’not getting a clinical benefit’.
Results are presented graphically and all figures follow the same
format. Each trial is presented as a single line within each category.
The point estimate of the treatment effect is represented by a
square, the size of which is proportional to the size of the trial. The
associated 95% CI is included as a horizontal line. The summary
in each category is represented by a diamond, the north-south axis
is the pooled estimate and the east-west axis is the 95% CI.
Unit of analysis issues
There were no unit of analysis issues in this review.
Dealing with missing data
The number of actual dropouts was very difficult to quantify as
the quantity and quality of reporting varied greatly. Only 10 trials
gave full details by treatment arm. Three trials quoted the number
of patients withdrawn due to toxicity as “a small number” (Buzdar
1996b; Buzdar 1996c; Kaufmann 2000). Thus the patients that
could be confidently identified as lost to follow up, refusals, or
withdrawals totalled 62.
Toxicity
Not all toxicities (also known as side effects or adverse events)
were reported in this review. We selected eight predefined tox-
icities from expert experience, reflecting side effects specific to
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AIs (nausea, vomiting, diarrhoea, rash, arthralgia) and other hor-
monal treatments (hot flushes, vaginal bleeding, thromboembolic
events). Each side effect was analysed as a dichotomous variable
(yes or no) with the effect of the AI considered separately to that of
the comparator. This was deemed the most informative method
of presentation as the different comparators have different toxicity
profiles, whereas AIs have similar toxicity profiles. An OR and its
associated 95% CI were calculated for each trial and a pooled OR
derived. Ratios of treatment effects for toxicity were reported so
that ORs less than 1.0 favoured the AI regimen.
Assessment of heterogeneity
Statistical heterogeneity between trials was assessed using the Chi
2 statistic. However, there were cases where the value for the I2
statistic was high but the Chi2 test was not statistically significant;
we advise caution in interpreting these results. Evidence of het-
erogeneity between trials was identified for tumour response rates
and progression-free survival though not overall survival, which
seems less susceptible to heterogeneity. The reasons for this are
unknown but this statistical heterogeneity may be explained by
clinical heterogeneity. It is possible that outcomes involving sub-
jective endpoints, that is tumour response, may be subject to vari-
ation whereas the hard endpoint used in the survival analysis is
unequivocal. With progression-free survival, the trials were under-
taken in populations that varied considerably. For example, some
trials were using the AI as first-line treatment, some as second-
line treatment, and in other trials as mixed first- and second-line.
Other contributory factorsmay be the difference in dosage of some
AIs and significant differences in the proportion of patients who
were truly hormone receptor positive. We stress that as this review
describes a very mixed range of studies of mixed patient popula-
tions, carried out over 30 years, the relative effect between treat-
ment arms would still be consistent even with this mix of different
patient groups.
Assessment of reporting biases
There is a lack of reporting of overall survival information com-
pared to tumour response. Many of the trials were carried out over
10 years ago but there have been no subsequent publications with
updated (or any) survival information.
Data synthesis
The Cochrane Review Manager Software (RevMan5) was used to
analyse the data.
A Mantel-Haenszel fixed-effect model was used for the primary
analyses (see the Cochrane Handbook for Systematic Reviews of
Interventions) unless there was significant heterogeneity, in which
case a random effects model was used (Higgins 2003). A fixed-ef-
fectmodel was used for all overall survival analyses, and all analyses
for any AI versus a different AI. For any AI versus a non-AI, and
current AIs versus non-AIs, a random-effects model was used for
progression-free survival, clinical benefit, and objective response.
When an AI was used as first-line therapy, a random-effects model
was used for the clinical response variables but not for progression-
free survival; whereas a fixed-effect model was used for the clinical
response variables for second-line therapy.
A pooled analysis was performed in each group, but the results
from each AI were considered separately within the same group,
where possible. Trials were pooled by type of AI for survival, pro-
gression-free survival, clinical benefit, and objective response out-
comes. For toxicity, the data were pooled by type of comparator,
that is tamoxifen, MA, MPA, or fulvestrant, as the toxicities of
different AIs are similar due to their mode of action. This ap-
proach was considered to be more informative due to differences
between the AIs (first versus second or third generation; steroidal
versus non-steroidal). Post hoc, it was also decided to separately
present the pooled results for the AIs that are in current clinical
use (by definition the newer, third generation AIs) as this is more
relevant to the clinical situation today. The AIs included were:
aminoglutethimide (first generation); formestane (second genera-
tion); and anastrozole, exemestane, fadrozole, letrozole and voro-
zole (third generation). The non-AIs included were: megestrol ac-
etate (MA), tamoxifen, fulvestrant, medroxyprogesterone acetate
(MPA), and hydrocortisone (HC).
Subgroup analysis and investigation of heterogeneity
In all cases, tests for heterogeneity have been performed across all
trials and in each of the treatment groupings outlined above. Some
of the trials that were pooled used different doses of AI, which
may have contributed to some of the heterogeneity. Instances of
statistically significant heterogeneity are discussed in the results
section.
Sensitivity analysis
All analyses were based on the intention-to-treat (ITT) principle
as far as was possible, that is comparing all women allocated to
one treatment versus all those allocated to the other irrespective
of compliance. Thus the results may slightly underestimate any
treatment effects. However, analysis of response used the number
of assessable women as the denominator as this is the accepted
method. As a sensitivity analysis, both denominators were used
(see Figures) and there was no major difference for response when
comparing assessable to ITT. For statistical tests a P value of less
than 0.05 was considered to denote statistical significance.
R E S U L T S
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Description of studies
Some references were excluded because they were either non-En-
glish language papers, reviews, non-randomised studies, or confer-
ence proceedings without the addition of published data. The ex-
ception to this was the conference abstract by Schmid 2001 which
was included as it presented several of the endpoints relevant to
this review in abstract form; there is no published paper for this
trial. Where a trial compared two doses of an AI with a compara-
tor, the trial was included using the arm with the standard or most
commonly used dose of that particular AI versus the comparator.
For anastrozole this was 1 mg; and for fadrozole it was 2.5 mg, or
2 mg if 2.5 mg was not used.
Results of the search
The original search (Gibson 2007) yielded 152 English language
references, of which 133 were possibly eligible. Twenty-five of
the 133 references, relating to 22 trials, were excluded as they
compared the same AI at different doses. Fifty relevant references
were identified relating to 25 randomised trials which fulfilled the
eligibility criteria. An additional five references for five trials were
identified by the authors from reference lists in papers and reviews.
The updated search (June 2008) yielded a further 54 references of
which 17 were possible inclusions. This resulted in a further seven
trials being assessed as eligible for inclusion.
Included studies
We included 37 trials which randomised 14,060 women. There
was a great deal of variation across the trials. Trials ranged in size
from 60 (Kleeberg 1997) to 1021 women (Bonneterre 2001).
Fourteen trials randomised patients frommultiple countries; of the
remaining 23 trials, three were limited to the UK, two were from
Spain, two from South Africa, two from Switzerland, six from the
US, and one each from North America (US and Canada), Den-
mark, France, Germany, Greece, Japan, Norway, and Switzerland.
The country was not formally reported in 14 trials but surmised
from the addresses of the authors.
In 32 trials comparing AIs with non-AIs,11,710 women were ran-
domised; 2350 women were randomised in five trials of one AI
versus a different AI. It should be noted that seven trials included
two different doses of an AI compared with a third comparison.
Data for 12,883 women were included in this review.
Of the 32 trials comparing AIs with non-AIs, 11 used the first gen-
eration AI aminogluthetimide, three used the second generation
AI formestane, and 18 used a third generationAI (anastrozole: four
trials; exemestane: three trials; fadrozole: six trials; letrozole: four
trials; vorozole: one trial). In these, tamoxifen was the comparator
in 12 trials, MA in 13 trials, MPA in four trials, hydrocortisone
(HC) in one trial, and fulvestrant in two trials.
The five trials of AIs versus a different AI compared letrozole ver-
sus anastrozole, aminoglutethimide, atamestane, or fadrozole; and
anastrozole versus formestane.
The AI arm in some of the older trials (Alonso-Munoz 1988;
Canney 1988; Ingle 1986; Powles 1984; Rose 1986; Russell 1997)
did not compare an AI by itself but in combination with another
treatment. One very recent trial (Goss 2007) compared an AI ver-
sus a new AI (atamestane) in conjunction with a selective oestro-
gen receptor modulator (SERM).
In 11 of the 37 trials (randomising 3876 women) in which any
AI was used as first-line treatment versus any other comparator,
tamoxifen was compared in all trials. In 19 of 37 trials (7413
randomised women) any AI was compared with any comparator
as second-line therapy. In four trials the AIs were used as both
first- and second-line treatments within the trials, but as the data
were not split by this variable they were not included in these
comparisons.
Data for all endpoints were not available in the published reports.
Where data were unavailable, authors were approached for supple-
mentary data. Five principal endpoints with sufficient data were
identified: overall survival, progression-free survival, response (ei-
ther based on clinical benefit or objective response), and treatment
toxicity. Likewise, data were not available in the published reports
for all subgroups proposed in the review protocol. The AI versus
any non-AI comparison had enough data for all five endpoints as
well as a subgroup consisting of data from the three most com-
monly prescribed AIs (anastrozole, exemestane, and letrozole). In
addition, the results of four of the five endpoints (not toxicity)
outlined above are presented in three separate groups based on:
individual AIs versus different AIs, AIs used as first-line treatment
only, AIs used as second-line therapy only.
Time to treatment end
No trial had a fixed treatment period. However, all but two of the
trials (Leitzel 1995; Samonis 1994) reported on at least one of the
following: time to progression, time to failure or time to death, or
both of the latter.
Excluded studies
Non-randomised studies, trials in premenopausal women, and
non-English language publicationswere criteria for exclusion from
the review. Trials which compared two different doses of the same
AI were also excluded (see the table ’Characteristics of excluded
studies’).
Risk of bias in included studies
Thirty-seven randomised trials were included in this review. One
of the included trials did not have data on the primary or secondary
endpoints so could not be included in any analysis (Leitzel 1995).
It should be noted that trials by the author of one of the included
trials (Bezwoda 1998), relating to high dose chemotherapy, have
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been found to include falsified data. However, no such findings
have been reported for trials included in this review. There was
therefore no reason to exclude the trial. Analysis was performed
with and without this trial and there was no difference in the
pooled results, although for clinical benefit the result became just
significant.
It was not possible to accurately assess the quality of all trials due to
lack of information in the published articles. Allocation conceal-
ment was rated as adequate in 23 trials but there were insufficient
details of the allocation concealment in the remaining 14 and so
they were labelled as unclear. Of these, no randomisation method
was given in eight trials and four were reported to have parallel
groups. No trials were deemed to have inadequate allocation con-
cealment, from the information given in the published papers, and
none were excluded for this reason. Six trials were double-blind,
double-dummy; seven were double-blind; one was double-blind
in one arm but open in the other (Buzdar 1996a); and one (which
consisted of two trials analysed together) was double-blind in one
and open in the other trial (Mauriac 2003).
Baseline characteristics were not commented upon in 12 trials, five
trials commented on a slight imbalance. One trial (Buzdar 1996a)
had an imbalance in the treatment arm but this was believed to
be an artefact. Another trial (Lundgren 1989) reported that “the
two groups were well balanced with regard to the most important
prognostic variables, with the exception of main metastatic site”.
All other trials reported balanced baseline characteristics in all
arms.
Summary of numbers of women used in the analysis
Women randomised, all arms: 14,060
Women randomised, included arms: 12,883
Women randomised, assessable (for response): 11,111
Effects of interventions
Over 12,000 women were randomised to the included arms of
37 trials but time-to-event data were only available for about half
of them. The results of the meta-analysis should be interpreted
bearing this in mind.
Aromatase inhibitors (AIs) versus any non-aromatase in-
hibitor
Of the 32 trials comparing an AI versus a non-AI, one had no
data on response or survival by treatment arm although these
were included as endpoints (Leitzel 1995). Of the remaining
31 trials, data were available on overall tumour response rates
in all 31, clinical benefit in 26, progression-free survival in 11
and overall survival in 13 trials. For overall survival, the re-
ported figures were available from the publications for six tri-
als (Bonneterre 2001; Buzdar 1996a; Buzdar 2001; Ingle 1986;
Dombernowsky 1998; Thuerlimann 1996) and were calculated
for seven trials (Bezwoda 1998; Gale 1994; Goss 1999; Kaufmann
2000; Milla-Santos 2003; Rose 1986; Russell 1997). In terms of
progression-free survival, HRs were reported in the publications
of five trials (Bonneterre 2001; Buzdar 2001; Chia 2008; Ingle
1986;Mourisden 2001). The remaining six trials (Dombernowsky
1998; Goss 1999; Kaufmann 2000; Mauriac 2003; Russell 1997;
Thuerlimann 1997) had sufficient data for calculation of theHRs.
1. Overall survival
Data on survival were available in 13 trials reporting an estimated
2776 events in 4789 women. No data were available for formes-
tane. The pooled HR of 0.90 (95% CI 0.84 to 0.97) showed a
statistically significant 10% benefit of treatment (P = 0.007) with
an AI, with a consistent effect across all subgroups. Data on indi-
vidual AIs were sparse and no conclusions could be drawn.
2. Progression-free survival
Data on progression-free survival (PFS) were available in 11 tri-
als reporting an estimated 4391 events in 5890 women. PFS was
not statistically significantly associated with the use of an AI (HR
0.98, 95% CI 0.84 to 1.13). This overall effect is virtually unin-
terpretable due to the significant heterogeneity (P < 0.00001) by
type of AI and also within specific AIs.
3. Proportion of women with clinical benefit (8789 assessable
women)
Datawere available for sevenAIs (aminoglutethimide, formestane,
anastrozole, exemestane, fadrozole, letrozole, vorozole) from 27
trials. Approximately one third of the data came from three trials
(Bonneterre 2001;Mauriac 2003;Mourisden 2001). The AIs were
shown to be superior to the non-AIs (OR 0.87, 94% CI 0.77
to 0.99) and there was statistically significant heterogeneity (P =
0.008) across trials.
4. Proportion of women with an objective response (9595 as-
sessable women)
Thirty-one trials reported objective response. Data were avail-
able for seven AIs (aminoglutethimide, formestane, anastrozole,
exemestane, fadrozole, letrozole, vorozole). The pooled OR sug-
gestedno statistically significant effect of treatmentwith anAI (OR
0.88, 95% CI 0.77 to 1.01) and again there was statistically signif-
icant heterogeneity (P = 0.02). Of the individual AIs, only letro-
zole was associated with a statistically significant benefit over the
non-AI (OR 0.65, 95% CI 0.51 to 0.82) in the 1637 women ran-
domised (Buzdar 2001; Dombernowsky 1998; Mourisden 2001;
Schmid 2001).
5. Toxicity
Not all trials provided data on toxicity and there were inconsisten-
cies among trials where it was reported. Toxicity datawere available
for only 26 of the trials comparing anAIwith a non-AI.Within tri-
als, the reported toxicities varied both in the number or range and
types of toxicities reported as well as the criteria used for reporting.
Some trials reported predefined or selected toxicities (Bonneterre
2001; Kaufmann 2000; Mauriac 2003), some chose to report tox-
icities occurring in a certain minimum percentage of participants
(Bezwoda 1998; Buzdar 2001; Chia 2008; Dombernowsky 1998;
Goss 1999; Mauriac 2003; Mourisden 2001), some used worst
toxicity grades (Falkson 1996; Thuerlimann 1996; Thuerlimann
1997) or major toxicity (Canney 1988); one reported toxicity
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grades 1 to 4 separately (Paridaens 2003), one used common toxic-
ities (Buzdar 1996a) though what this meant was not defined, two
reported adverse experiences (Buzdar 1996b; Buzdar 1996c), and
two reported all toxicities (Freue 2000; Rose 1986). Eight trials did
not state which reporting criteria they used. In addition, one trial
(Perez Carrion 1994) only reported on the toxicities considered
to be treatment related and has not been included. For the trial
of an AI against fulvestrant (Mauriac 2003), data on toxicity were
obtained from different sources. The combined analysis of the two
trials 0020 and 0021 reported predefined events and data on hot
flushes and thromboembolic events were available. The separate
publications of the results of 0020 and 0021 detailed toxicities
occurring in 10% or more of the participants. Trial 0020 reported
data on both nausea and vomiting so these were combined with
these data from 0021. In addition, trial 0021 had data on the fre-
quency of diarrhoea and rash.
Despite the different reporting criteria the data were pooled. This
must be borne in mind when looking at the absolute numbers.
The analyses are reported according to the comparator due to the
different toxicity profiles of each. An overall pooled result for AI
versus non AI is not provided.
Hot flushes
Hot flushes were the specific toxicity that was most widely re-
ported. Data on hot flushes were available from 20 of the 32 trials
with 8306 women. Of these, seven compared an AI with tamox-
ifen, 10 with MA, two with fulvestrant, and one with MPA. The
use of an AI had a very similar risk of hot flushes to tamoxifen and
fulvestrant. The AI was associated with statistically signficantly
more reports of hot flushes than with MA (OR 1.73, 95%CI 1.40
to 2.14) but less than withMPA (OR 0.20, 95% CI 0.06 to 0.73),
which had data from only one very small trial.
Nausea
Data on nausea were available from 18 trials with 7895 women.
Another two trials reported data on nausea and vomiting com-
bined. Of the 18, six compared an AI with tamoxifen, nine with
MA, two with fulvestrant, and one with MPA. AIs were associated
with a statistically significant increase in risk of nausea compared
to MA (OR 1.77, 95% CI 1.33 to 2.35) but there was no statisti-
cally significant difference between AIs and tamoxifen (P = 0.32)
or fulvestrant (P = 0.96).
Vomiting
Two trials had data on nausea and vomiting combined and so were
not included. Data on vomiting were available from two trials
comparing AIs with tamoxifen, five versus MA, and one versus
fulvestrant for a total of 4404 women. The AI was statistically
significantly worse when compared to MA (OR 2.03, 95% CI
1.42 to 2.90). The comparisons with tamoxifen and fulvestrant
suggested no statistically significant differences.
Diarrhoea
Ten trials with 5200 women had data on diarrhoea toxicity. Of
these, three compared anAIwith tamoxifen, fivewithMA, and two
with fulvestrant. AIs were associated with a statistically significant
higher rate of diarrhoea than either tamoxifen (OR 1.64, 95% CI
1.06 to 2.55) or MA (OR 1.48, 95% CI 1.02 to 2.13) but not
fulvestrant (P = 0.36).
Rash
Fifteen trials with 4598 women had data on rash toxicity. Of
these, four compared an AI with tamoxifen, eight with MA, two
with MPA, and one with fulvestrant. AIs were associated with
a statistically significant increased risk of rash when compared
with tamoxifen (OR 33.61, 95% CI 4.71 to 239.97) and for the
two trials versus MPA (OR 36.80, 95% CI 3.35 to 404.73) but
not against MA or fulvestrant. Within the comparison with MA
there was statistically significant heterogeneity (P = 0.0003) and
moderate heterogeneity with tamoxifen.
Vaginal bleeding
Data on vaginal bleedingwere reported in six trials of 2750women:
one compared an AI with tamoxifen, three with MA, and two
withMPA.ComparedwithMA, there was a statistically significant
benefit of 78% for treatment with the AI (OR 0.22, 95% CI
0.10 to 0.45). The two trials versus MPA also found a statistically
significant difference with an OR of 0.13 (95% CI 0.02 to 0.71).
In one of the larger trials (Bonneterre 2001) that compared an AI
with tamoxifen, there was no statistically significant difference (P
= 0.15).
Thromboembolic events
Thromboembolic event data were available from six trials with
2937 women. Two compared an AI with tamoxifen, three with
MA, and one with fulvestrant. The AI had a statistically significant
advantage only over tamoxifen (OR 0.48, 95% CI 0.27 to 0.85).
Arthralgia
Data on arthralgia were available for 2470 women in two trials
versus tamoxifen (1031 women) and four trials versus MA (1439
women). There was no statistically significant difference between
the AIs and either tamoxifen or MA.
Subgroup analysis: aromatase inhibitors (AIs) in current clin-
ical use versus any non-aromatase inhibitor
Eleven of the 32 trials comparing an AI with a non-AI were on the
three AIs in current clinical use, namely anastrozole, exemestane
and letrozole. The pooled results for these are reported. Data on
overall survival and time to progression were available from only
six and seven trials respectively, but response rates and clinical ben-
efit were available from all 11 trials. In terms of survival, HRs were
reported in the publications of four trials: anastrozole (Bonneterre
2001; Buzdar 1996a) and letrozole (Buzdar 2001;Dombernowsky
1998). Another two trials (Kaufmann 2000; Milla-Santos 2003)
had sufficient data for calculation of the HRs. For time to progres-
sion, the corresponding numbers of trials were four (Bonneterre
2001; Buzdar 2001; Chia 2008; Mourisden 2001) and three
(Dombernowsky 1998; Kaufmann 2000; Mauriac 2003), respec-
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tively.
1. Overall survival
Data on survival were available from six trials (Bonneterre 2001;
Buzdar 1996a; Buzdar 2001; Dombernowsky 1998; Kaufmann
2000; Milla-Santos 2003). The AI was statistically significantly
superior to the non-AI with a HR of 0.88 (95% CI 0.80 to 0.96),
equivalent to a 12% benefit of treatment with an AI. This effect
was consistent across all subgroups.
2. Progression-free survival
Data on progression were available from seven trials (Bonneterre
2001; Buzdar 2001; Chia 2008;Dombernowsky 1998; Kaufmann
2000; Mauriac 2003; Mourisden 2001) reporting an estimated
3660 events in 5004 women. Use of an AI was not statistically
significantly associated with a change in the hazard of progression
(HR 0.93, 95% CI 0.78 to 1.12). The results did not vary by type
of AI. There was significant heterogeneity in the pooled result (P
< 0.00001) within the anastrozole trials (P < 0.00001) and the
letrozole trials (P = 0.01).
3. Proportion of women with clinical benefit (5619 assessable
women)
Data were available from 11 trials. The pooled OR suggested a
statistically significant advantage of 20% for theAI (OR0.80, 95%
CI 0.66 to 0.97). There was statistically significant heterogeneity
among the trials (P = 0.002).
4. Proportion of women with an objective response (5619 as-
sessable women)
All 11 trials reported objective response. The pooled OR of 0.79
(95% CI 0.65 to 0.97) showed a statistically significant advantage
to the AI but there was statistically significant heterogeneity (P
= 0.03) across the trial results. There was also significant hetero-
geneity within the exemestane trials.
5. Toxicity
One of the suggested benefits of the third generation AIs is a re-
duced toxicity profile. The results were presented by comparator
as the comparators have different toxicity profiles whereas the AIs
have similar toxicity profiles. The denominators for the compari-
son of anastrozole with fulvestrant varied depending on whether
the combined trial results were available (hot flushes, nausea, vom-
iting, thromboembolic events) or not (diarrhoea, rash).
Hot flushes
Hotflusheswere the specific toxicity thatwas reportedmostwidely.
Data on hot flushes were available from nine of the 11 trials, with
5623 women. Three trials compared the AI with tamoxifen, four
with MA, and two with fulvestrant. The use of an AI had a very
similar risk of hot flushes to tamoxifen and fulvestrant but was
associated with statistically significant more reports of hot flushes
than with MA (OR 1.69, 95% CI 1.24 to 2.30).
Nausea
Data on nausea were available from nine of the 11 trials, involv-
ing 5623 women. Of the nine trials, three compared an AI with
tamoxifen, four with MA and two with fulvestrant. The AIs had
statistically signicantly more reports of nausea thanMA (OR1.45,
95% CI 1.09 to 1.95) but there was no statistically significant dif-
ference when the AIs were compared to tamoxifen or fulvestrant.
Vomiting
Five trials with 3499 women had data on vomiting alone and only
MA as the comparator had more than one trial. There was no sta-
tistically significant differences between the AI and either tamox-
ifen or fulvestrant. Compared with MA, the AIs had a statistically
significantly increased risk of vomiting (OR 1.77, 95% CI 1.11
to 2.83).
Diarrhoea
Seven trials with 4295 women had data on diarrhoea toxicity. Two
compared an AI with tamoxifen, three with MA, and two with
fulvestrant. There was a statistically significant increased risk of
diarrhoea with the AIs against MA (OR 2.40, 95% CI 1.34 to
4.29).
Rash
Four trials with 2033 women that compared AIs with MA or
fulvestrant (one trial only) haddata on rash. AIswere not associated
with a statistically significant increased risk of rash and there was
statistically significant heterogeneity among the three trials with
MA as the comparator (P = 0.04).
Vaginal bleeding
Data on vaginal bleeding were reported in three trials with 1932
women, one compared an AI with tamoxifen and two with MA.
There was a statistically significant benefit to treatment with the
AIs in comparison with MA (OR 0.29, 95% CI 0.13 to 0.65).
Thromboembolic events
Thromboembolic event data were available for 2378 women in
three trials but there was only one trial per comparator (tamoxifen,
MA, or fulvestrant). AIs were associated with a statistically signif-
icant lower incidence of thromboembolic events than tamoxifen
(OR 0.53, 95% CI 0.30 to 0.96) but not compared with MA or
fulvestrant.
Arthralgia
Data on arthralgia as a specific side effect were only available for
1394 women in three trials, two versus tamoxifen and one versus
MA. Against both comparators, the AI was not statistically signif-
icantly associated with a difference in the incidence of arthralgia.
Other analyses
Aromatase inhibitors (AIs) versus any different aromatase in-
hibitor
A total of 2346 women in five trials were randomised to one AI
versus a differentAI.Of these, all five haddata on response but only
two had results on overall survival and progression-free survival
(Gershanovich 1998; Goss 2007). Letrozole was compared with
a different AI in all the trials (Gershanovich 1998; Rose 2003;
Tominaga 2003) except that of Kleeberg 1997 which compared
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anastrozole with formestane. The trial by Rose and colleagues (
Rose 2003) compared letrozole to anastrozole and in this section
has been included in both the letrozole and anastrozole groups.
1. Overall survival
The Gershanovich 1998 and Goss 2007 trials were the only ones
that haddata onoverall survival and the resultswere drivenbyGoss
2007 as 70% data came from this trial. Letrozole had a reduced
HR of 0.91 (95% CI 0.82 to 1.02) but this was not statistically
significant and there was signficant trial heterogeneity (P = 0.006).
2. Progression-free survival
Two trials had data on progression from 1416 women (
Gershanovich 1998;Goss 2007) and, again, the results were driven
by the Goss 2007 trial. In these trials, letrozole was associated
with a slightly reduced hazard in terms of progression-free survival
compared to aminoglutethimide, but this was not statistically sig-
nificant and there was heterogeneity (P = 0.01) between the trials.
3. Proportion of women with clinical benefit (1747 assessable
patients)
Letrozole was associated with a statistically significant clinical ben-
efit compared with a different AI (OR 0.77, 95%CI 0.62 to 0.95).
There was no significant trial heterogeneity (P = 0.63).
4. Proportion of women with an objective response (1747 as-
sessable patients)
The pooled overall result was not presented as Rose 2003 was in-
cluded in both individual AI comparisons and sowould be counted
twice. Letrozole was statistically significantly different from any
other AI (OR 0.62, 95% CI 0.50 to 0.78). Results of all letrozole
trials were consistent (test for heterogeneity P = 0.32). Anastrozole
appeared to be significantly inferior to a different AI (OR 1.59,
95% CI 1.07 to 2.37).
Aromatase inhibition as first-line therapy versus any non-AI
therapy (tamoxifen)
Twelve trials that randomised 3746 women used AIs exclusively
as first-line therapy for advanced (metastatic) disease and all com-
parisons were against tamoxifen. We did not include any trials
that were mixed first- and second-line. Data from three trials with
1483 women (anastrozole, fadrozole, AG) were available for over-
all survival and four trials with 2390 women (one trial each on
formestane, anastrozole, and letrozole) for progression-free sur-
vival. Eleven trials reported results for objective response and nine
trials for clinical benefit.
1. Overall survival
There was no statistically significant difference in the effect of
treatment with an AI compared to tamoxifen.
2. Progression-free survival
The first-line AI regimen was statistically significantly superior to
tamoxifen with a decreased hazard of 0.78 (95% CI 0.71 to 0.86).
Anastrozole (Bonneterre 2001) and letrozole (Mourisden 2001)
were statistically significantly different from tamoxifen (reduced
hazard of 18% and 30%, respectively).
3. Proportion of women with clinical benefit (3252 assessable
women)
As results for individual AIs, except for aminoglutethimide and
anastrozole, were based on only a single trial the pooled result
is emphasised. The AIs were better than tamoxifen as first-line
therapy (OR 0.69, 95% CI 0.51 to 0.92) although there was
significant heterogeneity across the AIs (P = 0.002).
4. Proportion of womenwith objective response (3503 assessable
women)
Aminoglutethimide was the only AI with more than two trials
published. The AIs were better than tamoxifen as first-line therapy
(OR 0.77, 95% CI 0.59 to 1.00) although this was of borderline
statistical signficance. There was considerable heterogeneity (P =
0.003) by type of AI. Exemestane and letrozole were the only AIs
that were statistically significantly better than tamoxifen but in
both cases the results were only based on one trial.
Aromatase inhibition as second-line therapy versus any non-
AI therapy
Women who had previously been treated with endocrine therapy,
either a different AI or non-AI, for advanced (metastatic) disease
and received the trial AI as second-line therapy were included in
19 trials. The trial by Leitzel 1995 was of second-line therapy
but does not contribute to the results here, thus giving 18 trials.
Aminoglutethimide was used as second-line in five trials, formes-
tane in two, anastrozole in two, exemestane in two, fadrozole in
three, letrozole in three, and vorozole in one trial. The majority of
the comparisons (12) were against MA. We did not include trials
where there was a mixture of first- and second-line therapy.
Data on objective response were available from all of the trials;
clinical benefit from 16 trials; HRs for progression-free survival
from eight trials; and HRs for overall survival from two trials.
1. Overall survival
Data on overall survival were limited with data from two trials
of different AIs, anastrozole and letrozole. Second-line treatment
with an AI was statistically significantly associated with a decreased
hazard of death (HR 0.80, 95% CI 0.66 to 0.96). This effect was
consistent for both AIs (heterogeneity P = 0.79).
2. Progression-free survival
AI use was not associated with a statistically significant difference
in the risk of progression. There was significant heterogeneity (P
= 0.001) across trials, with use of either anastrozole or vorozole
associated with a significantly increased risk of progression.
3. Proportion of women with clinical benefit (5410 assessable
women)
There did not appear to be any effect in terms of a statistically
significant clinical benefit when an AI was used as second-line
therapy (OR 0.99, 95% CI 0.88 to 1.11). This lack of effect was
consistent across AI subgroups (heterogeneity P = 0.88).
4. Proportion of womenwith objective response (5937 assessable
women)
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Overall there was no statistically significant difference between the
use of an AI as second-line therapy and any other therapy (OR
0.98, 95% CI 0.86 to 1.13). When looking at individual AIs,
none showed any evidence of a benefit but this was based on small
numbers. There was no statistical heterogeneity (P = 0.52).
Other subgroup analysis
We were not able to perform subgroup analyses on the following
groups of patients as these data were not systematically reported:
• ER positive versus ER unknown;
• according to site of distant metastases and differential
treatment effect.
Quality of Life
Nine trials (Bezwoda 1998; Buzdar 1996b; Buzdar 1996c; Buzdar
2001; Chia 2008; Goss 1999; Kaufmann 2000; Mauriac 2003;
Thuerlimann 1997) quoted quality of life (QOL) as a secondary
endpoint. Three of the trials (Bezwoda 1998; Buzdar 1996b; Buz-
dar 1996c) did not report any QOL data. Only one (Thuerlimann
1997) has published two papers on the QOL data in detail. One
trial (Dombernowsky 1998) mentioned that a QOL instrument
was used, at baseline and at each visit whilst on treatment, but it
was not mentioned as an endpoint nor were any data included.
Chia 2008 reported that the difference in QOL between the treat-
ment arms was not statistically significant; however the graph was
shown on the online publication only.
There are several reasons why the limited QOL data are not in-
cluded in this review: heterogeneous changes among patients, that
is different symptoms and side effect profiles; different methods of
drug application, that is injection versus tablets; use of four differ-
ent QOL instruments at several different timepoints; some results
given as responders versus non-responders rather than by treat-
ment groups; some QOL measures based on clinician-reported
rather than patient-reported symptoms.
D I S C U S S I O N
Summary of main results
This review demonstrates a survival benefit of 10% with the use of
AIs for the treatment of advanced (metastatic) breast cancer. This
finding is not consistent across all AIs, with the greatest benefit (a
survival benefit of 12%) associated with the AIs in current clinical
use, namely anastrozole, exemestane and letrozole. However, data
on survival were only available for about half the women and one
of the trials (Buzdar 1996a) was not designed or powered to detect
significant differences in survival.
The positive effects of AIs in terms of tumour response were statis-
tically significant for first-line therapy where the comparator was
tamoxifen. There were no data available for other comparators.
When comparing the effect of the AI as second-line therapy there
was no statistically significant difference on tumour response. In
terms of progression-free survival, there was a statistically signifi-
cant decrease in hazard of progression for treatment with the AIs
as first-line therapy only. The paucity of data makes it difficult to
make any firm conclusions in terms of overall survival.
In terms of toxicity, AIs are known to be associated with a higher
incidence of nausea, diarrhoea, rash and arthralgia but a lower risk
of vaginal bleeding and thromboembolic events. However, com-
bining data across trials was difficult as both the toxicities reported
and the criteria for reporting toxicities, if reported at all, varied
greatly. We therefore did not have data on all predetermined tox-
icities with all comparators. Despite the inadequacies of the data,
our review corroborated the direction of the known side effects.
There was a higher incidence of hot flushes when compared toMA
but not to tamoxifen; nausea compared to MA but not tamoxifen
or fulvestrant; vomiting compared to MA but not tamoxifen or
fulvestrant; diarrhoea compared to tamoxifen and MA but not
fulvestrant; and rash compared to tamoxifen and MPA but not
MA or fulvestrant. The risk of vaginal bleeding was about 80%
lower with AI treatment and the incidence of thromboembolic
events halved. For arthralgia, there was no statistically significant
difference between the AIs and either tamoxifen or MA.
Overall completeness and applicability of
evidence
A lack of standardised reporting of clinical endpoints impacted
upon the analysis of all AIs, not just aminoglutethimide. There-
fore, it was not possible to include all trials in each section. This
reduced the power of certain analyses, especially overall and pro-
gression-free survival. In addition, many of the data required to
carry out analyses of prospectively identified subgroups, as set out
in the review protocol, were not available.We could not, therefore,
identify specific subgroups of women who may benefit from AI
use.
There are very limited data on quality of life reported in this set-
ting. The limited quality of life data which was reported did not
show any significant differences between the AI and comparator
groups; however, some differences were found with some subscales
in favour of the AI (Goss 1999; Kaufmann 2000). The patient’s
perspective in advanced disease treatment is an important end-
point and should be included in trials as it would aid interpreta-
tion in this mainly palliative setting.
Quality of the evidence
This review has combined data from a wide variety of trials that
were carried out over 20 years. Some of the trials did not use an AI
as a single agent but in combination with another endocrine ther-
apy. There was heterogeneity both across types of AI and within
each AI. The results of trials of three generations of AIs have
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been combined as well as results from trials of steroidal and non-
steroidal therapy. This has been forced, to some extent, by the lack
of data on individual AIs.
Within each AI, trials varied in terms of sample size, dose of AI,
comparison regimen, outcomes, length of follow up and qual-
ity of reporting. For example, the 11 trials of aminoglutethimide
consisted of between 62 and 313 patients; four of the trials were
of first-line therapy, five second-line, and two mixed. Doses of
aminoglutethimide used were 125 mg in one trial, 250 mg* in
three, 500 mg* in four, 750 mg in one, and 1000 mg in two (*
dose doubled after a specific period of treatment). The comparator
was tamoxifen in five trials (20 mg in three, 30 mg in one, 40 mg
in one), MA 160 mg in three trials, MPA 500 mg in one trial,
MPA 1000 mg in four trials, and HC 20 mg in one trial. Not
all endpoints were available in each trial and four reported overall
survival, three progression-free survival, eight clinical benefit, and
10 objective response.
Potential biases in the review process
If the descriptionof randomisation is used as a barometer of report-
ing trial quality, it appears that this has improved over time. For
example, in the trials of the first generation AI aminoglutethimide
six of 11 randomisations were categorised as unclear whereas only
two of the nine trials of third generation AI letrozole were consid-
ered as such.
Evidence of heterogeneity between trials was identified for tumour
response rates and progression-free survival though not overall sur-
vival. The reasons for this are unknown but this statistical het-
erogeneity might be explained by clinical heterogeneity. It may be
that outcomes involving the subjective endpoint, that is tumour
response, are subject to variation whereas the hard endpoint used
in the survival analysis is unequivocal. Other contributory factors
may be the difference in dosage of some AIs and significant dif-
ferences in the proportion of patients who were truly hormone
receptor positive.
Agreements and disagreements with other
studies or reviews
In September 2006, Mauri and colleagues published a paper en-
titled, “Survival with aromatase inhibitors and inactivators ver-
sus standard hormonal therapy in advanced breast cancer: meta-
analysis” Mauri 2006 which came to the same conclusion; that
is, “Inhibition of the AI system, in particular with third genera-
tion AIs, appears to be associated with statistically significant im-
proved survival of patients with advance breast cancer compared
with standard hormonal treatments”.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Historically, the treatment for advanced (metastatic) breast can-
cer has been with hormonal treatments such as tamoxifen or the
progestins MA orMPA. This review confirms a survival benefit of
treating advanced (metastatic) breast cancer with the third genera-
tion aromatase inhibitors (anastrozole, exemestane, and letrozole)
that are being used clinically today.
Implications for research
This review would benefit from additional publications with
greater survival details, that is median survival and number of
events, for those trials that did not publish them originally. Fur-
ther data from exemestane trials are required to evaluate this AI
more completely. Efforts should be made to standardise reporting
of toxicity and a quality of life component should also be included.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Alonso-Munoz 1988
Methods Spain, multicentre, N = 105, Dec 1982 - Dec 1985
Three arm trial (only two arms included in review N = 70)
Randomisation method not given
Baseline characteristics balanced
Participants Age range 37 - 75y
Proven metastatic breast cancer, measurable disease sites
No previous endocrine therapy
Interventions AG (500mg for 2w, then 100mg) versus TAM 40mg versus AG + TAM 40mg
Numbers in each treatment arm: 35 versus 35 versus 35
(AG+TAM arm data excluded from review N = 35)
Assessable patients (two included arms): 31 versus 34
Patients evaluable for toxicity (two included arms): 33 versus 34
Outcomes Toxicity, TTP, response rate
Not survival
Notes 11 not evaluable (4 AG, 6 TAM + AG, 1 TAM) due to: 4 died within 6w, 1 discontinued treatment, 5
toxicity, 1 lost to FU
FU duration not given
TTP not given by treatment arm
Risk of bias
Bias Authors’ judgement Support for judgement
Blinding?
All outcomes
High risk
Bezwoda 1998
Methods South Africa, multicentre, N = 96
Double-blind, double-dummy
Balanced block stratification by centre
Baseline slight imbalance in ER status: 28% versus 20% ER+
Participants Age range 44 - 82y
Measurable or evaluable metastatic breast cancer
Prior TAM treatment
No previous treatment with AI
ECOG perf status < 3
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Bezwoda 1998 (Continued)
Interventions Fadrozole 2mg versus MA 160mg
Numbers in each treatment arm: 46 versus 50
Assessable patients: 46 versus 50
Patients evaluable for toxicity: 46 versus 50
Treatment until progression or for 1y; median duration 20w
Outcomes Primary - response rate, TTP, TTF, survival
Secondary - QOL, performance status, pain assessment
Notes FU to relapse or death
Median FU not stated
Intention-to-treat analysis
Subsidiary analysis on a per protocol basis (41 versus 43)
7 major protocol violations, 2 refusals, 1 early death, 1 lost to FU (numbers not consistent)
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk balanced block stratification by centre
Allocation concealment? Low risk adequate
Blinding?
All outcomes
Low risk double-blind, double-dummy
Bonneterre 2001
Methods International, multicentre trial, combined results of two trials
Feb 1996 - July 1998
97 sites in US and Canada, N = 353
83 sites in Europe, Australia, New Zealand, South Africa, South Amercia, N = 668
Total randomised = 1021
Double-blind, double-dummy
Baseline characteristics well-balanced
Participants Age range 30 - 92y
Advanced or metastatic breast cancer
Interventions Anastrozole 1mg versus TAM 20mg
Numbers in each treatment arm: 171 versus 182 (N America) and 340 versus 328 (rest of world)
Assessable patients: 511 versus 510
Patients evaluable for toxicity: 506 versus 511
Treatment continued until disease progression
Outcomes Primary - objective response, TTP, tolerability
Secondary - TTF, survival
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Bonneterre 2001 (Continued)
Notes FU to progression and death
Median FU not known
Number of dropouts not given
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Low risk adequate
Blinding?
All outcomes
Low risk double-blind, double-dummy
Buzdar 1996a
Methods International, multicentre. 122 centres: 49 inNorth America, 73 in Europe, Australia, South Africa,
Double-blind anastrozole, open megestrol acetate
Randomisation method - blocks of 6 (Europe), blocks of 3 (N America), parallel groups
Two trials combined (N = 764): North America (N = 346) and Europe, Australia, South Africa (N
= 378)
Three-arm trial (only two arms included in review N = 516)
Baseline: apparent imbalance in one treatment group (believed to be artefact)
Participants Age range 29 - 97y
Advanced breast cancer
Progressed on anti-oestrogen for advanced disease or progressed on or during adjuvant TAM
WHO perf status < 3
Interventions anastrozole 1mg versus anastrozole 10mg versus MA 160mg
Numbers in each treatment arm: 263 versus 248 versus 253
(anastrozole 10mg arm excluded from review N = 248)
Assessable patients (two included arms): 263 versus 253
Patients evaluable for toxicity (two included arms): 262 versus 253
Treatment continued until disease progression or withdrawal from treatment for other reasons
Outcomes Primary - TTP, tumour response, tolerability
Secondary - TTF, response duration, survival
Clinical assessment every 4w until week 24, every 12w until week 48, then every 3m until progres-
sion
Notes FU median duration 6m
3 no treatment, 1 wrong treatment, 8 lost to FU
Intention-to-treat analysis
Risk of bias
Bias Authors’ judgement Support for judgement
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Buzdar 1996a (Continued)
Adequate sequence generation? Low risk blocks of 6 (Europe), blocks of 3 (N America),
parallel groups
Allocation concealment? Low risk adequate
Blinding?
All outcomes
Low risk double-blind anastrozole, openmegestrol acetate
Buzdar 1996b
Methods Protocol 03
Multicentre, 47 sites, N = 380
Feb 1989 - Dec 1991
Double-blind, parallel, controlled equivalence
Randomisation method not specified
Participants Age range 35 - 92y
Metastatic breast cancer
At least one prior hormonal treatment for metastic disease more than 3m previously
Prior AI use an exclusion
Performance status < 3
Interventions Fadrozole 2mg versus MA 160mg
Numbers in each treatment arm: 196 versus 184
Drug code broken 18m after end of enrolment
Assessable patients: 195 versus 184
Patients evaluable for toxicity: 196 versus 184
Treatment continued until disease progression
Outcomes Objective response rate, TTP, survival, toxicity, duration of response, survival, QOL
Notes Published together with protocol 06 (Buzdar 1996c)
FU until progression
Intention-to-treat analysis N = 379
1 patient excluded but included in safety and tolerability
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk randomisation method not specified
Allocation concealment? Low risk adequate
Blinding?
All outcomes
Low risk double-blind, parallel, controlled equivalence
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Buzdar 1996c
Methods Protocol 06
Multicentre, 55 sites, N = 303
Oct 1989 - Aug 1992
Double-blind, parallel, controlled equivalence
Randomisation method not specified
Participants Age range 36 - 92y
Metastatic breast cancer
At least one prior hormonal treatment for metastic disease more than 3m previously
Prior AI use an exclusion
Performance status<3
Interventions Fadrozole 2mg versus MA 160mg
Numbers in each treatment arm: 152 versus 151
Assessable patients: 150 versus 148
Patients evaluable for toxicity:152 versus 151
Drug code broken 18m after end of enrolment
Treatment continued until disease progression
Outcomes Primary - overall tumour response (TTP, TTF, survival)
Other - earliest diagnosis of PD, tolerability, safety, QOL
Notes Published together with protocol 03 (Buzdar 1996b)
FU: 33m for tumour response/safety (median 5.5m)
45m for survival (median 18 to 20m)
Intention-to-treat analysis N = 298
Not designed or powered to detect differences in survival
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk randomisation method not specified
Allocation concealment? Low risk adequate
Blinding?
All outcomes
Low risk double-blind, parallel, controlled equivalence
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Buzdar 2001
Methods International, multicentre, 120 sites in US, Canada, Europe, N = 602
Three-arm trial (only two arms included in review N = 400)
Double-blind, double dummy, phase III
Randomisation by country w/o stratification by centre
Enrolment over 30 months
Baseline characteristics no imbalance
Participants Age range not given
Locally advanced/locoregionally recurrent/metastatic breast cancer
At least one measurable/assessable lesion
Relapsed or progressed while on anti-oestrogen or relapsed within 12m of stopping antioestrogen
Chemotherapy for advanced disease allowed
KPF >=50%
Interventions Letrozole 2mg versus letrozole 10mg versus MA 160mg
Numbers in each treatment arm: 202 versus 199 versus 201
(letrozole 2mg arm excluded from review N = 202)
Assessable patients: 182 versus 180
Patients evaluable for toxicity: 199 versus 201
Treatment continued until disease progression or withdrawal for other reason
Outcomes Primary - tumour response
Secondary - TTF, TTP, survival, QOL
Notes FU period 48m after the first visit of the last patient randomised
Intention-to-treat analysis
23 ineligible and excluded from tumour analyses
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk randomisation by country w/o stratification by
centre
Allocation concealment? Low risk adequate
Blinding?
All outcomes
Low risk double-blind, double-dummy
Canney 1988
Methods UK, number of centres not given, N = 218
Randomised without stratification, performed centrally by phone over 24m
Participants Median age 64y
Actively progressive disease
Received hormonal therapy with tamoxifen
Received no anticancer therapy within preceding 4w
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Canney 1988 (Continued)
Interventions AG (250mg for 2w, increased to 500mg if not toxic effect plus 40mg HC) versus high dose MPA 1000mg
Numbers in each treatment arm: 106 versus 112
Patients evaluable for toxicity: 106 versus 112
Outcomes Duration of response, survival, time to response
Notes FU duration: minumum 9m, median 55w for AG, 57w MPA
7 patients either violated protocol or did not meet entry criteria but included in analyses
Crossover on failure
No variation between groups in known prognostic variables
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Low risk performed centrally by phone
Chia 2008
Methods International, multicentre, 138 centres, N = 693
Aug 2003 - Nov 2005
Double-blind, double-dummy, phase III
Trial acronym = EFECT
Randomisation method not given
Baseline characteristics well balanced except for ER+/PR+ ( 56.4% versus 67.5%)
Participants Age range 32 -91y
Locally advanced or metastatic disease
Disease progression after prior non-steroidal AI treatment
At least one measurable or assessable lesion
ER+/PR+
WHO perf status < 3
Interventions Exemestane 25mg versus fulvestrant 500mg on day 0, 250mg on days 14 and 28, followed by 250mg
every four weeks
Numbers in each treatment arm: 342 versus 351
Assessable patients: 270 versus 270
Treatment continued until disease progression
Outcomes Primary - TTP
Secondary - objective response, CB, response duration, TTF, overall survival, tolerability, QOL
Notes FU until death
Intention-to-treat analysis
90% power to detect HR≥1.31
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Chia 2008 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Blinding?
All outcomes
Low risk double-blind, double-dummy
Dombernowsky 1998
Methods International, multicentre, Mar 1993 - Sep 1994
10 countries, 91 sites, N = 551
Three-arm trial (only two arms included in review N=363)
Double-blind, randomisation stratified by country; computer-generated permuted blocks of size 6
or 3, 1:1:1 allocation
Baseline characteristics balanced
Participants Advanced/locoregionally recurrent/metastatic breast cancer
Measurable/assessable disease
Failure to respond to previous antioestrogen
WHO perf status < 3
Interventions Letrozole 0.5mg versus letrozole 2.5mg versus MA 160mg
Numbers in each treatment arm: 188 versus 174 versus 189
(letrozole 0.5mg arm excluded from review N = 188)
Assessable patients: 153 versus 166
Patients evaluable for toxicity: 174 versus 189
Outcomes Primary - overall tumour response (TTP, TTF, survival)
Other - earliest diagnosis of PD, tolerability, safety
Notes FU: 33m for tumour response/safety (median 5.5m)
45m for survival (median 18 to 20m)
Intention-to-treat analysis
Not designed or powered to detect differences in survival as significant
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk stratified by country; computer-generated per-
muted blocks of size 6 or 3, 1:1:1 allocation
Allocation concealment? Low risk adequate
Blinding?
All outcomes
Low risk double-blind
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Falkson 1996
Methods South Africa, single centre, N = 80
Sep 1991 - Dec 1994
Randomisation method not given
Baseline: difference of 10y in median age of patients in arm 1 versus arm 2
Participants Age range 43 - 90y
Progressive, inoperable, recurrent or metastatic breast cancer
No prior treatment for advanced disease
ECOG perf status < 3
Interventions Fadrozole 2mg versus TAM 20mg
Numbers in each treatment arm: 40 versus 40
Assessable patients: 36 versus 38
Patients evaluable for toxicity: 40 versus 40
Minimum treatment 8w
Outcomes Survival, TTF, duration of overall response, toxicity, objective response rates
Notes FU 14 to 1122d, median FU 153d
Intention-to-treat analysis
2 ineligible, 1 lost to FU
74 patients evaluable
Freue 2000
Methods International, multicentre, 9 countries, 78 centres, N = 547
Aug 1991 - Mar 1995
Computer-generated random allocation w/o stratification
Open study
No difference in baseline characteristics
Participants Age range not given
Advanced disease
Measurable disease
ER/PR positive or unknown
WHO perf status < 3
Only TAM as 1st line endocrine therapy
Interventions Formestane 250mg im every 2w versus MA 160mg
Numbers in each treatment arm: 276 versus 271
Assessable patients: 242 versus 237
Numbers for safety analysis: 276 versus 271
Treatment duration 12m
Outcomes TTF, TTP, overall survival, overall response
Notes FU until death
Median FU not given
90% power to detect 33% difference in median TTF
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Freue 2000 (Continued)
Intention-to-treat analysis
Ineligible/non-evaluable: 34 versus 34
Non-cancer deaths: 2 versus 4
Discontinued for AE: 3 versus 13
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk computer-generated random allocation without
stratification
Allocation concealment? Low risk adequate
Blinding?
All outcomes
High risk open
Gale 1994
Methods ECOG trial, multicentre, US, N = 249
1977 - 1983
Stratified randomly permuted blocks of four
Baseline characteristics relatively evenly balanced
One institution had 60% versus 4% response rates
Participants Age range not given
Progressive, recurrent, metastatic breast cancer
Measurable disease
ECOG perf status < 4
No previous treatment with AG or TAM
Interventions AG 250mg qid versus TAM 20mg
Numbers in each treatment arm: 122 versus 119
Assessable patients: 108 versus 108
Outcomes Tumour response, TTF, overall survival
Notes Initial trial design changed in May 1979 (adrenalectomy treatment arm discontinued)
Crossover on progression
Crossover results not included
Intention-to-treat analysis
Adrenalectomy patients (N = 8) were excluded
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk stratified randomly permuted blocks of four
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Gale 1994 (Continued)
Allocation concealment? Low risk adequate
Garcia-Giralt 1992
Methods France, multicentre, N = 257
No randomisation details
Participants Age range 36 - 91y
Histologically confirmed metastatic breast cancer
ER+/PR+
Initial response to TAM before relapse
Interventions AG 500mg + HC versus MPA 1000mg
Numbers in each treatment arm: 131 versus 119
Assessable patients: 124 versus 112
Second-line therapy after TAM
Outcomes Tumour response, TTP, new metastases, AEs
Notes Median FU not known
Treatment until progression
Crossover on progression
6 lost to FU, 1 man
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk not used
Gershanovich 1998
Methods International, multicentre, 11 countries, 86 sites N = 555
Three-arm trial (only two arms included in review N = 363)
Open-label 1:1:1
Baseline no major differences
Participants Median age letrozole 2.5mg 66y, letrozole 0.5 mg 64y, AG 65y
Advanced or metastatic breast cancer
Measurable/evaluable advanced disease
WHO perf status < 3
Interventions Letrozole 2.5mg versus letrozole 0.5mg versus AG 500 mg
Numbers in each treatment arm: 185 versus 192 versus 178
(letrozole 2.5mg arm excluded from review N = 192)
Assessable patients: 173 versus 162
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Gershanovich 1998 (Continued)
Outcomes Response, TTP, TTF, survival, tolerability and safety, overall survival
Notes FU duration median > 20m
44 not assessable, counted as non-responders in the analysis
Median duration of treatment 5m
Modified intention-to-treat population ie enrolled and received trial medication
Risk of bias
Bias Authors’ judgement Support for judgement
Blinding?
All outcomes
High risk
Goss 1999
Methods Nov 1991 - Dec 1995
Multicentre, 29 sites in Canada and 38 in US, N = 452
Open-label, stratified by disease status
Baseline characteristics comparable
Participants Age range 39 - 90y
Advanced breast cancer, histologically confirmed
Progressed after tamoxifen treatment
Interventions Vorozole 2.5mg versus MA 160mg
Numbers in each treatment arm: 225 versus 227
Assessable patients: 190 versus 185
Patients evaluable for toxicity: 195 versus 198
2nd line treatment after tamoxifen
Outcomes Primary - response rate
Secondary - TTP, survival, duration of response, safety subjective symptoms, QOL
Notes Median FU 11.6m (vorozole), 9.9m (MA)
1 withdrawn before treatment
4 ineligible, 18 adverse events, 1 lost to FU, 18 other
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk stratified by disease status
Allocation concealment? Low risk adequate
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Goss 1999 (Continued)
Blinding?
All outcomes
High risk open-label
Goss 2007
Methods Multinational, multicentre, 60 centres in US, Canada, Russia, Ukraine, N = 865
Randomised, double-blind, active control, phase III
Randomisation in blocks of four, stratified by centre. Performed centrally, site notified by fax
Treatment code unblinded after database lock
Baseline characteristics well balanced
Participants Median age letrozole 63y atamestane 65y
Locally recurrent/advanced/ metastatic disease
Measurable disease
No AI or antioestrogen/SERM treatment in previous 12m
ECOG perf status < 3
Interventions Letrozole 2.5mg versus atamestane 500mg + toremifene 60mg
Numbers in each treatment arm: 431 versus 434
Assessable patients: 297 versus 298
Outcomes Primary - TTP
Secondary - overall survival, TTF, tumour response, toxicity
Notes FU to death
Intention-to-treat analysis
Treatment continued until disease progression or withdrawal for other reasons
80% power to detect a 24% increase in TTP
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk blocks of four, stratified by centre
Allocation concealment? Low risk performed centrally, site notified by fax
Blinding?
All outcomes
Low risk double-blind
Ingle 1986
Methods US, number of centres not known, N = 102
Randomised using Pocock-Simon approach to adaptive randomisation, stratified
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Ingle 1986 (Continued)
Participants Age range 38 - 83y
Progressive metastatic disease
Measurable or evaluable lesion
ECOG perf status < 4
No prior therapy with either AG or TAM
Interventions TAM 20mg versus TAM (20mg) + AG (500mg for 2 weeks then 1000mg) + HC (100mg daily for
2 weeks then 40mg)
Numbers in each treatment arm: 49 versus 51
Assessable patients:49 versus 51
Patients evaluable for toxicity: 48 versus 46
Outcomes Objective response, TTP, survival, toxicity
Notes No data on duration of FU
Target accrual = 160 but terminated early due to excess toxicity on the TAM + AG + HC arm
2 patients ineligible
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk used Pocock-Simon approach to adaptive ran-
domisation, stratified
Kaufmann 2000
Methods International, multicentre, Oct 1995 - May 1998
19 countries, 144 centres N = 769
Double-blind, parallel-group, phase III
Baseline characteristics comparable
Participants Age range 30 - 91y
Advanced breast cancer
Progressed or relapsed during tamoxifen treatment
Interventions Exemestane 25mg versus MA 160mg
Numbers in each treatment arm: 366 versus 403
Assessable patients: 337 versus 366
Patients evaluable for toxicity: 358 versus 400
Outcomes Objective response, TTP, TTF, survival, tumour response, duration of tumour control, tumour related
signs and symptoms, QOL, tolerability
Notes FU median duration 48.9w
6 randomised but not treated
66 not evaluable for tumour response
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Kaufmann 2000 (Continued)
Intention-to-treat analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Low risk adequate
Blinding?
All outcomes
Low risk double-blind
Kleeberg 1997
Methods International, multicentre, 27 Jun - 1 Dec 1995
18 centres, Europe and South Africa, N = 60
open-label, parallel-group, comparative
Baseline good balance re age, weight, prior tamoxifen treatment
Participants Age range 40 - 84y
Advanced breast cancer
Measurable or evaluable disease
Interventions Anastrozole 1mg oral per day versus formestane 250mg im every 2w
Numbers in each treatment arm: 29 versus 31
Assessable patients: 29 versus 31
Treatment until disease progression
Outcomes Primary - oestradiol suppression and tolerability
Secondary - response rates, TTP, adverse events, blood oestrone sulphate, patient and doctor perception
of treatment
Notes No details re randomisation exclusions or FU
Not powered to detect clinically significant difference in oestrogen suppression between the two arms
Risk of bias
Bias Authors’ judgement Support for judgement
Blinding?
All outcomes
High risk open-label
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Leitzel 1995
Methods Location and date of trial not given
Multicentre, N = 300
Double-blind, double-dummy, parallel
Randomisation method not given
Participants Age range 18 - 85y
Metastatic breast cancer
ECOG < 3
Interventions Fadrozole 2mg versus MA 160mg
Numbers in each treatment arm not given
Duration of intervention not given
Second-line treatment
Outcomes Tumour response, progression, c-erbB-2 antigen in serum
Notes FU until death
Results not given by treatment group
Survival was not given by treatment group although it was measured
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Low risk adequate
Blinding?
All outcomes
Low risk double-blind, double-dummy
Lundgren 1989
Methods Norway, multicentre, N = 176
Randomisation without stratification, details not given
Baseline characteristics well balanced for most important prognostic variables, except main
metastatic site
Participants Mean age 62.0y versus 62.7y
Advanced breast cancer
Evaluable disease
Previous treatment with TAM
KPS >50
Interventions AG 250mg bid for 2w then 250mg qid versus MA 160mg
Numbers in each treatment arm: 86 versus 90
Assessable patients: 76 versus 74
Second-line treatment
Outcomes Response rate, reponse duration, survival, toxicity
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Lundgren 1989 (Continued)
Notes Intention-to-treat analysis
Excluded patients: 10 protocol violations/patient refusal; 12 early deaths; 4 adverse events
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk randomisation without stratification, details not
given
Allocation concealment? Unclear risk not used
Mauriac 2003
Methods Data were combined and published from two trials 0020 and 0021 (May 1997 - September 1999)
Trial 0020: multicentre, phase III, open, parallel group
Europe, Australia and South Africa, 83 centres, N = 451
Trial 0021: multicentre, phase III, double-blind, double-dummy, parallel group
North America, N = 400
Combined data from both trials included in review N = 851
Participants Age range 33 - 89y
Locally advanced or metastatic breast cancer
Progressed during adjuvant endocrine therapy or first-line therapy for advanced disease
WHO performance status < 3
Interventions Anastrozole 1mg versus fulvestrant 250mg/month im
Trial 0020: numbers in each treatment arm: 222 versus 229
Trial 0021: numbers in each treatment arm: 206 versus 194
Combined trials (included in review): numbers in each treatment arm: 423 versus 428
Assessable patients: 423 versus 428
Patients evaluable for toxicity: 423 versus 423
Continued until objective disease progression or other events required withdrawal
Outcomes TTP, objective response, tolerability, QOL
Notes Median FU 15.1m (combined data)
Intention-to-treat analysis
Additional to protocol: non-inferiority of fulvestrant with anastrozole was carried out retrospectively
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Low risk adequate
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Mauriac 2003 (Continued)
Blinding?
All outcomes
Low risk Trial 0020 open
Trial 0021 double-blind
Mercer 1993
Methods UK, query single-centre, Jan 1987 - Dec 1990, N = 61
No information regarding randomisation
Groups well matched but after exclusions numbers small
Participants Eligibility >50y
Age range 45 - 86y
Advanced breast cancer
Progressive disease on tamoxifen (adjuvant or treatment)
Interventions Low dose AG 125mg versus HC 20mg
Number in each treatment arm: 28 versus 33
Assessable patients: 27 versus 29
Outcomes Tumour response, TTF, side-effects, overall survival
Notes FU details not given
5 patients excluded
Milla-Santos 2003
Methods Spain, single-centre, N = 238, May 1997 - Dec 1999
Randomisation following Meinert’s methodology.
Baseline characteristics comparable
Participants Age range 55 - 77y
Histologically confirmed advanced breast cancer, measurable disease sites
No previous endocrine therapy
ECOG<3
Interventions Anastrozole 1mg versus TAM 40mg
Numbers in each treatment arm: 121 versus 117
Assessable patients: 121 versus 117
Outcomes Primary - response rates, clinical benefit, TTP in patients achieving a CB, overall survival, toxicity
Notes FU to 35m
intention-to-treat analysis
All patients evaluable
Analysis cutoff 1 April 2001
Risk of bias
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Milla-Santos 2003 (Continued)
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk randomisation followingMeinert’smethodology
Mourisden 2001
Methods International, multicentre, Nov 1996 - Jan 1999
29 countries, 201 sites, N = 939
Double-blind, double-dummy, parallel group
Baseline characteristics well balanced
Participants Age range 31 - 96y
Locally advanced/locoregionally recurrent/metastatic breast cancer which is measurable/assessable
Previous chemotherapy allowed for advanced disease
WHO perf status < 3
Interventions Letrozole 2.5mg versus TAM 20mg
Numbers in each treatment arm: 453 versus 454
Assessable patients: 421 versus 423
Patients evaluable for toxicity: 455 versus 455
Treatment continued until disease progression
Outcomes Primary - TTP
Secondary - tumour response rate, TTF, ORR, survival, tolerability, KPS
Notes FU median 32m
Intention-to-treat analysis
907 analysed, 32 excluded
Analysis cutoff March 2000
Survival not reported
729 discontinued treatment of which 391 ’crossed over’
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Low risk adequate
Blinding?
All outcomes
Low risk double-blind, double-dummy
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Paridaens 2003
Methods International, multicentre, October 96 - May 99
13 centres in 6 countries, N = 122
Open-label phase II, randomised centrally using minimisation by EORTC, stratified by centre,
adjuvant TAM, CT for metastatic disease, dominant disease site
The trial was designed as a randomised phase II trial not to enable comparison of the efficacy of
the two drugs but to establish a ’go, no-go’ rule for exemestane activity and safety before a formal
randomised phase III trial. Patients randomised into the phase II trial will be incorporated into the
phase III trial
Participants Age range 37 - 87y
Measurable metastatic or locally recurrent inoperable breast cancer
No prior hormone therapy for metastatic disease
ECOG perf status < 3
Interventions Exemestane 25mg versus TAM 20mg
Numbers in each treatment arm: 62 versus 60
Intention-to-treat analysis: 61 versus 59
Toxicity data: 62 versus 59
Assessable patients: 56 versus 57
Patients evaluable for toxicity: 62 versus 59
Treatment continued until disease progression
Outcomes Response rates
Stop-go for phase III
Phase II therefore inadequate power, no statistical comparison of efficacy of endpoints between the
two treatments were planned or performed
Notes FU details
2 patients (1 exemestane, 1 TAM) ineligible as not having metastatic breast cancer, 7 additional (5
exemestane, 2 TAM) not evaluable for response, 1 lost to FU
Phase II patients to be included in phase III trial
Intention-to-treat analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk stratified by centre, randomised centrally by
EORTC using minimisation
Allocation concealment? Low risk adequate
Blinding?
All outcomes
High risk open-label
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Perez Carrion 1994
Methods International, multicentre, May 1988 - December 1990, N = 409
Open study, equivalence trial
Baseline characteristics well matched
Participants Age range 38 - 87y
WHO perf status < 3
Interventions Formestane 250mg im versus TAM 30mg
Numbers in each treatment arm: 203 versus 206
Assessable patients: 173 versus 175
Outcomes Response, survival, TTP, TTF, tolerability
Notes FU details not reported
61 patients not evaluable, 10 lost to FU, 3 refusals
Intention-to-treat analysis
Trial closed early due to changes in clinical practice, ie increasing use of TAM in the adjuvant setting
Risk of bias
Bias Authors’ judgement Support for judgement
Blinding?
All outcomes
High risk open
Powles 1984
Methods Sept 1979 - June 1983
UK, single-centre, N = 222
Previously determined allocation list unknown to clinician.
Baseline characteristics mean age marginally greater for TAM patients
Participants Patients with disseminated breast cancer who had not previously received TAM, AG, or danazol
No endocrine or chemotherapy within 6w
Interventions TAM 20mg versus TAM 20mg + AG 750mg + danazol 300mg + HC 40mg
Number on each treatment arm: 111 versus 111
Assessable patients: 99 versus 99
Patients evaluable for toxicity: 111 versus 111
Treatment continued until 3m assessment (unless rapid development of tumour in meantime) otherwise
stopped when evidence of tumour progression arose either through failure to respond or because of relapse
after response or stabilisation of disease
Outcomes Tumour response
Notes FU duration not reported
Risk of bias
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Powles 1984 (Continued)
Bias Authors’ judgement Support for judgement
Allocation concealment? Low risk previously determined allocation list unknown to
clinician
Rose 1986
Methods Denmark, multicentre, June 1979 - Sept 1988, 4 centres N = 313
Three-arm trial (only two arms included in review N = 215)
Randomised by centre, non-stratified, stochastic array of numbers, closed envelope system
Baseline characteristics well balanced
Participants Age > 65y, age range 66 - 84y
First recurrence of metastatic breast cancer
Progressive disease with measurable and/or evaluable lesions
Performance status < 4
Interventions TAM 30mg versus TAM 30mg + AG 250mg qid + HC 60mg v TAM 30mg + fluoxymesterone
20mg
Numbers in each treatment arm: 108 versus 107 versus 98
(TAM + fluoxymesterone excluded from review N = 98)
Assessable patients: 83 versus 94
Patients evaluable for toxicity: 87 versus 97
Treatment until progression (minimum 12 weeks)
Outcomes TTF, TTP, survival, toxicity
Notes FU duration not reported
34 ineligible
21 not evaluable
9 lost to FU
258 fully evaluable
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk randomised by centre, non-stratified, stochastic
array of numbers
Allocation concealment? Low risk closed envelope system
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Rose 2003
Methods International phase IIIb/IV, 19 countries, multicentre, 112 sites, N = 713
Dec 1997 - Nov 1999
Open, random assignation stratified by centre via predetermined randomisation list
Baseline characteristics well balanced
Participants Age range 27 - 92y
Advanced or metastatic breast cancer with measurable and/or evaluable disease
Histologically/cytologically confirmed
Previous treatment with antioestrogen
WHO performance status 0-2
Interventions Letrozole 2.5mg versus anastrozole 1mg
Numbers in each treatment arm: 356 versus 357
Assessable patients: 299 versus 304
Outcomes Primary - TTP
Secondary- objective response, duration of response, rate and duration of overall clinical benefit,
overall survival, general safety
Notes FU duration not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk random assignation stratified by centre
Allocation concealment? Low risk predetermined randomisation list
Blinding?
All outcomes
High risk open-label
Russell 1997
Methods May 1984 - November 1990, Phase III, N = 288
Three-arm trial (only two arms included in review N = 155)
No stratification
Treatment arms reasonably well balanced
Participants Age range 33 - 92y
Progressive metastatic disease
Measurable or evaluable lesion
Patients had received TAM in advanced setting
No prior MA or AG
Interventions MA 160mg versus AG (500mg for 2w then 1000mg) + HC (100mg for 2w then 40mg) versus MA
160mg + AG (500mg for 2w then 1000mg) + hydrocortisone
Numbers in each treatment arm: 75 versus 80 versus 80
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Russell 1997 (Continued)
(MA 160mg + AG (500mg for 2w then 1000mg) + hydrocortisone arm data excluded from review
N = 80)
Assessable patients: 42 versus 32
Patients evaluable for toxicity: 88 versus 89
Outcomes Response, TTF, survival, toxicity
Notes FU median duration amongst those still alive = 5.2y (213 had died)
53 ineligible (38 re misunderstanding re prior TAM use,7 due to life threatening visceral involve-
ment, 3 with less than 6 months of TAM, 2 ER -, 1 prior hormonal therapy other than TAM, 1
no confirmed disease sites)
Patients on MA or AG alone were crossed over after progression
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk no stratification
Samonis 1994
Methods Greece, single-centre, N = 85
trial duration 2.5y
Three-arm trial (only two arms included in the review N = 57)
Stratified randomisation - statified into four groups by previous adjuvant treatment
Table of baseline characteristics
Participants Age range 50 - 73y
Metastatic breast cancer
Measurable disease
No previous treatment with AG or MPA
KPS > 70%
Interventions AG (250mg for 3d, then to 1000mg) versus MPA (500mg for 1m then twice weekly) versus AG +
MPA
Numbers in each treatment arm:28 versus 29 versus 28
(AG + MPA data excluded from review)
Assessable patients (two included arms): 26 versus 27
Outcomes Response to treatment, toxicity
Notes FU duration not given
Excluded patients: 1 accidental death, 4 lost to FU
Risk of bias
Bias Authors’ judgement Support for judgement
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Samonis 1994 (Continued)
Adequate sequence generation? Unclear risk statified into four groups by previous adjuvant
treatment
Schmid 2001
Methods International, multicentre, N = 171
Three-arm trial (only two arms included in review N = 112)
Double-blind
Participants Mean age 64.5
Advanced breast cancer with bone metastases
Interventions Letrozole 2.5mg versus letrozole 0.5mg versus MA 160mg
Number in each treatment arm: 52 versus 59 versus 60
(letrozole 0.5mg arm excluded from review N = 59)
Assessable patients: 48 versus 53
Outcomes Objective response, clinical benefit, TTP, survival
Notes Publication only available as abstract but sufficient data to include
Risk of bias
Bias Authors’ judgement Support for judgement
Blinding?
All outcomes
Low risk double-blind
Thuerlimann 1996
Methods Switzerland, Phase III multicentre, 7 sites, N = 221
June 1988 - Dec 1994
Phone randomisation, stratified, minimisation not double blind
Baseline: prognostic factors well balanced apart from metastatic site
Participants Age range 39 - 87y
Measurable/evaluable advanced breast cancer
Indication for hormone treatment
ECOG < 2
Interventions Fadrozole 2mg versus TAM 20mg
Numbers in each treatment arm: 111 versus 110
Eligible patients: 105 versus 107
Assessable patients: 103 versus 106
Patients evaluable for toxicity: 104 versus 107
First-line treatment
Treatment until progression
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Thuerlimann 1996 (Continued)
Outcomes TTF, response rate, toxicity, overall survival, TTP, subjective benefit (not reported), duration of
response
Notes FU 7½ y
Eligible patients: 212
9 ineligible(6 fadrozole, 3 TAM)
12 withdrawals
Crossover only after failure so not analysed
Analysis on data to Dec 1995, median FU of survivors 3y
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk minimisation, stratified
Allocation concealment? Low risk phone randomisation
Blinding?
All outcomes
Unclear risk not double blind
Thuerlimann 1997
Methods Feb 1991 - Jun 1995, N = 179
Stratified, central randomisation
Baseline characteristics well balanced (only difference in weight)
Participants Age range 43 - 87y
Advanced breast cancer
Histologically and/or cytologically proven with measurable/evaluable disease
Failed prior adjuvant and/or palliative tamoxifen treatment ie second-line treatment
Prior chemotherapy allowed
ECOG perf status < 3
Interventions Formestane 250mg im (biweekly) versus MA 160mg
Numbers in each treatment arm: 91 versus 86
Assessable patients: 90 versus 83
Patients evaluable for toxicity: 90 versus 81
Outcomes TTF, toxicity
Notes FU duration not reported
2 ineligible, 4 dropouts
173 fully evaluable
After failure of randomised treatment 75 patients ’crossed over’
Risk of bias
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Thuerlimann 1997 (Continued)
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk stratified
Allocation concealment? Low risk central randomisation
Tominaga 2003
Methods Japan, multicentre, 62 sites, N = 157
Double-blind, double-dummy, parallel groups
Adaptive dynamic balancing method
Participants Mean age 59.7y (letrozole) and 61.0y (fadrozole)
Advanced disease
Measurable or assessable pathological lesions
Interventions Letrozole 1mg versus fadrozole 2mg
Numbers in each treatment arm: 79 versus 78
Assessable patients: 77 versus 77
Minimum 8w treatment
Treatment until disease progressed or patient experienced toxicity resulting in discontinuation
Outcomes ORR, safety of letrozole compared to fadrozole
Notes FU median 13.3m
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk adaptive dynamic balancing method
Allocation concealment? Low risk adequate
Blinding?
All outcomes
Low risk double-blind
KPS - Karnofsky Performance Status
AG - aminoglutethimide
AI - aromatase inhibitor
CB - clinical benefit
ECOG - Eastern Cooperative Oncology Group
EORTC - European Organization for the Research and Treatment of Cancer
ER - oestrogen receptor
FU - follow up
im - intramuscular
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mg - milligram
TAM - tamoxifen
MA - megestrol acetate
MPA - medroxy progesterone acetate
HC - hydrocortisone
N - number of patients
ORR - objective response rate
PD - progressive disease
perf status - performance status
qid - four times daily
QOL - quality of life
TTF - time to failure
TTP - time to progression
d - days
w - weeks
m - months
y - years
WHO - World Health Organisation
w/o - without
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abe 2002 dose comparison of same AI (letrozole)
Bajetta 1994 dose comparison of same AI (formestane)
Bajetta 1997 dose comparison of same AI (exemestane)
Bajetta 1997a dose comparison of same AI (letrozole)
Bajetta 1999 dose comparison of same AI (letrozole)
Beretta 1990 dose comparison of same AI (letrozole)
Bruning 1989 dose comparison of same AI (aminoglutethimide)
Bruning 1990 dose comparison of same AI (aminoglutethimide)
Castelazo 2004 non-English (Spanish) paper
Cataliotti 2006 comparison of anastrozole versus tamoxifen as neoadjuvant treatment
Dixon 2000 dose-comparison of same AI (anastrozole)
Dowsett 1989 dose-comparison of same AI (formestane)
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(Continued)
Dowsett 1990 dose-comparison of same AI (fadrozole)
Dowsett 1994 dose-comparison of same AI (fadrozole)
Dowsett 1995 dose-comparison of same AI (letrozole)
Eiermann 2001 comparison of letrozole versus tamoxifen as pre-operative treatment
Geisler 1996 outcome: aromatase levels and plasma oestrogen levels
Geisler 2002 outcome: aromatase levels and plasma oestrogen levels
Ingle 1997 dose comparison of same AI (letrozole)
Johnston 1994 dose comparison of same AI (vorozole)
Miller 1996b dose comparison of same AI (fadrozole)
Pronzato 1993 AI (aminoglutethimide) versus same AI plus tamoxifen
Raats 1992 dose comparison of same AI (fadrozole)
Smith 2005 comparison of anastrozole versus tamoxifen as neoadjuvant treatment
Svenstrup 1994 dose comparison of same AI (fadrozole)
Wang 2003 non-English (Chinese) paper
Characteristics of ongoing studies [ordered by study ID]
CAAN
Trial name or title CAAN
Methods
Participants Target accrual = 90 postmenopausal women with histologically proven advanced breast cancer
Interventions Exemestane + celecoxib versus exemestane versus letrozole
Outcomes Levels of serum lipids and cholesterol
Starting date February 2002
Contact information LWC Chow
lwcchow@hkucc.hku.hk
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CAAN (Continued)
Notes initial report published in 2005
ECOG E4101
Trial name or title ECOG E4101
Methods
Participants Target accrual = 148 postmenopausal women with HR+ metastatic breast cancer previously treated with up
to two chemotherapy regimens and/or one prior endocrine therapy
Interventions Faslodex + gefitinib versus arimidex + gefitinib
Outcomes
Starting date
Contact information Dr RW Carlson or AstroZeneca
Notes currently recruiting in the USA
ICR-CTSU Sofea
Trial name or title Sofea
Phase III
Methods
Participants Target accrual = 750 women with metastatic disease who have failed after non-steroidal AI
Interventions Faslodes versus faslodex + anastrozole versus exemestane
Outcomes
Starting date March 2004
Contact information Dr SRD Johnston, Royal Marsden Hospital email: sofea-icrctsu@icr.ac.uk
Notes Open to recruitment in UK
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Paridaens 2003
Trial name or title Phase III EORTC-10951
Methods
Participants Postmenopausal women with metastatic and progressive disease or locally recurrent and inoperable
Interventions exemestane versus tamoxifen
Outcomes
Starting date
Contact information robert.paridaens@uz.kuleven.ac.be
Notes phase II to phase III study
HR+ HER positive
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D A T A A N D A N A L Y S E S
Comparison 1. AI versus non-AI
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall survival (reported or
calculated)
13 HR (Fixed, 95% CI) 0.90 [0.84, 0.97]
1.1 aminoglutethimide (any
dose)
4 HR (Fixed, 95% CI) 0.94 [0.80, 1.12]
1.2 anastrozole 1 mg 3 HR (Fixed, 95% CI) 0.90 [0.79, 1.03]
1.3 exemestane 25 mg 1 HR (Fixed, 95% CI) 0.85 [0.72, 0.99]
1.4 fadrozole 2 mg 2 HR (Fixed, 95% CI) 1.04 [0.77, 1.40]
1.5 letrozole 2.5 mg 2 HR (Fixed, 95% CI) 0.88 [0.73, 1.05]
1.6 vorozole 2.5 mg 1 HR (Fixed, 95% CI) 1.10 [0.49, 2.47]
2 Progression-free survival
(reported or calculated)
11 HR (Random, 95% CI) 0.98 [0.84, 1.13]
2.1 aminoglutethimide (any
dose)
2 HR (Random, 95% CI) 1.07 [0.73, 1.55]
2.2 formestane 250 mg 1 HR (Random, 95% CI) 0.93 [0.68, 1.28]
2.3 anastrozole 1 mg 2 HR (Random, 95% CI) 1.05 [0.65, 1.70]
2.4 exemestane 25 mg 2 HR (Random, 95% CI) 0.91 [0.72, 1.14]
2.5 letrozole 2.5 mg 3 HR (Random, 95% CI) 0.87 [0.68, 1.11]
2.6 vorozole 2.5 mg 1 HR (Random, 95% CI) 1.27 [1.04, 1.56]
3 Clinical benefit (assessable) 27 8789 Odds Ratio (M-H, Random, 95% CI) 0.87 [0.77, 0.99]
3.1 aminoglutethimide (any
dose)
9 1292 Odds Ratio (M-H, Random, 95% CI) 0.79 [0.63, 1.00]
3.2 formestane 250 mg 2 521 Odds Ratio (M-H, Random, 95% CI) 1.05 [0.59, 1.86]
3.3 anastrozole 1 mg 4 2626 Odds Ratio (M-H, Random, 95% CI) 0.74 [0.48, 1.12]
3.4 exemestane 25 mg 3 1356 Odds Ratio (M-H, Random, 95% CI) 0.86 [0.63, 1.19]
3.5 fadrozole 2 mg 4 982 Odds Ratio (M-H, Random, 95% CI) 1.05 [0.80, 1.38]
3.6 letrozole 2.5 mg 4 1637 Odds Ratio (M-H, Random, 95% CI) 0.77 [0.60, 1.00]
3.7 vorozole 2.5 mg 1 375 Odds Ratio (M-H, Random, 95% CI) 1.35 [0.88, 2.07]
4 Objective response (assessable) 31 9595 Odds Ratio (M-H, Random, 95% CI) 0.88 [0.77, 1.01]
4.1 aminoglutethimide (any
dose)
11 1545 Odds Ratio (M-H, Random, 95% CI) 0.83 [0.63, 1.09]
4.2 formestane 250 mg 3 1000 Odds Ratio (M-H, Random, 95% CI) 1.23 [0.92, 1.64]
4.3 anastrozole 1 mg 4 2626 Odds Ratio (M-H, Random, 95% CI) 0.95 [0.77, 1.17]
4.4 exemestane 25 mg 3 1356 Odds Ratio (M-H, Random, 95% CI) 0.67 [0.33, 1.33]
4.5 fadrozole 2 mg 5 1056 Odds Ratio (M-H, Random, 95% CI) 1.18 [0.85, 1.65]
4.6 letrozole 2.5 mg 4 1637 Odds Ratio (M-H, Random, 95% CI) 0.65 [0.51, 0.82]
4.7 vorozole 2.5 mg 1 375 Odds Ratio (M-H, Random, 95% CI) 0.70 [0.34, 1.42]
5 Clinical benefit (randomised) 27 9425 Odds Ratio (M-H, Random, 95% CI) 0.88 [0.78, 0.99]
5.1 aminoglutethimide (any
dose)
9 1395 Odds Ratio (M-H, Random, 95% CI) 0.81 [0.65, 1.01]
5.2 formestane 250 mg 2 586 Odds Ratio (M-H, Random, 95% CI) 1.00 [0.58, 1.70]
5.3 anastrozole 1 mg 4 2626 Odds Ratio (M-H, Random, 95% CI) 0.74 [0.48, 1.12]
5.4 exemestane 25 mg 3 1584 Odds Ratio (M-H, Random, 95% CI) 0.88 [0.71, 1.11]
5.5 fadrozole 2 mg 4 1000 Odds Ratio (M-H, Random, 95% CI) 1.08 [0.82, 1.41]
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5.6 letrozole 2.5 mg 4 1782 Odds Ratio (M-H, Random, 95% CI) 0.77 [0.61, 0.96]
5.7 vorozole 2.5 mg 1 452 Odds Ratio (M-H, Random, 95% CI) 1.25 [0.83, 1.88]
6 Objective response (randomised) 31 10422 Odds Ratio (M-H, Random, 95% CI) 0.90 [0.78, 1.03]
6.1 aminoglutethimide (any
dose)
11 1765 Odds Ratio (M-H, Random, 95% CI) 0.89 [0.66, 1.20]
6.2 formestane 250 mg 3 1133 Odds Ratio (M-H, Random, 95% CI) 1.20 [0.91, 1.60]
6.3 anastrozole 1 mg 4 2626 Odds Ratio (M-H, Random, 95% CI) 0.95 [0.77, 1.17]
6.4 exemestane 25 mg 3 1584 Odds Ratio (M-H, Random, 95% CI) 0.68 [0.37, 1.27]
6.5 fadrozole 2 mg 5 1080 Odds Ratio (M-H, Random, 95% CI) 1.21 [0.87, 1.69]
6.6 letrozole 2.5 mg 4 1782 Odds Ratio (M-H, Random, 95% CI) 0.65 [0.52, 0.82]
6.7 vorozole 2.5 mg 1 452 Odds Ratio (M-H, Random, 95% CI) 0.67 [0.33, 1.37]
Comparison 2. AI versus non-AI: Toxicity
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 hot flushes 20 8306 Odds Ratio (M-H, Fixed, 95% CI) 1.24 [1.10, 1.41]
1.1 AI versus tamoxifen 7 2616 Odds Ratio (M-H, Fixed, 95% CI) 1.07 [0.88, 1.29]
1.2 AI versus megestrol acetate 10 3926 Odds Ratio (M-H, Fixed, 95% CI) 1.73 [1.40, 2.14]
1.3 AI versus fulvestrant 2 1546 Odds Ratio (M-H, Fixed, 95% CI) 1.08 [0.82, 1.42]
1.4 AI versus
medroxyprogesterone acetate
1 218 Odds Ratio (M-H, Fixed, 95% CI) 0.20 [0.06, 0.73]
2 nausea 18 Odds Ratio (M-H, Random, 95% CI) Subtotals only
2.1 AI versus tamoxifen 6 2548 Odds Ratio (M-H, Random, 95% CI) 1.29 [0.78, 2.13]
2.2 AI versus megestrol acetate 9 3755 Odds Ratio (M-H, Random, 95% CI) 1.77 [1.33, 2.35]
2.3 AI versus
medroxyprogesterone acetate
1 53 Odds Ratio (M-H, Random, 95% CI) 8.19 [0.40, 166.83]
2.4 AI versus fulvestrant 2 1539 Odds Ratio (M-H, Random, 95% CI) 1.01 [0.77, 1.32]
3 vomiting 8 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 AI versus tamoxifen 2 1239 Odds Ratio (M-H, Fixed, 95% CI) 1.23 [0.79, 1.90]
3.2 AI versus megestrol acetate 5 2319 Odds Ratio (M-H, Fixed, 95% CI) 2.03 [1.42, 2.90]
3.3 AI versus fulvestrant 1 846 Odds Ratio (M-H, Fixed, 95% CI) 0.90 [0.60, 1.35]
4 diarrhoea 10 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 AI versus tamoxifen 3 2149 Odds Ratio (M-H, Fixed, 95% CI) 1.64 [1.06, 2.55]
4.2 AI versus megestrol acetate 5 1961 Odds Ratio (M-H, Fixed, 95% CI) 1.48 [1.02, 2.13]
4.3 AI versus fulvestrant 2 1090 Odds Ratio (M-H, Fixed, 95% CI) 1.23 [0.79, 1.90]
5 rash 15 Odds Ratio (M-H, Random, 95% CI) Subtotals only
5.1 AI versus tamoxifen 4 711 Odds Ratio (M-H, Random, 95% CI) 33.61 [4.71, 239.97]
5.2 AI versus megestrol acetate 8 3219 Odds Ratio (M-H, Random, 95% CI) 2.06 [0.92, 4.62]
5.3 AI versus
medroxyprogesterone acetate
2 271 Odds Ratio (M-H, Random, 95% CI) 36.80 [3.35, 404.73]
5.4 AI versus fulvestrant 1 397 Odds Ratio (M-H, Random, 95% CI) 1.39 [0.77, 2.50]
6 vaginal bleeding 6 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 AI versus tamoxifen 1 1017 Odds Ratio (M-H, Fixed, 95% CI) 0.45 [0.16, 1.32]
6.2 AI versus megestrol acetate 3 1462 Odds Ratio (M-H, Fixed, 95% CI) 0.22 [0.10, 0.45]
6.3 AI versus
medroxyprogesterone acetate
2 271 Odds Ratio (M-H, Fixed, 95% CI) 0.13 [0.02, 0.71]
7 thromboembolic 6 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
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7.1 AI versus tamoxifen 2 1228 Odds Ratio (M-H, Fixed, 95% CI) 0.48 [0.27, 0.85]
7.2 AI versus megestrol acetate 3 863 Odds Ratio (M-H, Fixed, 95% CI) 0.54 [0.26, 1.10]
7.3 AI versus fulvestrant 1 846 Odds Ratio (M-H, Fixed, 95% CI) 1.14 [0.56, 2.31]
8 arthralgia 6 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 AI versus tamoxifen 2 1031 Odds Ratio (M-H, Fixed, 95% CI) 1.14 [0.81, 1.60]
8.2 AI versus megestrol acetate 4 1439 Odds Ratio (M-H, Fixed, 95% CI) 1.40 [0.98, 2.00]
Comparison 3. Current AIs versus non-AI
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall survival (reported or
calculated)
6 HR (Fixed, 95% CI) 0.88 [0.80, 0.96]
1.1 anastrozole 1 mg 3 HR (Fixed, 95% CI) 0.90 [0.79, 1.03]
1.2 exemestane 25 mg 1 HR (Fixed, 95% CI) 0.85 [0.72, 0.99]
1.3 letrozole 2.5 mg 2 HR (Fixed, 95% CI) 0.88 [0.73, 1.05]
2 Progression-free survival
(reported or calculated)
7 HR (Random, 95% CI) 0.93 [0.78, 1.12]
2.1 anastrozole 1 mg 2 HR (Random, 95% CI) 1.05 [0.65, 1.70]
2.2 exemestane 25 mg 2 HR (Random, 95% CI) 0.91 [0.72, 1.14]
2.3 letrozole 2.5 mg 3 HR (Random, 95% CI) 0.87 [0.68, 1.11]
3 Clinical benefit (assessable) 11 5619 Odds Ratio (M-H, Random, 95% CI) 0.80 [0.66, 0.97]
3.1 anastrozole 1 mg 4 2626 Odds Ratio (M-H, Random, 95% CI) 0.74 [0.48, 1.12]
3.2 exemestane 25 mg 3 1356 Odds Ratio (M-H, Random, 95% CI) 0.86 [0.63, 1.19]
3.3 letrozole 2.5 mg 4 1637 Odds Ratio (M-H, Random, 95% CI) 0.77 [0.60, 1.00]
4 Objective response (assessable) 11 5619 Odds Ratio (M-H, Random, 95% CI) 0.79 [0.65, 0.97]
4.1 anastrozole 1 mg 4 2626 Odds Ratio (M-H, Random, 95% CI) 0.95 [0.77, 1.17]
4.2 exemestane 25 mg 3 1356 Odds Ratio (M-H, Random, 95% CI) 0.67 [0.33, 1.33]
4.3 letrozole 2.5 mg 4 1637 Odds Ratio (M-H, Random, 95% CI) 0.65 [0.51, 0.82]
5 Clinical benefit (randomised) 11 5992 Odds Ratio (M-H, Random, 95% CI) 0.81 [0.67, 0.97]
5.1 anastrozole 1 mg 4 2626 Odds Ratio (M-H, Random, 95% CI) 0.74 [0.48, 1.12]
5.2 exemestane 25 mg 3 1584 Odds Ratio (M-H, Random, 95% CI) 0.88 [0.71, 1.11]
5.3 letrozole 2.5 mg 4 1782 Odds Ratio (M-H, Random, 95% CI) 0.77 [0.61, 0.96]
6 Objective response (randomised) 11 5992 Odds Ratio (M-H, Random, 95% CI) 0.80 [0.66, 0.96]
6.1 anastrozole 1 mg 4 2626 Odds Ratio (M-H, Random, 95% CI) 0.95 [0.77, 1.17]
6.2 exemestane 25 mg 3 1584 Odds Ratio (M-H, Random, 95% CI) 0.68 [0.37, 1.27]
6.3 letrozole 2.5 mg 4 1782 Odds Ratio (M-H, Random, 95% CI) 0.65 [0.52, 0.82]
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Comparison 4. Current AIs versus non-AI: Toxicity
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 hot flushes 9 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 AI versus tamoxifen 3 2048 Odds Ratio (M-H, Fixed, 95% CI) 1.13 [0.91, 1.39]
1.2 AI versus megestrol acetate 4 2036 Odds Ratio (M-H, Fixed, 95% CI) 1.69 [1.24, 2.30]
1.3 AI versus fulvestrant 2 1539 Odds Ratio (M-H, Fixed, 95% CI) 1.07 [0.81, 1.41]
2 nausea 9 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 AI versus tamoxifen 3 2048 Odds Ratio (M-H, Fixed, 95% CI) 0.89 [0.72, 1.11]
2.2 AI versus megestrol acetate 4 2036 Odds Ratio (M-H, Fixed, 95% CI) 1.45 [1.09, 1.95]
2.3 AI versus fulvestrant 2 1539 Odds Ratio (M-H, Fixed, 95% CI) 1.01 [0.77, 1.32]
3 vomiting 5 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 AI versus tamoxifen 1 1017 Odds Ratio (M-H, Fixed, 95% CI) 1.07 [0.67, 1.72]
3.2 AI versus megestrol acetate 3 1636 Odds Ratio (M-H, Fixed, 95% CI) 1.77 [1.11, 2.83]
3.3 AI versus fulvestrant 1 846 Odds Ratio (M-H, Fixed, 95% CI) 0.90 [0.60, 1.35]
4 diarrhoea 7 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 AI versus tamoxifen 2 1927 Odds Ratio (M-H, Fixed, 95% CI) 1.49 [0.95, 2.35]
4.2 AI versus megestrol acetate 3 1278 Odds Ratio (M-H, Fixed, 95% CI) 2.40 [1.34, 4.29]
4.3 AI versus fulvestrant 2 1090 Odds Ratio (M-H, Fixed, 95% CI) 1.23 [0.79, 1.90]
5 rash 4 Odds Ratio (M-H, Random, 95% CI) Subtotals only
5.1 AI versus megestrol acetate 3 1636 Odds Ratio (M-H, Random, 95% CI) 1.63 [0.47, 5.70]
5.2 AI versus fulvestrant 1 397 Odds Ratio (M-H, Random, 95% CI) 1.39 [0.77, 2.50]
6 vaginal bleeding 3 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 AI versus tamoxifen 1 1017 Odds Ratio (M-H, Fixed, 95% CI) 0.45 [0.16, 1.32]
6.2 AI versus megestrol acetate 2 915 Odds Ratio (M-H, Fixed, 95% CI) 0.29 [0.13, 0.65]
7 thromboembolic 3 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 AI versus tamoxifen 1 1017 Odds Ratio (M-H, Fixed, 95% CI) 0.53 [0.30, 0.96]
7.2 AI versus megestrol acetate 1 515 Odds Ratio (M-H, Fixed, 95% CI) 0.71 [0.30, 1.73]
7.3 AI versus fulvestrant 1 846 Odds Ratio (M-H, Fixed, 95% CI) 1.14 [0.56, 2.31]
8 arthralgia 3 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 AI versus tamoxifen 2 1031 Odds Ratio (M-H, Fixed, 95% CI) 1.14 [0.81, 1.60]
8.2 AI versus megestrol acetate 1 363 Odds Ratio (M-H, Fixed, 95% CI) 1.77 [0.89, 3.51]
Comparison 5. AI versus different AI
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall survival (reported) 2 HR (Fixed, 95% CI) Subtotals only
1.1 letrozole 2 HR (Fixed, 95% CI) 0.91 [0.82, 1.02]
2 Progession-free survival
(reported or calculated)
2 HR (Fixed, 95% CI) Subtotals only
2.1 letrozole 2 HR (Fixed, 95% CI) 0.97 [0.90, 1.04]
3 Clinical benefit (assessable) 5 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 letrozole 4 1687 Odds Ratio (M-H, Fixed, 95% CI) 0.77 [0.62, 0.95]
3.2 anastrozole 2 663 Odds Ratio (M-H, Fixed, 95% CI) 1.29 [0.92, 1.79]
4 Objective response (assessable) 5 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
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4.1 letrozole 4 1687 Odds Ratio (M-H, Fixed, 95% CI) 0.62 [0.50, 0.78]
4.2 anastrozole 2 663 Odds Ratio (M-H, Fixed, 95% CI) 1.59 [1.07, 2.37]
5 Clinical benefit (randomised) 5 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 letrozole 4 2098 Odds Ratio (M-H, Fixed, 95% CI) 0.82 [0.68, 0.98]
5.2 anastrozole 2 773 Odds Ratio (M-H, Fixed, 95% CI) 1.25 [0.90, 1.72]
6 Objective response (randomised) 5 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 letrozole 4 2098 Odds Ratio (M-H, Fixed, 95% CI) 0.66 [0.54, 0.82]
6.2 anastrozole 2 782 Odds Ratio (M-H, Fixed, 95% CI) 1.50 [1.01, 2.23]
Comparison 6. AI as first-line therapy versus any other therapy (tamoxifen)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall survival (reported or
calculated)
3 HR (Fixed, 95% CI) 0.99 [0.86, 1.14]
1.1 aminoglutethimide as
first-line therapy
1 HR (Fixed, 95% CI) 1.12 [0.82, 1.53]
1.2 anastrozole as first-line
therapy
1 HR (Fixed, 95% CI) 0.97 [0.81, 1.16]
1.3 fadrozole as first-line
therapy
1 HR (Fixed, 95% CI) 0.91 [0.63, 1.32]
2 Progression-free survival
(reported or calculated)
4 HR (Fixed, 95% CI) 0.78 [0.71, 0.86]
2.1 aminoglutethimide 1 HR (Fixed, 95% CI) 0.84 [0.65, 1.08]
2.2 formestane as first-line
therapy
1 HR (Fixed, 95% CI) 0.93 [0.68, 1.28]
2.3 anastrozole as first-line
therapy
1 HR (Fixed, 95% CI) 0.82 [0.71, 0.95]
2.4 letrozole as first-line
therapy
1 HR (Fixed, 95% CI) 0.70 [0.60, 0.82]
3 Clinical benefit (assessable) 9 3252 Odds Ratio (M-H, Random, 95% CI) 0.69 [0.51, 0.92]
3.1 aminoglutethimide (any
dose)
3 479 Odds Ratio (M-H, Random, 95% CI) 0.63 [0.42, 0.93]
3.2 formestane 250 mg 1 348 Odds Ratio (M-H, Random, 95% CI) 1.36 [0.87, 2.13]
3.3 anastrozole 1 mg 2 1259 Odds Ratio (M-H, Random, 95% CI) 0.48 [0.16, 1.44]
3.4 exemestane 25 mg 1 113 Odds Ratio (M-H, Random, 95% CI) 0.47 [0.22, 0.99]
3.5 fadrozole 2 mg 1 209 Odds Ratio (M-H, Random, 95% CI) 1.09 [0.58, 2.06]
3.6 letrozole 2.5 mg 1 844 Odds Ratio (M-H, Random, 95% CI) 0.63 [0.48, 0.82]
4 Objective response (assessable) 11 3503 Odds Ratio (M-H, Random, 95% CI) 0.77 [0.59, 1.00]
4.1 aminoglutethimide (any
dose)
4 656 Odds Ratio (M-H, Random, 95% CI) 0.75 [0.45, 1.25]
4.2 formestane 250 mg 1 348 Odds Ratio (M-H, Random, 95% CI) 1.20 [0.77, 1.87]
4.3 anastrozole 1 mg 2 1259 Odds Ratio (M-H, Random, 95% CI) 0.85 [0.65, 1.11]
4.4 exemestane 25 mg 1 113 Odds Ratio (M-H, Random, 95% CI) 0.26 [0.11, 0.62]
4.5 fadrozole 2 mg 2 283 Odds Ratio (M-H, Random, 95% CI) 1.20 [0.69, 2.09]
4.6 letrozole 2.5 mg 1 844 Odds Ratio (M-H, Random, 95% CI) 0.58 [0.42, 0.78]
5 Clinical benefit (randomised) 9 3451 Odds Ratio (M-H, Random, 95% CI) 0.74 [0.56, 0.98]
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5.1 aminoglutethimide (any
dose)
3 533 Odds Ratio (M-H, Random, 95% CI) 0.74 [0.51, 1.08]
5.2 formestane 250 mg 1 409 Odds Ratio (M-H, Random, 95% CI) 1.25 [0.85, 1.86]
5.3 anastrozole 1 mg 2 1259 Odds Ratio (M-H, Random, 95% CI) 0.48 [0.16, 1.44]
5.4 exemestane 25 mg 1 122 Odds Ratio (M-H, Random, 95% CI) 0.55 [0.27, 1.13]
5.5 fadrozole 2 mg 1 221 Odds Ratio (M-H, Random, 95% CI) 1.23 [0.69, 2.21]
5.6 letrozole 2.5 mg 1 907 Odds Ratio (M-H, Random, 95% CI) 0.65 [0.50, 0.84]
6 Objective response (randomised) 11 3746 Odds Ratio (M-H, Random, 95% CI) 0.81 [0.62, 1.05]
6.1 aminoglutethimide (any
dose)
4 748 Odds Ratio (M-H, Random, 95% CI) 0.83 [0.48, 1.45]
6.2 formestane 250 mg 1 409 Odds Ratio (M-H, Random, 95% CI) 1.18 [0.77, 1.80]
6.3 anastrozole 1 mg 2 1259 Odds Ratio (M-H, Random, 95% CI) 0.85 [0.65, 1.11]
6.4 exemestane 25 mg 1 122 Odds Ratio (M-H, Random, 95% CI) 0.30 [0.13, 0.69]
6.5 fadrozole 2 mg 2 301 Odds Ratio (M-H, Random, 95% CI) 1.28 [0.76, 2.15]
6.6 letrozole 2.5 mg 1 907 Odds Ratio (M-H, Random, 95% CI) 0.59 [0.43, 0.79]
Comparison 7. AI as second-line therapy versus any other therapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall survival (reported or
calculated)
2 HR (Fixed, 95% CI) 0.80 [0.66, 0.96]
1.1 anastrozole as second-line
therapy
1 HR (Fixed, 95% CI) 0.78 [0.61, 1.00]
1.2 letrozole as second-line
therapy
1 HR (Fixed, 95% CI) 0.82 [0.63, 1.07]
2 Progression-free survival
(reported or calculated)
8 HR (Random, 95% CI) 1.08 [0.94, 1.23]
2.1 aminoglutethimide (any
dose)
1 HR (Random, 95% CI) 1.25 [0.91, 1.72]
2.2 formestane 250 mg
biweekly
2 HR (Random, 95% CI) 1.03 [0.90, 1.19]
2.3 anastrozole 1 mg 1 HR (Random, 95% CI) 1.34 [1.16, 1.55]
2.4 exemestane 25 mg 2 HR (Random, 95% CI) 0.91 [0.72, 1.14]
2.5 letrozole 2.5 mg 1 HR (Random, 95% CI) 0.98 [0.77, 1.25]
2.6 vorozole 2.5 mg 1 HR (Random, 95% CI) 1.27 [1.04, 1.56]
3 Clinical benefit (assessable) 16 5410 Odds Ratio (M-H, Fixed, 95% CI) 0.99 [0.88, 1.11]
3.1 aminoglutethimide (any
dose)
4 686 Odds Ratio (M-H, Fixed, 95% CI) 0.90 [0.66, 1.23]
3.2 formestane 250 mg
biweekly
1 173 Odds Ratio (M-H, Fixed, 95% CI) 0.75 [0.41, 1.39]
3.3 anastrozole 1mg 2 1367 Odds Ratio (M-H, Fixed, 95% CI) 1.04 [0.84, 1.29]
3.4 exemestane 25 mg 2 1243 Odds Ratio (M-H, Fixed, 95% CI) 0.95 [0.75, 1.20]
3.5 fadrozole 2 mg 3 773 Odds Ratio (M-H, Fixed, 95% CI) 1.04 [0.77, 1.41]
3.6 letrozole 2.5 mg 3 793 Odds Ratio (M-H, Fixed, 95% CI) 0.91 [0.68, 1.23]
3.7 vorozole 2.5mg 1 375 Odds Ratio (M-H, Fixed, 95% CI) 1.35 [0.88, 2.07]
4 Objective response (assessable) 18 5937 Odds Ratio (M-H, Fixed, 95% CI) 0.98 [0.86, 1.13]
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4.1 aminoglutethimide (any
dose)
5 734 Odds Ratio (M-H, Fixed, 95% CI) 0.94 [0.68, 1.30]
4.2 formestane 250 mg
biweekly
2 652 Odds Ratio (M-H, Fixed, 95% CI) 1.24 [0.84, 1.83]
4.3 anastrozole 1 mg 2 1367 Odds Ratio (M-H, Fixed, 95% CI) 1.12 [0.84, 1.50]
4.4 exemestane 25 mg 2 1243 Odds Ratio (M-H, Fixed, 95% CI) 0.89 [0.63, 1.26]
4.5 fadrozole 2 mg 3 773 Odds Ratio (M-H, Fixed, 95% CI) 1.17 [0.76, 1.80]
4.6 letrozole 2.5 mg 3 793 Odds Ratio (M-H, Fixed, 95% CI) 0.76 [0.53, 1.08]
4.7 vorozole 2.5 mg 1 375 Odds Ratio (M-H, Fixed, 95% CI) 0.70 [0.34, 1.42]
5 Clinical benefit (randomised) 16 6432 Odds Ratio (M-H, Fixed, 95% CI) 1.00 [0.90, 1.11]
5.1 aminoglutethimide (any
dose)
4 1320 Odds Ratio (M-H, Fixed, 95% CI) 1.06 [0.85, 1.31]
5.2 formestane 250 mg
biweekly
1 177 Odds Ratio (M-H, Fixed, 95% CI) 0.72 [0.40, 1.31]
5.3 anastrozole 1 mg 2 1367 Odds Ratio (M-H, Fixed, 95% CI) 1.04 [0.84, 1.29]
5.4 exemestane 25 mg 2 1462 Odds Ratio (M-H, Fixed, 95% CI) 0.93 [0.74, 1.16]
5.5 fadrozole 2 mg 3 779 Odds Ratio (M-H, Fixed, 95% CI) 1.04 [0.77, 1.41]
5.6 letrozole 2.5 mg 3 875 Odds Ratio (M-H, Fixed, 95% CI) 0.91 [0.68, 1.21]
5.7 vorozole 2.5mg 1 452 Odds Ratio (M-H, Fixed, 95% CI) 1.25 [0.83, 1.88]
6 Objective response (randomised) 18 7113 Odds Ratio (M-H, Fixed, 95% CI) 1.04 [0.92, 1.18]
6.1 aminoglutethimide (any
dose)
5 1475 Odds Ratio (M-H, Fixed, 95% CI) 1.15 [0.91, 1.45]
6.2 formestane 250 mg
biweekly
2 724 Odds Ratio (M-H, Fixed, 95% CI) 1.22 [0.84, 1.79]
6.3 anastrozole 1 mg 2 1367 Odds Ratio (M-H, Fixed, 95% CI) 1.12 [0.84, 1.50]
6.4 exemestane 25 mg 2 1462 Odds Ratio (M-H, Fixed, 95% CI) 0.87 [0.62, 1.24]
6.5 fadrozole 2 mg 3 779 Odds Ratio (M-H, Fixed, 95% CI) 1.17 [0.76, 1.80]
6.6 letrozole 2.5 mg 3 854 Odds Ratio (M-H, Fixed, 95% CI) 0.80 [0.56, 1.13]
6.7 vorozole 2.5 mg 1 452 Odds Ratio (M-H, Fixed, 95% CI) 0.67 [0.33, 1.37]
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Analysis 1.1. Comparison 1 AI versus non-AI, Outcome 1 Overall survival (reported or calculated).
Review: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Comparison: 1 AI versus non-AI
Outcome: 1 Overall survival (reported or calculated)
Study or subgroup log [HR] HR Weight HR
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 aminoglutethimide (any dose)
Gale 1994 0.11 (0.16) 5.8 % 1.12 [ 0.82, 1.53 ]
Ingle 1986 -0.2357 (0.2502) 2.4 % 0.79 [ 0.48, 1.29 ]
Rose 1986 -0.0943 (0.1491) 6.6 % 0.91 [ 0.68, 1.22 ]
Russell 1997 -0.1165 (0.1708) 5.1 % 0.89 [ 0.64, 1.24 ]
Subtotal (95% CI) 19.8 % 0.94 [ 0.80, 1.12 ]
Heterogeneity: Chi2 = 1.78, df = 3 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.66 (P = 0.51)
2 anastrozole 1 mg
Bonneterre 2001 -0.0305 (0.0931) 17.0 % 0.97 [ 0.81, 1.16 ]
Buzdar 1996a -0.2485 (0.1277) 9.0 % 0.78 [ 0.61, 1.00 ]
Milla-Santos 2003 -0.0834 (0.1533) 6.3 % 0.92 [ 0.68, 1.24 ]
Subtotal (95% CI) 32.4 % 0.90 [ 0.79, 1.03 ]
Heterogeneity: Chi2 = 1.92, df = 2 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 1.51 (P = 0.13)
3 exemestane 25 mg
Kaufmann 2000 -0.1661 (0.0805) 22.8 % 0.85 [ 0.72, 0.99 ]
Subtotal (95% CI) 22.8 % 0.85 [ 0.72, 0.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.06 (P = 0.039)
4 fadrozole 2 mg
Bezwoda 1998 0.3001 (0.2683) 2.0 % 1.35 [ 0.80, 2.28 ]
Thuerlimann 1996 -0.0943 (0.1887) 4.1 % 0.91 [ 0.63, 1.32 ]
Subtotal (95% CI) 6.2 % 1.04 [ 0.77, 1.40 ]
Heterogeneity: Chi2 = 1.45, df = 1 (P = 0.23); I2 =31%
Test for overall effect: Z = 0.23 (P = 0.81)
5 letrozole 2.5 mg
Buzdar 2001 -0.0834 (0.1203) 10.2 % 0.92 [ 0.73, 1.16 ]
Dombernowsky 1998 -0.1985 (0.1375) 7.8 % 0.82 [ 0.63, 1.07 ]
Subtotal (95% CI) 18.0 % 0.88 [ 0.73, 1.05 ]
Heterogeneity: Chi2 = 0.40, df = 1 (P = 0.53); I2 =0.0%
0.5 0.7 1 1.5 2
AI better non-AI better
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(. . . Continued)
Study or subgroup log [HR] HR Weight HR
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Test for overall effect: Z = 1.47 (P = 0.14)
6 vorozole 2.5 mg
Goss 1999 0.0953 (0.4121) 0.9 % 1.10 [ 0.49, 2.47 ]
Subtotal (95% CI) 0.9 % 1.10 [ 0.49, 2.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
Total (95% CI) 100.0 % 0.90 [ 0.84, 0.97 ]
Heterogeneity: Chi2 = 7.60, df = 12 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 2.68 (P = 0.0073)
Test for subgroup differences: Chi2 = 2.05, df = 5 (P = 0.84), I2 =0.0%
0.5 0.7 1 1.5 2
AI better non-AI better
Analysis 1.2. Comparison 1 AI versus non-AI, Outcome 2 Progression-free survival (reported or calculated).
Review: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Comparison: 1 AI versus non-AI
Outcome: 2 Progression-free survival (reported or calculated)
Study or subgroup log [HR] HR Weight HR
(SE) IV,Random,95% CI IV,Random,95% CI
1 aminoglutethimide (any dose)
Ingle 1986 -0.1625 (0.228) 5.7 % 0.85 [ 0.54, 1.33 ]
Russell 1997 0.2231 (0.1624) 7.6 % 1.25 [ 0.91, 1.72 ]
Subtotal (95% CI) 13.3 % 1.07 [ 0.73, 1.55 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 1.90, df = 1 (P = 0.17); I2 =47%
Test for overall effect: Z = 0.33 (P = 0.74)
2 formestane 250 mg
Thuerlimann 1997 -0.0726 (0.1631) 7.6 % 0.93 [ 0.68, 1.28 ]
Subtotal (95% CI) 7.6 % 0.93 [ 0.68, 1.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.66)
0.5 0.7 1 1.5 2
AI better non-AI better
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Study or subgroup log [HR] HR Weight HR
(SE) IV,Random,95% CI IV,Random,95% CI
3 anastrozole 1 mg
Bonneterre 2001 -0.1985 (0.0743) 10.6 % 0.82 [ 0.71, 0.95 ]
Mauriac 2003 0.2927 (0.0739) 10.6 % 1.34 [ 1.16, 1.55 ]
Subtotal (95% CI) 21.2 % 1.05 [ 0.65, 1.70 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 21.97, df = 1 (P<0.00001); I2 =95%
Test for overall effect: Z = 0.19 (P = 0.85)
4 exemestane 25 mg
Chia 2008 0.0377 (0.1237) 9.0 % 1.04 [ 0.81, 1.32 ]
Kaufmann 2000 -0.1985 (0.0842) 10.3 % 0.82 [ 0.70, 0.97 ]
Subtotal (95% CI) 19.3 % 0.91 [ 0.72, 1.14 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 2.49, df = 1 (P = 0.11); I2 =60%
Test for overall effect: Z = 0.84 (P = 0.40)
5 letrozole 2.5 mg
Buzdar 2001 -0.0101 (0.1129) 9.4 % 0.99 [ 0.79, 1.24 ]
Dombernowsky 1998 -0.0202 (0.1236) 9.0 % 0.98 [ 0.77, 1.25 ]
Mourisden 2001 -0.3567 (0.0797) 10.5 % 0.70 [ 0.60, 0.82 ]
Subtotal (95% CI) 28.8 % 0.87 [ 0.68, 1.11 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 8.80, df = 2 (P = 0.01); I2 =77%
Test for overall effect: Z = 1.12 (P = 0.26)
6 vorozole 2.5 mg
Goss 1999 0.239 (0.1034) 9.7 % 1.27 [ 1.04, 1.56 ]
Subtotal (95% CI) 9.7 % 1.27 [ 1.04, 1.56 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.31 (P = 0.021)
Total (95% CI) 100.0 % 0.98 [ 0.84, 1.13 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 54.88, df = 10 (P<0.00001); I2 =82%
Test for overall effect: Z = 0.29 (P = 0.77)
0.5 0.7 1 1.5 2
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Analysis 1.3. Comparison 1 AI versus non-AI, Outcome 3 Clinical benefit (assessable).
Review: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Comparison: 1 AI versus non-AI
Outcome: 3 Clinical benefit (assessable)
Study or subgroup non-AI AI Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 aminoglutethimide (any dose)
Alonso-Munoz 1988 28/34 25/31 0.9 % 1.12 [ 0.32, 3.92 ]
Canney 1988 61/112 54/106 3.6 % 1.15 [ 0.68, 1.96 ]
Gale 1994 71/108 83/108 3.1 % 0.58 [ 0.32, 1.05 ]
Garcia-Giralt 1992 78/112 98/124 3.2 % 0.61 [ 0.34, 1.10 ]
Ingle 1986 21/49 25/51 2.1 % 0.78 [ 0.35, 1.72 ]
Lundgren 1989 49/74 51/76 2.6 % 0.96 [ 0.49, 1.89 ]
Mercer 1993 13/29 10/27 1.2 % 1.38 [ 0.47, 4.03 ]
Powles 1984 55/99 67/99 3.3 % 0.60 [ 0.33, 1.06 ]
Samonis 1994 18/27 18/26 1.1 % 0.89 [ 0.28, 2.82 ]
Subtotal (95% CI) 644 648 21.1 % 0.79 [ 0.63, 1.00 ]
Total events: 394 (non-AI), 431 (AI)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.33, df = 8 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 1.94 (P = 0.053)
2 formestane 250 mg
Perez Carrion 1994 124/175 111/173 4.4 % 1.36 [ 0.87, 2.13 ]
Thuerlimann 1997 46/83 56/90 3.0 % 0.75 [ 0.41, 1.39 ]
Subtotal (95% CI) 258 263 7.5 % 1.05 [ 0.59, 1.86 ]
Total events: 170 (non-AI), 167 (AI)
Heterogeneity: Tau2 = 0.10; Chi2 = 2.32, df = 1 (P = 0.13); I2 =57%
Test for overall effect: Z = 0.17 (P = 0.87)
3 anastrozole 1 mg
Bonneterre 2001 265/510 292/511 7.2 % 0.81 [ 0.63, 1.04 ]
Buzdar 1996a 102/253 111/263 5.6 % 0.93 [ 0.65, 1.31 ]
Mauriac 2003 186/428 173/423 6.8 % 1.11 [ 0.85, 1.46 ]
Milla-Santos 2003 65/117 100/121 3.1 % 0.26 [ 0.14, 0.48 ]
Subtotal (95% CI) 1308 1318 22.7 % 0.74 [ 0.48, 1.12 ]
Total events: 618 (non-AI), 676 (AI)
Heterogeneity: Tau2 = 0.15; Chi2 = 19.04, df = 3 (P = 0.00027); I2 =84%
0.2 0.5 1 2 5
AI better non-AI better
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Study or subgroup non-AI AI Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 1.42 (P = 0.16)
4 exemestane 25 mg
Chia 2008 87/270 85/270 5.5 % 1.03 [ 0.72, 1.49 ]
Kaufmann 2000 135/366 133/337 6.3 % 0.90 [ 0.66, 1.22 ]
Paridaens 2003 25/57 35/56 2.2 % 0.47 [ 0.22, 0.99 ]
Subtotal (95% CI) 693 663 14.0 % 0.86 [ 0.63, 1.19 ]
Total events: 247 (non-AI), 253 (AI)
Heterogeneity: Tau2 = 0.03; Chi2 = 3.45, df = 2 (P = 0.18); I2 =42%
Test for overall effect: Z = 0.91 (P = 0.36)
5 fadrozole 2 mg
Bezwoda 1998 4/50 5/46 0.8 % 0.71 [ 0.18, 2.84 ]
Buzdar 1996b 65/184 70/195 4.7 % 0.98 [ 0.64, 1.49 ]
Buzdar 1996c 61/148 56/150 4.3 % 1.18 [ 0.74, 1.87 ]
Thuerlimann 1996 81/106 77/103 2.9 % 1.09 [ 0.58, 2.06 ]
Subtotal (95% CI) 488 494 12.7 % 1.05 [ 0.80, 1.38 ]
Total events: 211 (non-AI), 208 (AI)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.67, df = 3 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.72)
6 letrozole 2.5 mg
Buzdar 2001 47/180 53/182 4.3 % 0.86 [ 0.54, 1.36 ]
Dombernowsky 1998 60/166 60/153 4.4 % 0.88 [ 0.56, 1.38 ]
Mourisden 2001 173/423 221/421 6.8 % 0.63 [ 0.48, 0.82 ]
Schmid 2001 19/60 14/52 1.9 % 1.26 [ 0.55, 2.85 ]
Subtotal (95% CI) 829 808 17.4 % 0.77 [ 0.60, 1.00 ]
Total events: 299 (non-AI), 348 (AI)
Heterogeneity: Tau2 = 0.02; Chi2 = 4.00, df = 3 (P = 0.26); I2 =25%
Test for overall effect: Z = 2.00 (P = 0.046)
7 vorozole 2.5 mg
Goss 1999 71/185 60/190 4.7 % 1.35 [ 0.88, 2.07 ]
Subtotal (95% CI) 185 190 4.7 % 1.35 [ 0.88, 2.07 ]
Total events: 71 (non-AI), 60 (AI)
Heterogeneity: not applicable
Test for overall effect: Z = 1.38 (P = 0.17)
Total (95% CI) 4405 4384 100.0 % 0.87 [ 0.77, 0.99 ]
Total events: 2010 (non-AI), 2143 (AI)
Heterogeneity: Tau2 = 0.04; Chi2 = 46.41, df = 26 (P = 0.01); I2 =44%
Test for overall effect: Z = 2.11 (P = 0.035)
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Review: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Comparison: 1 AI versus non-AI
Outcome: 4 Objective response (assessable)
Study or subgroup non-AI AI Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 aminoglutethimide (any dose)
Alonso-Munoz 1988 18/34 15/31 1.6 % 1.20 [ 0.45, 3.18 ]
Canney 1988 35/112 26/106 3.4 % 1.40 [ 0.77, 2.54 ]
Gale 1994 30/108 49/108 3.6 % 0.46 [ 0.26, 0.82 ]
Garcia-Giralt 1992 39/112 48/124 3.9 % 0.85 [ 0.50, 1.44 ]
Ingle 1986 21/49 25/51 2.3 % 0.78 [ 0.35, 1.72 ]
Lundgren 1989 23/74 26/76 2.8 % 0.87 [ 0.44, 1.72 ]
Mercer 1993 5/29 3/27 0.7 % 1.67 [ 0.36, 7.77 ]
Powles 1984 34/99 48/99 3.6 % 0.56 [ 0.31, 0.98 ]
Rose 1986 32/94 24/83 3.1 % 1.27 [ 0.67, 2.40 ]
Russell 1997 2/32 10/42 0.7 % 0.21 [ 0.04, 1.05 ]
Samonis 1994 9/27 10/28 1.3 % 0.90 [ 0.30, 2.74 ]
Subtotal (95% CI) 770 775 27.1 % 0.83 [ 0.63, 1.09 ]
Total events: 248 (non-AI), 284 (AI)
Heterogeneity: Tau2 = 0.07; Chi2 = 14.78, df = 10 (P = 0.14); I2 =32%
Test for overall effect: Z = 1.35 (P = 0.18)
2 formestane 250 mg
Freue 2000 55/237 45/242 4.8 % 1.32 [ 0.85, 2.06 ]
Perez Carrion 1994 65/175 57/173 4.8 % 1.20 [ 0.77, 1.87 ]
Thuerlimann 1997 14/83 15/90 2.2 % 1.01 [ 0.46, 2.25 ]
Subtotal (95% CI) 495 505 11.9 % 1.23 [ 0.92, 1.64 ]
Total events: 134 (non-AI), 117 (AI)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.34, df = 2 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 1.37 (P = 0.17)
3 anastrozole 1 mg
Bonneterre 2001 138/510 148/511 7.0 % 0.91 [ 0.69, 1.20 ]
Buzdar 1996a 31/253 33/263 4.0 % 0.97 [ 0.58, 1.64 ]
0.2 0.5 1 2 5
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Study or subgroup non-AI AI Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Mauriac 2003 82/428 70/423 5.9 % 1.20 [ 0.84, 1.70 ]
Milla-Santos 2003 31/117 43/121 3.7 % 0.65 [ 0.38, 1.14 ]
Subtotal (95% CI) 1308 1318 20.6 % 0.95 [ 0.77, 1.17 ]
Total events: 282 (non-AI), 294 (AI)
Heterogeneity: Tau2 = 0.01; Chi2 = 3.48, df = 3 (P = 0.32); I2 =14%
Test for overall effect: Z = 0.46 (P = 0.65)
4 exemestane 25 mg
Chia 2008 20/270 18/270 3.0 % 1.12 [ 0.58, 2.17 ]
Kaufmann 2000 50/366 55/337 5.1 % 0.81 [ 0.54, 1.23 ]
Paridaens 2003 10/57 25/56 2.0 % 0.26 [ 0.11, 0.62 ]
Subtotal (95% CI) 693 663 10.1 % 0.67 [ 0.33, 1.33 ]
Total events: 80 (non-AI), 98 (AI)
Heterogeneity: Tau2 = 0.26; Chi2 = 7.20, df = 2 (P = 0.03); I2 =72%
Test for overall effect: Z = 1.16 (P = 0.25)
5 fadrozole 2 mg
Bezwoda 1998 3/50 3/46 0.6 % 0.91 [ 0.18, 4.78 ]
Buzdar 1996b 30/184 22/195 3.4 % 1.53 [ 0.85, 2.77 ]
Buzdar 1996c 17/148 20/150 2.8 % 0.84 [ 0.42, 1.68 ]
Falkson 1996 17/38 18/36 1.8 % 0.81 [ 0.32, 2.02 ]
Thuerlimann 1996 29/106 21/103 3.1 % 1.47 [ 0.77, 2.79 ]
Subtotal (95% CI) 526 530 11.8 % 1.18 [ 0.85, 1.65 ]
Total events: 96 (non-AI), 84 (AI)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.85, df = 4 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.99 (P = 0.32)
6 letrozole 2.5 mg
Buzdar 2001 30/180 32/182 3.8 % 0.94 [ 0.54, 1.62 ]
Dombernowsky 1998 31/166 41/153 3.9 % 0.63 [ 0.37, 1.07 ]
Mourisden 2001 92/423 137/421 6.5 % 0.58 [ 0.42, 0.78 ]
Schmid 2001 9/60 10/52 1.6 % 0.74 [ 0.28, 1.99 ]
Subtotal (95% CI) 829 808 15.8 % 0.65 [ 0.51, 0.82 ]
Total events: 162 (non-AI), 220 (AI)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.39, df = 3 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 3.65 (P = 0.00027)
7 vorozole 2.5 mg
Goss 1999 14/185 20/190 2.7 % 0.70 [ 0.34, 1.42 ]
Subtotal (95% CI) 185 190 2.7 % 0.70 [ 0.34, 1.42 ]
Total events: 14 (non-AI), 20 (AI)
Heterogeneity: not applicable
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Study or subgroup non-AI AI Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 0.99 (P = 0.32)
Total (95% CI) 4806 4789 100.0 % 0.88 [ 0.77, 1.01 ]
Total events: 1016 (non-AI), 1117 (AI)
Heterogeneity: Tau2 = 0.05; Chi2 = 48.15, df = 30 (P = 0.02); I2 =38%
Test for overall effect: Z = 1.86 (P = 0.063)
0.2 0.5 1 2 5
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Analysis 1.5. Comparison 1 AI versus non-AI, Outcome 5 Clinical benefit (randomised).
Review: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Comparison: 1 AI versus non-AI
Outcome: 5 Clinical benefit (randomised)
Study or subgroup non-AI AI Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 aminoglutethimide (any dose)
Alonso-Munoz 1988 28/35 25/35 1.0 % 1.60 [ 0.53, 4.84 ]
Canney 1988 61/112 54/106 3.4 % 1.15 [ 0.68, 1.96 ]
Gale 1994 71/119 83/122 3.4 % 0.70 [ 0.41, 1.18 ]
Garcia-Giralt 1992 78/119 98/131 3.2 % 0.64 [ 0.37, 1.11 ]
Ingle 1986 21/49 25/51 1.8 % 0.78 [ 0.35, 1.72 ]
Lundgren 1989 49/90 51/86 2.9 % 0.82 [ 0.45, 1.49 ]
Mercer 1993 13/33 10/28 1.1 % 1.17 [ 0.41, 3.32 ]
Powles 1984 55/111 67/111 3.4 % 0.64 [ 0.38, 1.10 ]
Samonis 1994 18/29 18/28 1.1 % 0.91 [ 0.31, 2.67 ]
Subtotal (95% CI) 697 698 21.3 % 0.81 [ 0.65, 1.01 ]
Total events: 394 (non-AI), 431 (AI)
0.2 0.5 1 2 5
AI better non-AI better
(Continued . . . )
65Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup non-AI AI Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: Tau2 = 0.0; Chi2 = 5.40, df = 8 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 1.86 (P = 0.063)
2 formestane 250 mg
Perez Carrion 1994 124/206 111/203 4.9 % 1.25 [ 0.85, 1.86 ]
Thuerlimann 1997 46/86 56/91 2.9 % 0.72 [ 0.40, 1.31 ]
Subtotal (95% CI) 292 294 7.8 % 1.00 [ 0.58, 1.70 ]
Total events: 170 (non-AI), 167 (AI)
Heterogeneity: Tau2 = 0.09; Chi2 = 2.32, df = 1 (P = 0.13); I2 =57%
Test for overall effect: Z = 0.02 (P = 0.99)
3 anastrozole 1 mg
Bonneterre 2001 265/510 292/511 7.3 % 0.81 [ 0.63, 1.04 ]
Buzdar 1996a 102/253 111/263 5.5 % 0.93 [ 0.65, 1.31 ]
Mauriac 2003 186/428 173/423 6.9 % 1.11 [ 0.85, 1.46 ]
Milla-Santos 2003 65/117 100/121 2.9 % 0.26 [ 0.14, 0.48 ]
Subtotal (95% CI) 1308 1318 22.6 % 0.74 [ 0.48, 1.12 ]
Total events: 618 (non-AI), 676 (AI)
Heterogeneity: Tau2 = 0.15; Chi2 = 19.04, df = 3 (P = 0.00027); I2 =84%
Test for overall effect: Z = 1.42 (P = 0.16)
4 exemestane 25 mg
Chia 2008 87/351 85/342 5.6 % 1.00 [ 0.71, 1.41 ]
Kaufmann 2000 135/403 133/366 6.4 % 0.88 [ 0.66, 1.19 ]
Paridaens 2003 25/60 35/62 2.2 % 0.55 [ 0.27, 1.13 ]
Subtotal (95% CI) 814 770 14.2 % 0.88 [ 0.71, 1.11 ]
Total events: 247 (non-AI), 253 (AI)
Heterogeneity: Tau2 = 0.00; Chi2 = 2.13, df = 2 (P = 0.35); I2 =6%
Test for overall effect: Z = 1.07 (P = 0.28)
5 fadrozole 2 mg
Bezwoda 1998 4/50 5/46 0.7 % 0.71 [ 0.18, 2.84 ]
Buzdar 1996b 65/184 70/196 4.5 % 0.98 [ 0.65, 1.50 ]
Buzdar 1996c 61/151 56/152 4.0 % 1.16 [ 0.73, 1.85 ]
Thuerlimann 1996 81/110 77/111 2.9 % 1.23 [ 0.69, 2.21 ]
Subtotal (95% CI) 495 505 12.2 % 1.08 [ 0.82, 1.41 ]
Total events: 211 (non-AI), 208 (AI)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.83, df = 3 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.55 (P = 0.58)
6 letrozole 2.5 mg
Buzdar 2001 47/201 53/199 4.2 % 0.84 [ 0.53, 1.32 ]
Dombernowsky 1998 60/189 60/174 4.3 % 0.88 [ 0.57, 1.37 ]
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(. . . Continued)
Study or subgroup non-AI AI Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Mourisden 2001 173/454 221/453 7.0 % 0.65 [ 0.50, 0.84 ]
Schmid 2001 19/60 14/52 1.7 % 1.26 [ 0.55, 2.85 ]
Subtotal (95% CI) 904 878 17.2 % 0.77 [ 0.61, 0.96 ]
Total events: 299 (non-AI), 348 (AI)
Heterogeneity: Tau2 = 0.01; Chi2 = 3.53, df = 3 (P = 0.32); I2 =15%
Test for overall effect: Z = 2.29 (P = 0.022)
7 vorozole 2.5 mg
Goss 1999 71/227 60/225 4.7 % 1.25 [ 0.83, 1.88 ]
Subtotal (95% CI) 227 225 4.7 % 1.25 [ 0.83, 1.88 ]
Total events: 71 (non-AI), 60 (AI)
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
Total (95% CI) 4737 4688 100.0 % 0.88 [ 0.78, 0.99 ]
Total events: 2010 (non-AI), 2143 (AI)
Heterogeneity: Tau2 = 0.03; Chi2 = 42.67, df = 26 (P = 0.02); I2 =39%
Test for overall effect: Z = 2.18 (P = 0.029)
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Analysis 1.6. Comparison 1 AI versus non-AI, Outcome 6 Objective response (randomised).
Review: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Comparison: 1 AI versus non-AI
Outcome: 6 Objective response (randomised)
Study or subgroup non-AI AI Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 aminoglutethimide (any dose)
Alonso-Munoz 1988 18/35 15/35 1.7 % 1.41 [ 0.55, 3.62 ]
Canney 1988 35/112 26/106 3.4 % 1.40 [ 0.77, 2.54 ]
Gale 1994 30/119 49/122 3.7 % 0.50 [ 0.29, 0.87 ]
Garcia-Giralt 1992 39/119 48/131 3.9 % 0.84 [ 0.50, 1.42 ]
Ingle 1986 25/49 21/51 2.3 % 1.49 [ 0.68, 3.28 ]
Lundgren 1989 23/90 26/86 2.9 % 0.79 [ 0.41, 1.53 ]
Mercer 1993 5/33 3/28 0.7 % 1.49 [ 0.32, 6.87 ]
Powles 1984 34/111 48/111 3.7 % 0.58 [ 0.33, 1.01 ]
Rose 1986 32/108 24/107 3.2 % 1.46 [ 0.79, 2.69 ]
Russell 1997 2/75 10/80 0.7 % 0.19 [ 0.04, 0.91 ]
Samonis 1994 9/29 10/28 1.3 % 0.81 [ 0.27, 2.44 ]
Subtotal (95% CI) 880 885 27.7 % 0.89 [ 0.66, 1.20 ]
Total events: 252 (non-AI), 280 (AI)
Heterogeneity: Tau2 = 0.11; Chi2 = 18.08, df = 10 (P = 0.05); I2 =45%
Test for overall effect: Z = 0.74 (P = 0.46)
2 formestane 250 mg
Freue 2000 55/271 45/276 4.8 % 1.31 [ 0.85, 2.02 ]
Perez Carrion 1994 65/206 57/203 4.9 % 1.18 [ 0.77, 1.80 ]
Thuerlimann 1997 14/86 15/91 2.2 % 0.99 [ 0.44, 2.18 ]
Subtotal (95% CI) 563 570 11.9 % 1.20 [ 0.91, 1.60 ]
Total events: 134 (non-AI), 117 (AI)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.39, df = 2 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 1.29 (P = 0.20)
3 anastrozole 1 mg
Bonneterre 2001 138/510 148/511 6.8 % 0.91 [ 0.69, 1.20 ]
Buzdar 1996a 31/253 33/263 3.9 % 0.97 [ 0.58, 1.64 ]
Mauriac 2003 82/428 70/423 5.8 % 1.20 [ 0.84, 1.70 ]
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(. . . Continued)
Study or subgroup non-AI AI Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Milla-Santos 2003 31/117 43/121 3.7 % 0.65 [ 0.38, 1.14 ]
Subtotal (95% CI) 1308 1318 20.1 % 0.95 [ 0.77, 1.17 ]
Total events: 282 (non-AI), 294 (AI)
Heterogeneity: Tau2 = 0.01; Chi2 = 3.48, df = 3 (P = 0.32); I2 =14%
Test for overall effect: Z = 0.46 (P = 0.65)
4 exemestane 25 mg
Chia 2008 20/351 18/342 3.0 % 1.09 [ 0.56, 2.09 ]
Kaufmann 2000 50/403 55/366 5.0 % 0.80 [ 0.53, 1.21 ]
Paridaens 2003 10/60 25/62 2.0 % 0.30 [ 0.13, 0.69 ]
Subtotal (95% CI) 814 770 10.1 % 0.68 [ 0.37, 1.27 ]
Total events: 80 (non-AI), 98 (AI)
Heterogeneity: Tau2 = 0.20; Chi2 = 5.96, df = 2 (P = 0.05); I2 =66%
Test for overall effect: Z = 1.21 (P = 0.23)
5 fadrozole 2 mg
Bezwoda 1998 3/50 3/46 0.6 % 0.91 [ 0.18, 4.78 ]
Buzdar 1996b 30/184 22/196 3.4 % 1.54 [ 0.85, 2.78 ]
Buzdar 1996c 17/151 20/152 2.8 % 0.84 [ 0.42, 1.67 ]
Falkson 1996 17/40 18/40 1.9 % 0.90 [ 0.37, 2.19 ]
Thuerlimann 1996 29/110 21/111 3.1 % 1.53 [ 0.81, 2.90 ]
Subtotal (95% CI) 535 545 11.8 % 1.21 [ 0.87, 1.69 ]
Total events: 96 (non-AI), 84 (AI)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.80, df = 4 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 1.14 (P = 0.25)
6 letrozole 2.5 mg
Buzdar 2001 30/201 32/199 3.8 % 0.92 [ 0.53, 1.57 ]
Dombernowsky 1998 31/189 41/174 4.0 % 0.64 [ 0.38, 1.07 ]
Mourisden 2001 92/454 137/453 6.4 % 0.59 [ 0.43, 0.79 ]
Schmid 2001 9/60 10/52 1.6 % 0.74 [ 0.28, 1.99 ]
Subtotal (95% CI) 904 878 15.7 % 0.65 [ 0.52, 0.82 ]
Total events: 162 (non-AI), 220 (AI)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.05, df = 3 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 3.62 (P = 0.00029)
7 vorozole 2.5 mg
Goss 1999 14/227 20/225 2.7 % 0.67 [ 0.33, 1.37 ]
Subtotal (95% CI) 227 225 2.7 % 0.67 [ 0.33, 1.37 ]
Total events: 14 (non-AI), 20 (AI)
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.28)
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Study or subgroup non-AI AI Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total (95% CI) 5231 5191 100.0 % 0.90 [ 0.78, 1.03 ]
Total events: 1020 (non-AI), 1113 (AI)
Heterogeneity: Tau2 = 0.05; Chi2 = 49.68, df = 30 (P = 0.01); I2 =40%
Test for overall effect: Z = 1.55 (P = 0.12)
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Analysis 2.1. Comparison 2 AI versus non-AI: Toxicity, Outcome 1 hot flushes.
Review: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Comparison: 2 AI versus non-AI: Toxicity
Outcome: 1 hot flushes
Study or subgroup AI comparison Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 AI versus tamoxifen
Bonneterre 2001 134/506 118/511 19.4 % 1.20 [ 0.90, 1.60 ]
Falkson 1996 13/37 15/39 2.1 % 0.87 [ 0.34, 2.20 ]
Ingle 1986 46/48 49/49 0.6 % 0.19 [ 0.01, 4.02 ]
Mourisden 2001 84/455 74/455 13.6 % 1.17 [ 0.83, 1.64 ]
Paridaens 2003 24/62 29/59 4.1 % 0.65 [ 0.32, 1.35 ]
Rose 1986 0/87 4/97 1.0 % 0.12 [ 0.01, 2.24 ]
Thuerlimann 1996 25/104 26/107 4.4 % 0.99 [ 0.52, 1.85 ]
Subtotal (95% CI) 1299 1317 45.2 % 1.07 [ 0.88, 1.29 ]
Total events: 326 (AI), 315 (comparison)
Heterogeneity: Chi2 = 6.31, df = 6 (P = 0.39); I2 =5%
Test for overall effect: Z = 0.67 (P = 0.50)
2 AI versus megestrol acetate
Bezwoda 1998 8/46 3/50 0.5 % 3.30 [ 0.82, 13.30 ]
Buzdar 1996a 34/262 21/253 4.2 % 1.65 [ 0.93, 2.92 ]
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Study or subgroup AI comparison Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Buzdar 1996b 23/196 17/184 3.5 % 1.31 [ 0.67, 2.53 ]
Buzdar 1996c 22/152 17/151 3.3 % 1.33 [ 0.68, 2.63 ]
Buzdar 2001 24/199 25/201 4.9 % 0.97 [ 0.53, 1.76 ]
Dombernowsky 1998 10/174 7/189 1.4 % 1.59 [ 0.59, 4.26 ]
Freue 2000 11/276 9/271 2.0 % 1.21 [ 0.49, 2.96 ]
Goss 1999 44/195 16/198 2.8 % 3.31 [ 1.80, 6.11 ]
Kaufmann 2000 45/358 20/400 3.7 % 2.73 [ 1.58, 4.72 ]
Thuerlimann 1997 39/90 27/81 3.6 % 1.53 [ 0.82, 2.85 ]
Subtotal (95% CI) 1948 1978 29.9 % 1.73 [ 1.40, 2.14 ]
Total events: 260 (AI), 162 (comparison)
Heterogeneity: Chi2 = 13.58, df = 9 (P = 0.14); I2 =34%
Test for overall effect: Z = 5.09 (P < 0.00001)
3 AI versus fulvestrant
Chia 2008 39/342 31/358 6.0 % 1.36 [ 0.83, 2.23 ]
Mauriac 2003 87/423 89/423 15.9 % 0.97 [ 0.70, 1.35 ]
Subtotal (95% CI) 765 781 22.0 % 1.08 [ 0.82, 1.42 ]
Total events: 126 (AI), 120 (comparison)
Heterogeneity: Chi2 = 1.20, df = 1 (P = 0.27); I2 =17%
Test for overall effect: Z = 0.53 (P = 0.59)
4 AI versus medroxyprogesterone acetate
Canney 1988 3/106 14/112 3.0 % 0.20 [ 0.06, 0.73 ]
Subtotal (95% CI) 106 112 3.0 % 0.20 [ 0.06, 0.73 ]
Total events: 3 (AI), 14 (comparison)
Heterogeneity: not applicable
Test for overall effect: Z = 2.44 (P = 0.015)
Total (95% CI) 4118 4188 100.0 % 1.24 [ 1.10, 1.41 ]
Total events: 715 (AI), 611 (comparison)
Heterogeneity: Chi2 = 40.22, df = 19 (P = 0.003); I2 =53%
Test for overall effect: Z = 3.42 (P = 0.00062)
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Analysis 2.2. Comparison 2 AI versus non-AI: Toxicity, Outcome 2 nausea.
Review: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Comparison: 2 AI versus non-AI: Toxicity
Outcome: 2 nausea
Study or subgroup AI comparison Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 AI versus tamoxifen
Bonneterre 2001 94/506 106/511 25.6 % 0.87 [ 0.64, 1.19 ]
Ingle 1986 27/48 12/46 13.6 % 3.64 [ 1.52, 8.70 ]
Mourisden 2001 78/455 77/455 24.8 % 1.02 [ 0.72, 1.44 ]
Paridaens 2003 14/62 21/59 14.9 % 0.53 [ 0.24, 1.17 ]
Powles 1984 27/111 10/111 15.2 % 3.25 [ 1.49, 7.09 ]
Rose 1986 3/87 3/97 5.9 % 1.12 [ 0.22, 5.70 ]
Subtotal (95% CI) 1269 1279 100.0 % 1.29 [ 0.78, 2.13 ]
Total events: 243 (AI), 229 (comparison)
Heterogeneity: Tau2 = 0.25; Chi2 = 20.15, df = 5 (P = 0.001); I2 =75%
Test for overall effect: Z = 1.00 (P = 0.32)
2 AI versus megestrol acetate
Buzdar 1996c 55/152 17/151 11.8 % 4.47 [ 2.44, 8.17 ]
Bezwoda 1998 11/46 8/50 7.2 % 1.65 [ 0.60, 4.55 ]
Buzdar 1996a 46/262 32/253 13.5 % 1.47 [ 0.90, 2.40 ]
Buzdar 1996b 43/196 24/184 12.7 % 1.87 [ 1.08, 3.24 ]
Buzdar 2001 21/199 19/201 11.2 % 1.13 [ 0.59, 2.17 ]
Dombernowsky 1998 19/174 17/189 10.7 % 1.24 [ 0.62, 2.47 ]
Goss 1999 46/195 25/198 12.8 % 2.14 [ 1.25, 3.64 ]
Kaufmann 2000 33/358 20/400 12.3 % 1.93 [ 1.09, 3.43 ]
Freue 2000 9/276 9/271 7.9 % 0.98 [ 0.38, 2.51 ]
Subtotal (95% CI) 1858 1897 100.0 % 1.77 [ 1.33, 2.35 ]
Total events: 283 (AI), 171 (comparison)
Heterogeneity: Tau2 = 0.08; Chi2 = 14.57, df = 8 (P = 0.07); I2 =45%
Test for overall effect: Z = 3.89 (P = 0.00010)
3 AI versus medroxyprogesterone acetate
Samonis 1994 3/26 0/27 100.0 % 8.19 [ 0.40, 166.83 ]
Subtotal (95% CI) 26 27 100.0 % 8.19 [ 0.40, 166.83 ]
Total events: 3 (AI), 0 (comparison)
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(. . . Continued)
Study or subgroup AI comparison Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
4 AI versus fulvestrant
Mauriac 2003 107/423 110/423 56.6 % 0.96 [ 0.71, 1.31 ]
Chia 2008 27/342 24/351 43.4 % 1.17 [ 0.66, 2.07 ]
Subtotal (95% CI) 765 774 100.0 % 1.01 [ 0.77, 1.32 ]
Total events: 134 (AI), 134 (comparison)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.34, df = 1 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
0.1 0.2 0.5 1 2 5 10
AI better AI worse
Analysis 2.3. Comparison 2 AI versus non-AI: Toxicity, Outcome 3 vomiting.
Review: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Comparison: 2 AI versus non-AI: Toxicity
Outcome: 3 vomiting
Study or subgroup AI non-AI Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 AI versus tamoxifen
Bonneterre 2001 38/506 36/511 90.1 % 1.07 [ 0.67, 1.72 ]
Powles 1984 10/111 4/111 9.9 % 2.65 [ 0.80, 8.71 ]
Subtotal (95% CI) 617 622 100.0 % 1.23 [ 0.79, 1.90 ]
Total events: 48 (AI), 40 (non-AI)
Heterogeneity: Chi2 = 1.92, df = 1 (P = 0.17); I2 =48%
Test for overall effect: Z = 0.92 (P = 0.36)
2 AI versus megestrol acetate
Buzdar 1996a 27/262 17/253 34.8 % 1.59 [ 0.85, 3.00 ]
Buzdar 1996b 18/196 9/184 18.9 % 1.97 [ 0.86, 4.50 ]
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(. . . Continued)
Study or subgroup AI non-AI Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Buzdar 1996c 28/152 11/151 20.2 % 2.87 [ 1.37, 6.01 ]
Dombernowsky 1998 13/174 10/189 19.9 % 1.45 [ 0.62, 3.39 ]
Kaufmann 2000 10/358 3/400 6.2 % 3.80 [ 1.04, 13.93 ]
Subtotal (95% CI) 1142 1177 100.0 % 2.03 [ 1.42, 2.90 ]
Total events: 96 (AI), 50 (non-AI)
Heterogeneity: Chi2 = 2.92, df = 4 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 3.90 (P = 0.000094)
3 AI versus fulvestrant
Mauriac 2003 50/423 55/423 100.0 % 0.90 [ 0.60, 1.35 ]
Subtotal (95% CI) 423 423 100.0 % 0.90 [ 0.60, 1.35 ]
Total events: 50 (AI), 55 (non-AI)
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
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Analysis 2.4. Comparison 2 AI versus non-AI: Toxicity, Outcome 4 diarrhoea.
Review: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Comparison: 2 AI versus non-AI: Toxicity
Outcome: 4 diarrhoea
Study or subgroup AI comparison Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 AI versus tamoxifen
Bonneterre 2001 40/506 33/511 95.4 % 1.24 [ 0.77, 2.01 ]
Mourisden 2001 9/455 1/455 3.1 % 9.16 [ 1.16, 72.61 ]
Powles 1984 5/111 0/111 1.5 % 11.52 [ 0.63, 210.82 ]
Subtotal (95% CI) 1072 1077 100.0 % 1.64 [ 1.06, 2.55 ]
Total events: 54 (AI), 34 (comparison)
Heterogeneity: Chi2 = 5.67, df = 2 (P = 0.06); I2 =65%
Test for overall effect: Z = 2.21 (P = 0.027)
2 AI versus megestrol acetate
Buzdar 1996a 23/262 7/253 13.6 % 3.38 [ 1.42, 8.03 ]
Buzdar 1996b 22/196 18/184 34.6 % 1.17 [ 0.60, 2.25 ]
Buzdar 1996c 15/152 17/151 32.2 % 0.86 [ 0.41, 1.80 ]
Buzdar 2001 5/199 5/201 10.2 % 1.01 [ 0.29, 3.55 ]
Dombernowsky 1998 11/174 5/189 9.4 % 2.48 [ 0.85, 7.30 ]
Subtotal (95% CI) 983 978 100.0 % 1.48 [ 1.02, 2.13 ]
Total events: 76 (AI), 52 (comparison)
Heterogeneity: Chi2 = 7.33, df = 4 (P = 0.12); I2 =45%
Test for overall effect: Z = 2.09 (P = 0.037)
3 AI versus fulvestrant
Chia 2008 10/342 12/351 31.8 % 0.85 [ 0.36, 2.00 ]
Mauriac 2003 40/193 32/204 68.2 % 1.41 [ 0.84, 2.35 ]
Subtotal (95% CI) 535 555 100.0 % 1.23 [ 0.79, 1.90 ]
Total events: 50 (AI), 44 (comparison)
Heterogeneity: Chi2 = 0.98, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 0.92 (P = 0.36)
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Analysis 2.5. Comparison 2 AI versus non-AI: Toxicity, Outcome 5 rash.
Review: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Comparison: 2 AI versus non-AI: Toxicity
Outcome: 5 rash
Study or subgroup AI comparison Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 AI versus tamoxifen
Ingle 1986 48/48 6/46 23.2 % 604.38 [ 33.04, 11056.23 ]
Powles 1984 16/111 1/111 32.3 % 18.53 [ 2.41, 142.31 ]
Rose 1986 13/87 0/97 23.8 % 35.34 [ 2.07, 604.03 ]
Thuerlimann 1996 1/104 0/107 20.7 % 3.12 [ 0.13, 77.36 ]
Subtotal (95% CI) 350 361 100.0 % 33.61 [ 4.71, 239.97 ]
Total events: 78 (AI), 7 (comparison)
Heterogeneity: Tau2 = 2.10; Chi2 = 6.33, df = 3 (P = 0.10); I2 =53%
Test for overall effect: Z = 3.50 (P = 0.00046)
2 AI versus megestrol acetate
Buzdar 1996a 16/262 21/253 15.5 % 0.72 [ 0.37, 1.41 ]
Buzdar 1996b 11/196 16/184 15.1 % 0.62 [ 0.28, 1.38 ]
Buzdar 1996c 18/152 13/151 15.3 % 1.43 [ 0.67, 3.02 ]
Dombernowsky 1998 10/174 6/189 14.3 % 1.86 [ 0.66, 5.23 ]
Freue 2000 4/276 3/271 12.4 % 1.31 [ 0.29, 5.93 ]
Kaufmann 2000 7/358 0/400 7.5 % 17.09 [ 0.97, 300.32 ]
Lundgren 1989 10/86 0/90 7.5 % 24.84 [ 1.43, 430.91 ]
Russell 1997 24/88 2/89 12.5 % 16.31 [ 3.72, 71.53 ]
Subtotal (95% CI) 1592 1627 100.0 % 2.06 [ 0.92, 4.62 ]
Total events: 100 (AI), 61 (comparison)
Heterogeneity: Tau2 = 0.87; Chi2 = 27.30, df = 7 (P = 0.00029); I2 =74%
Test for overall effect: Z = 1.75 (P = 0.080)
3 AI versus medroxyprogesterone acetate
Canney 1988 35/106 0/112 51.6 % 111.71 [ 6.75, 1849.91 ]
Samonis 1994 4/26 0/27 48.4 % 11.00 [ 0.56, 215.35 ]
Subtotal (95% CI) 132 139 100.0 % 36.80 [ 3.35, 404.73 ]
Total events: 39 (AI), 0 (comparison)
Heterogeneity: Tau2 = 0.82; Chi2 = 1.38, df = 1 (P = 0.24); I2 =27%
Test for overall effect: Z = 2.95 (P = 0.0032)
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Study or subgroup AI comparison Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
4 AI versus fulvestrant
Mauriac 2003 29/193 23/204 100.0 % 1.39 [ 0.77, 2.50 ]
Subtotal (95% CI) 193 204 100.0 % 1.39 [ 0.77, 2.50 ]
Total events: 29 (AI), 23 (comparison)
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
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Analysis 2.6. Comparison 2 AI versus non-AI: Toxicity, Outcome 6 vaginal bleeding.
Review: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Comparison: 2 AI versus non-AI: Toxicity
Outcome: 6 vaginal bleeding
Study or subgroup AI comparison Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 AI versus tamoxifen
Bonneterre 2001 5/506 11/511 100.0 % 0.45 [ 0.16, 1.32 ]
Subtotal (95% CI) 506 511 100.0 % 0.45 [ 0.16, 1.32 ]
Total events: 5 (AI), 11 (comparison)
Heterogeneity: not applicable
Test for overall effect: Z = 1.46 (P = 0.15)
2 AI versus megestrol acetate
Buzdar 1996a 7/262 14/253 35.7 % 0.47 [ 0.19, 1.18 ]
Buzdar 2001 1/199 12/201 30.6 % 0.08 [ 0.01, 0.62 ]
Freue 2000 1/276 13/271 33.7 % 0.07 [ 0.01, 0.56 ]
Subtotal (95% CI) 737 725 100.0 % 0.22 [ 0.10, 0.45 ]
Total events: 9 (AI), 39 (comparison)
Heterogeneity: Chi2 = 4.72, df = 2 (P = 0.09); I2 =58%
Test for overall effect: Z = 4.09 (P = 0.000044)
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(. . . Continued)
Study or subgroup AI comparison Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
3 AI versus medroxyprogesterone acetate
Canney 1988 1/106 10/112 87.0 % 0.10 [ 0.01, 0.77 ]
Samonis 1994 0/26 1/27 13.0 % 0.33 [ 0.01, 8.56 ]
Subtotal (95% CI) 132 139 100.0 % 0.13 [ 0.02, 0.71 ]
Total events: 1 (AI), 11 (comparison)
Heterogeneity: Chi2 = 0.40, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 2.35 (P = 0.019)
0.01 0.1 1 10 100
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Analysis 2.7. Comparison 2 AI versus non-AI: Toxicity, Outcome 7 thromboembolic.
Review: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Comparison: 2 AI versus non-AI: Toxicity
Outcome: 7 thromboembolic
Study or subgroup AI comparison Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 AI versus tamoxifen
Bonneterre 2001 18/506 33/511 87.8 % 0.53 [ 0.30, 0.96 ]
Thuerlimann 1996 0/104 4/107 12.2 % 0.11 [ 0.01, 2.07 ]
Subtotal (95% CI) 610 618 100.0 % 0.48 [ 0.27, 0.85 ]
Total events: 18 (AI), 37 (comparison)
Heterogeneity: Chi2 = 1.09, df = 1 (P = 0.30); I2 =8%
Test for overall effect: Z = 2.51 (P = 0.012)
2 AI versus megestrol acetate
Buzdar 1996a 9/262 12/253 56.1 % 0.71 [ 0.30, 1.73 ]
Russell 1997 2/88 2/89 9.2 % 1.01 [ 0.14, 7.35 ]
Thuerlimann 1997 1/90 7/81 34.7 % 0.12 [ 0.01, 0.99 ]
Subtotal (95% CI) 440 423 100.0 % 0.54 [ 0.26, 1.10 ]
Total events: 12 (AI), 21 (comparison)
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Study or subgroup AI comparison Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: Chi2 = 2.75, df = 2 (P = 0.25); I2 =27%
Test for overall effect: Z = 1.70 (P = 0.089)
3 AI versus fulvestrant
Mauriac 2003 17/423 15/423 100.0 % 1.14 [ 0.56, 2.31 ]
Subtotal (95% CI) 423 423 100.0 % 1.14 [ 0.56, 2.31 ]
Total events: 17 (AI), 15 (comparison)
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
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Analysis 2.8. Comparison 2 AI versus non-AI: Toxicity, Outcome 8 arthralgia.
Review: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Comparison: 2 AI versus non-AI: Toxicity
Outcome: 8 arthralgia
Study or subgroup AI comparison Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 AI versus tamoxifen
Mourisden 2001 71/455 67/455 91.8 % 1.07 [ 0.75, 1.54 ]
Paridaens 2003 11/62 6/59 8.2 % 1.91 [ 0.66, 5.53 ]
Subtotal (95% CI) 517 514 100.0 % 1.14 [ 0.81, 1.60 ]
Total events: 82 (AI), 73 (comparison)
Heterogeneity: Chi2 = 1.01, df = 1 (P = 0.32); I2 =1%
Test for overall effect: Z = 0.75 (P = 0.46)
2 AI versus megestrol acetate
Buzdar 1996b 7/196 12/184 23.3 % 0.53 [ 0.20, 1.38 ]
Buzdar 1996c 17/152 14/151 24.4 % 1.23 [ 0.58, 2.60 ]
Dombernowsky 1998 23/174 15/189 24.4 % 1.77 [ 0.89, 3.51 ]
Goss 1999 30/195 17/198 27.9 % 1.94 [ 1.03, 3.64 ]
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Study or subgroup AI comparison Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 717 722 100.0 % 1.40 [ 0.98, 2.00 ]
Total events: 77 (AI), 58 (comparison)
Heterogeneity: Chi2 = 5.53, df = 3 (P = 0.14); I2 =46%
Test for overall effect: Z = 1.83 (P = 0.068)
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AI better AI worse
Analysis 3.1. Comparison 3 Current AIs versus non-AI, Outcome 1 Overall survival (reported or calculated).
Review: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Comparison: 3 Current AIs versus non-AI
Outcome: 1 Overall survival (reported or calculated)
Study or subgroup log [HR] HR Weight HR
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 anastrozole 1 mg
Bonneterre 2001 -0.0305 (0.0931) 23.3 % 0.97 [ 0.81, 1.16 ]
Buzdar 1996a -0.2485 (0.1277) 12.4 % 0.78 [ 0.61, 1.00 ]
Milla-Santos 2003 -0.0834 (0.1533) 8.6 % 0.92 [ 0.68, 1.24 ]
Subtotal (95% CI) 44.2 % 0.90 [ 0.79, 1.03 ]
Heterogeneity: Chi2 = 1.92, df = 2 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 1.51 (P = 0.13)
2 exemestane 25 mg
Kaufmann 2000 -0.1661 (0.0805) 31.1 % 0.85 [ 0.72, 0.99 ]
Subtotal (95% CI) 31.1 % 0.85 [ 0.72, 0.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.06 (P = 0.039)
3 letrozole 2.5 mg
Buzdar 2001 -0.0834 (0.1203) 13.9 % 0.92 [ 0.73, 1.16 ]
Dombernowsky 1998 -0.1985 (0.1375) 10.7 % 0.82 [ 0.63, 1.07 ]
Subtotal (95% CI) 24.6 % 0.88 [ 0.73, 1.05 ]
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Study or subgroup log [HR] HR Weight HR
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Heterogeneity: Chi2 = 0.40, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 1.47 (P = 0.14)
Total (95% CI) 100.0 % 0.88 [ 0.80, 0.96 ]
Heterogeneity: Chi2 = 2.69, df = 5 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 2.88 (P = 0.0039)
Test for subgroup differences: Chi2 = 0.38, df = 2 (P = 0.83), I2 =0.0%
0.5 0.7 1 1.5 2
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Analysis 3.2. Comparison 3 Current AIs versus non-AI, Outcome 2 Progression-free survival (reported or
calculated).
Review: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Comparison: 3 Current AIs versus non-AI
Outcome: 2 Progression-free survival (reported or calculated)
Study or subgroup log [HR] HR Weight HR
(SE) IV,Random,95% CI IV,Random,95% CI
1 anastrozole 1 mg
Bonneterre 2001 -0.1985 (0.0743) 15.3 % 0.82 [ 0.71, 0.95 ]
Mauriac 2003 0.2927 (0.0739) 15.3 % 1.34 [ 1.16, 1.55 ]
Subtotal (95% CI) 30.5 % 1.05 [ 0.65, 1.70 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 21.97, df = 1 (P<0.00001); I2 =95%
Test for overall effect: Z = 0.19 (P = 0.85)
2 exemestane 25 mg
Chia 2008 0.0377 (0.1237) 13.0 % 1.04 [ 0.81, 1.32 ]
Kaufmann 2000 -0.1985 (0.0842) 14.8 % 0.82 [ 0.70, 0.97 ]
Subtotal (95% CI) 27.9 % 0.91 [ 0.72, 1.14 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 2.49, df = 1 (P = 0.11); I2 =60%
Test for overall effect: Z = 0.84 (P = 0.40)
3 letrozole 2.5 mg
Buzdar 2001 -0.0101 (0.1129) 13.5 % 0.99 [ 0.79, 1.24 ]
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(. . . Continued)
Study or subgroup log [HR] HR Weight HR
(SE) IV,Random,95% CI IV,Random,95% CI
Dombernowsky 1998 -0.0202 (0.1236) 13.0 % 0.98 [ 0.77, 1.25 ]
Mourisden 2001 -0.3567 (0.0797) 15.0 % 0.70 [ 0.60, 0.82 ]
Subtotal (95% CI) 41.6 % 0.87 [ 0.68, 1.11 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 8.80, df = 2 (P = 0.01); I2 =77%
Test for overall effect: Z = 1.12 (P = 0.26)
Total (95% CI) 100.0 % 0.93 [ 0.78, 1.12 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 43.52, df = 6 (P<0.00001); I2 =86%
Test for overall effect: Z = 0.73 (P = 0.47)
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Analysis 3.3. Comparison 3 Current AIs versus non-AI, Outcome 3 Clinical benefit (assessable).
Review: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Comparison: 3 Current AIs versus non-AI
Outcome: 3 Clinical benefit (assessable)
Study or subgroup non-AI AI Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 anastrozole 1 mg
Bonneterre 2001 265/510 292/511 12.5 % 0.81 [ 0.63, 1.04 ]
Buzdar 1996a 102/253 111/263 10.3 % 0.93 [ 0.65, 1.31 ]
Mauriac 2003 186/428 173/423 11.9 % 1.11 [ 0.85, 1.46 ]
Milla-Santos 2003 65/117 100/121 6.3 % 0.26 [ 0.14, 0.48 ]
Subtotal (95% CI) 1308 1318 41.1 % 0.74 [ 0.48, 1.12 ]
Total events: 618 (non-AI), 676 (AI)
Heterogeneity: Tau2 = 0.15; Chi2 = 19.04, df = 3 (P = 0.00027); I2 =84%
Test for overall effect: Z = 1.42 (P = 0.16)
2 exemestane 25 mg
Chia 2008 87/270 85/270 10.1 % 1.03 [ 0.72, 1.49 ]
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Study or subgroup non-AI AI Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kaufmann 2000 135/366 133/337 11.3 % 0.90 [ 0.66, 1.22 ]
Paridaens 2003 25/57 35/56 4.7 % 0.47 [ 0.22, 0.99 ]
Subtotal (95% CI) 693 663 26.1 % 0.86 [ 0.63, 1.19 ]
Total events: 247 (non-AI), 253 (AI)
Heterogeneity: Tau2 = 0.03; Chi2 = 3.45, df = 2 (P = 0.18); I2 =42%
Test for overall effect: Z = 0.91 (P = 0.36)
3 letrozole 2.5 mg
Buzdar 2001 47/180 53/182 8.3 % 0.86 [ 0.54, 1.36 ]
Dombernowsky 1998 60/166 60/153 8.4 % 0.88 [ 0.56, 1.38 ]
Mourisden 2001 173/423 221/421 11.9 % 0.63 [ 0.48, 0.82 ]
Schmid 2001 19/60 14/52 4.1 % 1.26 [ 0.55, 2.85 ]
Subtotal (95% CI) 829 808 32.8 % 0.77 [ 0.60, 1.00 ]
Total events: 299 (non-AI), 348 (AI)
Heterogeneity: Tau2 = 0.02; Chi2 = 4.00, df = 3 (P = 0.26); I2 =25%
Test for overall effect: Z = 2.00 (P = 0.046)
Total (95% CI) 2830 2789 100.0 % 0.80 [ 0.66, 0.97 ]
Total events: 1164 (non-AI), 1277 (AI)
Heterogeneity: Tau2 = 0.06; Chi2 = 28.23, df = 10 (P = 0.002); I2 =65%
Test for overall effect: Z = 2.22 (P = 0.026)
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Analysis 3.4. Comparison 3 Current AIs versus non-AI, Outcome 4 Objective response (assessable).
Review: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Comparison: 3 Current AIs versus non-AI
Outcome: 4 Objective response (assessable)
Study or subgroup non-AI AI Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 anastrozole 1 mg
Bonneterre 2001 138/510 148/511 14.9 % 0.91 [ 0.69, 1.20 ]
Buzdar 1996a 31/253 33/263 8.6 % 0.97 [ 0.58, 1.64 ]
Mauriac 2003 82/428 70/423 12.6 % 1.20 [ 0.84, 1.70 ]
Milla-Santos 2003 31/117 43/121 8.1 % 0.65 [ 0.38, 1.14 ]
Subtotal (95% CI) 1308 1318 44.2 % 0.95 [ 0.77, 1.17 ]
Total events: 282 (non-AI), 294 (AI)
Heterogeneity: Tau2 = 0.01; Chi2 = 3.48, df = 3 (P = 0.32); I2 =14%
Test for overall effect: Z = 0.46 (P = 0.65)
2 exemestane 25 mg
Chia 2008 20/270 18/270 6.4 % 1.12 [ 0.58, 2.17 ]
Kaufmann 2000 50/366 55/337 11.0 % 0.81 [ 0.54, 1.23 ]
Paridaens 2003 10/57 25/56 4.3 % 0.26 [ 0.11, 0.62 ]
Subtotal (95% CI) 693 663 21.8 % 0.67 [ 0.33, 1.33 ]
Total events: 80 (non-AI), 98 (AI)
Heterogeneity: Tau2 = 0.26; Chi2 = 7.20, df = 2 (P = 0.03); I2 =72%
Test for overall effect: Z = 1.16 (P = 0.25)
3 letrozole 2.5 mg
Buzdar 2001 30/180 32/182 8.2 % 0.94 [ 0.54, 1.62 ]
Dombernowsky 1998 31/166 41/153 8.5 % 0.63 [ 0.37, 1.07 ]
Mourisden 2001 92/423 137/421 13.8 % 0.58 [ 0.42, 0.78 ]
Schmid 2001 9/60 10/52 3.5 % 0.74 [ 0.28, 1.99 ]
Subtotal (95% CI) 829 808 34.1 % 0.65 [ 0.51, 0.82 ]
Total events: 162 (non-AI), 220 (AI)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.39, df = 3 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 3.65 (P = 0.00027)
Total (95% CI) 2830 2789 100.0 % 0.79 [ 0.65, 0.97 ]
Total events: 524 (non-AI), 612 (AI)
Heterogeneity: Tau2 = 0.05; Chi2 = 19.76, df = 10 (P = 0.03); I2 =49%
Test for overall effect: Z = 2.26 (P = 0.024)
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Analysis 3.5. Comparison 3 Current AIs versus non-AI, Outcome 5 Clinical benefit (randomised).
Review: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Comparison: 3 Current AIs versus non-AI
Outcome: 5 Clinical benefit (randomised)
Study or subgroup non-AI AI Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 anastrozole 1 mg
Bonneterre 2001 265/510 292/511 12.6 % 0.81 [ 0.63, 1.04 ]
Buzdar 1996a 102/253 111/263 10.2 % 0.93 [ 0.65, 1.31 ]
Mauriac 2003 186/428 173/423 12.0 % 1.11 [ 0.85, 1.46 ]
Milla-Santos 2003 65/117 100/121 6.0 % 0.26 [ 0.14, 0.48 ]
Subtotal (95% CI) 1308 1318 40.8 % 0.74 [ 0.48, 1.12 ]
Total events: 618 (non-AI), 676 (AI)
Heterogeneity: Tau2 = 0.15; Chi2 = 19.04, df = 3 (P = 0.00027); I2 =84%
Test for overall effect: Z = 1.42 (P = 0.16)
2 exemestane 25 mg
Chia 2008 87/351 85/342 10.4 % 1.00 [ 0.71, 1.41 ]
Kaufmann 2000 135/403 133/366 11.4 % 0.88 [ 0.66, 1.19 ]
Paridaens 2003 25/60 35/62 4.7 % 0.55 [ 0.27, 1.13 ]
Subtotal (95% CI) 814 770 26.5 % 0.88 [ 0.71, 1.11 ]
Total events: 247 (non-AI), 253 (AI)
Heterogeneity: Tau2 = 0.00; Chi2 = 2.13, df = 2 (P = 0.35); I2 =6%
Test for overall effect: Z = 1.07 (P = 0.28)
3 letrozole 2.5 mg
Buzdar 2001 47/201 53/199 8.2 % 0.84 [ 0.53, 1.32 ]
Dombernowsky 1998 60/189 60/174 8.5 % 0.88 [ 0.57, 1.37 ]
Mourisden 2001 173/454 221/453 12.2 % 0.65 [ 0.50, 0.84 ]
Schmid 2001 19/60 14/52 3.9 % 1.26 [ 0.55, 2.85 ]
Subtotal (95% CI) 904 878 32.7 % 0.77 [ 0.61, 0.96 ]
Total events: 299 (non-AI), 348 (AI)
Heterogeneity: Tau2 = 0.01; Chi2 = 3.53, df = 3 (P = 0.32); I2 =15%
Test for overall effect: Z = 2.29 (P = 0.022)
Total (95% CI) 3026 2966 100.0 % 0.81 [ 0.67, 0.97 ]
Total events: 1164 (non-AI), 1277 (AI)
Heterogeneity: Tau2 = 0.05; Chi2 = 26.18, df = 10 (P = 0.004); I2 =62%
Test for overall effect: Z = 2.27 (P = 0.023)
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Analysis 3.6. Comparison 3 Current AIs versus non-AI, Outcome 6 Objective response (randomised).
Review: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Comparison: 3 Current AIs versus non-AI
Outcome: 6 Objective response (randomised)
Study or subgroup non-AI AI Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 anastrozole 1 mg
Bonneterre 2001 138/510 148/511 15.4 % 0.91 [ 0.69, 1.20 ]
Buzdar 1996a 31/253 33/263 8.4 % 0.97 [ 0.58, 1.64 ]
Mauriac 2003 82/428 70/423 12.8 % 1.20 [ 0.84, 1.70 ]
Milla-Santos 2003 31/117 43/121 7.8 % 0.65 [ 0.38, 1.14 ]
Subtotal (95% CI) 1308 1318 44.5 % 0.95 [ 0.77, 1.17 ]
Total events: 282 (non-AI), 294 (AI)
Heterogeneity: Tau2 = 0.01; Chi2 = 3.48, df = 3 (P = 0.32); I2 =14%
Test for overall effect: Z = 0.46 (P = 0.65)
2 exemestane 25 mg
Chia 2008 20/351 18/342 6.2 % 1.09 [ 0.56, 2.09 ]
Kaufmann 2000 50/403 55/366 11.0 % 0.80 [ 0.53, 1.21 ]
Paridaens 2003 10/60 25/62 4.2 % 0.30 [ 0.13, 0.69 ]
Subtotal (95% CI) 814 770 21.4 % 0.68 [ 0.37, 1.27 ]
Total events: 80 (non-AI), 98 (AI)
Heterogeneity: Tau2 = 0.20; Chi2 = 5.96, df = 2 (P = 0.05); I2 =66%
Test for overall effect: Z = 1.21 (P = 0.23)
3 letrozole 2.5 mg
Buzdar 2001 30/201 32/199 8.1 % 0.92 [ 0.53, 1.57 ]
Dombernowsky 1998 31/189 41/174 8.5 % 0.64 [ 0.38, 1.07 ]
Mourisden 2001 92/454 137/453 14.4 % 0.59 [ 0.43, 0.79 ]
Schmid 2001 9/60 10/52 3.2 % 0.74 [ 0.28, 1.99 ]
Subtotal (95% CI) 904 878 34.1 % 0.65 [ 0.52, 0.82 ]
Total events: 162 (non-AI), 220 (AI)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.05, df = 3 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 3.62 (P = 0.00029)
Total (95% CI) 3026 2966 100.0 % 0.80 [ 0.66, 0.96 ]
Total events: 524 (non-AI), 612 (AI)
Heterogeneity: Tau2 = 0.04; Chi2 = 18.03, df = 10 (P = 0.05); I2 =45%
Test for overall effect: Z = 2.34 (P = 0.019)
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Analysis 4.1. Comparison 4 Current AIs versus non-AI: Toxicity, Outcome 1 hot flushes.
Review: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Comparison: 4 Current AIs versus non-AI: Toxicity
Outcome: 1 hot flushes
Study or subgroup AI non-AI Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 AI versus tamoxifen
Bonneterre 2001 134/506 118/511 52.4 % 1.20 [ 0.90, 1.60 ]
Mourisden 2001 84/455 74/455 36.6 % 1.17 [ 0.83, 1.64 ]
Paridaens 2003 24/62 29/59 11.0 % 0.65 [ 0.32, 1.35 ]
Subtotal (95% CI) 1023 1025 100.0 % 1.13 [ 0.91, 1.39 ]
Total events: 242 (AI), 221 (non-AI)
Heterogeneity: Chi2 = 2.41, df = 2 (P = 0.30); I2 =17%
Test for overall effect: Z = 1.12 (P = 0.26)
2 AI versus megestrol acetate
Buzdar 1996a 34/262 21/253 29.4 % 1.65 [ 0.93, 2.92 ]
Buzdar 2001 24/199 25/201 34.6 % 0.97 [ 0.53, 1.76 ]
Dombernowsky 1998 10/174 7/189 10.0 % 1.59 [ 0.59, 4.26 ]
Kaufmann 2000 45/358 20/400 26.1 % 2.73 [ 1.58, 4.72 ]
Subtotal (95% CI) 993 1043 100.0 % 1.69 [ 1.24, 2.30 ]
Total events: 113 (AI), 73 (non-AI)
Heterogeneity: Chi2 = 6.35, df = 3 (P = 0.10); I2 =53%
Test for overall effect: Z = 3.33 (P = 0.00088)
3 AI versus fulvestrant
Chia 2008 39/342 31/351 27.7 % 1.33 [ 0.81, 2.18 ]
Mauriac 2003 87/423 89/423 72.3 % 0.97 [ 0.70, 1.35 ]
Subtotal (95% CI) 765 774 100.0 % 1.07 [ 0.81, 1.41 ]
Total events: 126 (AI), 120 (non-AI)
Heterogeneity: Chi2 = 1.05, df = 1 (P = 0.30); I2 =5%
Test for overall effect: Z = 0.49 (P = 0.63)
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Analysis 4.2. Comparison 4 Current AIs versus non-AI: Toxicity, Outcome 2 nausea.
Review: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Comparison: 4 Current AIs versus non-AI: Toxicity
Outcome: 2 nausea
Study or subgroup AI comparison Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 AI versus tamoxifen
Bonneterre 2001 94/506 106/511 51.6 % 0.87 [ 0.64, 1.19 ]
Mourisden 2001 78/455 77/455 38.4 % 1.02 [ 0.72, 1.44 ]
Paridaens 2003 14/62 21/59 10.0 % 0.53 [ 0.24, 1.17 ]
Subtotal (95% CI) 1023 1025 100.0 % 0.89 [ 0.72, 1.11 ]
Total events: 186 (AI), 204 (comparison)
Heterogeneity: Chi2 = 2.22, df = 2 (P = 0.33); I2 =10%
Test for overall effect: Z = 1.01 (P = 0.31)
2 AI versus megestrol acetate
Buzdar 1996a 46/262 32/253 35.6 % 1.47 [ 0.90, 2.40 ]
Buzdar 2001 21/199 19/201 22.4 % 1.13 [ 0.59, 2.17 ]
Dombernowsky 1998 19/174 17/189 19.2 % 1.24 [ 0.62, 2.47 ]
Kaufmann 2000 33/358 20/400 22.7 % 1.93 [ 1.09, 3.43 ]
Subtotal (95% CI) 993 1043 100.0 % 1.45 [ 1.09, 1.95 ]
Total events: 119 (AI), 88 (comparison)
Heterogeneity: Chi2 = 1.71, df = 3 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 2.52 (P = 0.012)
3 AI versus fulvestrant
Chia 2008 27/342 24/351 21.0 % 1.17 [ 0.66, 2.07 ]
Mauriac 2003 107/423 110/423 79.0 % 0.96 [ 0.71, 1.31 ]
Subtotal (95% CI) 765 774 100.0 % 1.01 [ 0.77, 1.32 ]
Total events: 134 (AI), 134 (comparison)
Heterogeneity: Chi2 = 0.34, df = 1 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
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Analysis 4.3. Comparison 4 Current AIs versus non-AI: Toxicity, Outcome 3 vomiting.
Review: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Comparison: 4 Current AIs versus non-AI: Toxicity
Outcome: 3 vomiting
Study or subgroup AI non-AI Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 AI versus tamoxifen
Bonneterre 2001 38/506 36/511 100.0 % 1.07 [ 0.67, 1.72 ]
Subtotal (95% CI) 506 511 100.0 % 1.07 [ 0.67, 1.72 ]
Total events: 38 (AI), 36 (non-AI)
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.78)
2 AI versus megestrol acetate
Buzdar 1996a 27/262 17/253 57.2 % 1.59 [ 0.85, 3.00 ]
Dombernowsky 1998 13/174 10/189 32.7 % 1.45 [ 0.62, 3.39 ]
Kaufmann 2000 10/358 3/400 10.1 % 3.80 [ 1.04, 13.93 ]
Subtotal (95% CI) 794 842 100.0 % 1.77 [ 1.11, 2.83 ]
Total events: 50 (AI), 30 (non-AI)
Heterogeneity: Chi2 = 1.65, df = 2 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 2.39 (P = 0.017)
3 AI versus fulvestrant
Mauriac 2003 50/423 55/423 100.0 % 0.90 [ 0.60, 1.35 ]
Subtotal (95% CI) 423 423 100.0 % 0.90 [ 0.60, 1.35 ]
Total events: 50 (AI), 55 (non-AI)
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
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Analysis 4.4. Comparison 4 Current AIs versus non-AI: Toxicity, Outcome 4 diarrhoea.
Review: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Comparison: 4 Current AIs versus non-AI: Toxicity
Outcome: 4 diarrhoea
Study or subgroup AI comparison Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 AI versus tamoxifen
Bonneterre 2001 40/506 33/511 96.9 % 1.24 [ 0.77, 2.01 ]
Mourisden 2001 9/455 1/455 3.1 % 9.16 [ 1.16, 72.61 ]
Subtotal (95% CI) 961 966 100.0 % 1.49 [ 0.95, 2.35 ]
Total events: 49 (AI), 34 (comparison)
Heterogeneity: Chi2 = 3.51, df = 1 (P = 0.06); I2 =72%
Test for overall effect: Z = 1.73 (P = 0.083)
2 AI versus megestrol acetate
Buzdar 1996a 23/262 7/253 41.0 % 3.38 [ 1.42, 8.03 ]
Buzdar 2001 5/199 5/201 30.6 % 1.01 [ 0.29, 3.55 ]
Dombernowsky 1998 11/174 5/189 28.4 % 2.48 [ 0.85, 7.30 ]
Subtotal (95% CI) 635 643 100.0 % 2.40 [ 1.34, 4.29 ]
Total events: 39 (AI), 17 (comparison)
Heterogeneity: Chi2 = 2.43, df = 2 (P = 0.30); I2 =18%
Test for overall effect: Z = 2.96 (P = 0.0031)
3 AI versus fulvestrant
Chia 2008 10/342 12/351 31.8 % 0.85 [ 0.36, 2.00 ]
Mauriac 2003 40/193 32/204 68.2 % 1.41 [ 0.84, 2.35 ]
Subtotal (95% CI) 535 555 100.0 % 1.23 [ 0.79, 1.90 ]
Total events: 50 (AI), 44 (comparison)
Heterogeneity: Chi2 = 0.98, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 0.92 (P = 0.36)
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Analysis 4.5. Comparison 4 Current AIs versus non-AI: Toxicity, Outcome 5 rash.
Review: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Comparison: 4 Current AIs versus non-AI: Toxicity
Outcome: 5 rash
Study or subgroup comparison AI Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 AI versus megestrol acetate
Buzdar 1996a 16/262 21/253 54.2 % 0.72 [ 0.37, 1.41 ]
Dombernowsky 1998 10/174 6/189 37.6 % 1.86 [ 0.66, 5.23 ]
Kaufmann 2000 7/358 0/400 8.2 % 17.09 [ 0.97, 300.32 ]
Subtotal (95% CI) 794 842 100.0 % 1.63 [ 0.47, 5.70 ]
Total events: 33 (comparison), 27 (AI)
Heterogeneity: Tau2 = 0.76; Chi2 = 6.35, df = 2 (P = 0.04); I2 =68%
Test for overall effect: Z = 0.77 (P = 0.44)
2 AI versus fulvestrant
Mauriac 2003 29/193 23/204 100.0 % 1.39 [ 0.77, 2.50 ]
Subtotal (95% CI) 193 204 100.0 % 1.39 [ 0.77, 2.50 ]
Total events: 29 (comparison), 23 (AI)
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
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Analysis 4.6. Comparison 4 Current AIs versus non-AI: Toxicity, Outcome 6 vaginal bleeding.
Review: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Comparison: 4 Current AIs versus non-AI: Toxicity
Outcome: 6 vaginal bleeding
Study or subgroup AI comparison Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 AI versus tamoxifen
Bonneterre 2001 5/506 11/511 100.0 % 0.45 [ 0.16, 1.32 ]
Subtotal (95% CI) 506 511 100.0 % 0.45 [ 0.16, 1.32 ]
Total events: 5 (AI), 11 (comparison)
Heterogeneity: not applicable
Test for overall effect: Z = 1.46 (P = 0.15)
2 AI versus megestrol acetate
Buzdar 1996a 7/262 14/253 53.9 % 0.47 [ 0.19, 1.18 ]
Buzdar 2001 1/199 12/201 46.1 % 0.08 [ 0.01, 0.62 ]
Subtotal (95% CI) 461 454 100.0 % 0.29 [ 0.13, 0.65 ]
Total events: 8 (AI), 26 (comparison)
Heterogeneity: Chi2 = 2.57, df = 1 (P = 0.11); I2 =61%
Test for overall effect: Z = 3.02 (P = 0.0025)
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Analysis 4.7. Comparison 4 Current AIs versus non-AI: Toxicity, Outcome 7 thromboembolic.
Review: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Comparison: 4 Current AIs versus non-AI: Toxicity
Outcome: 7 thromboembolic
Study or subgroup AI comparison Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 AI versus tamoxifen
Bonneterre 2001 18/506 33/511 100.0 % 0.53 [ 0.30, 0.96 ]
Subtotal (95% CI) 506 511 100.0 % 0.53 [ 0.30, 0.96 ]
Total events: 18 (AI), 33 (comparison)
Heterogeneity: not applicable
Test for overall effect: Z = 2.09 (P = 0.037)
2 AI versus megestrol acetate
Buzdar 1996a 9/262 12/253 100.0 % 0.71 [ 0.30, 1.73 ]
Subtotal (95% CI) 262 253 100.0 % 0.71 [ 0.30, 1.73 ]
Total events: 9 (AI), 12 (comparison)
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
3 AI versus fulvestrant
Mauriac 2003 17/423 15/423 100.0 % 1.14 [ 0.56, 2.31 ]
Subtotal (95% CI) 423 423 100.0 % 1.14 [ 0.56, 2.31 ]
Total events: 17 (AI), 15 (comparison)
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
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Analysis 4.8. Comparison 4 Current AIs versus non-AI: Toxicity, Outcome 8 arthralgia.
Review: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Comparison: 4 Current AIs versus non-AI: Toxicity
Outcome: 8 arthralgia
Study or subgroup AI comparison Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 AI versus tamoxifen
Mourisden 2001 71/455 67/455 91.8 % 1.07 [ 0.75, 1.54 ]
Paridaens 2003 11/62 6/59 8.2 % 1.91 [ 0.66, 5.53 ]
Subtotal (95% CI) 517 514 100.0 % 1.14 [ 0.81, 1.60 ]
Total events: 82 (AI), 73 (comparison)
Heterogeneity: Chi2 = 1.01, df = 1 (P = 0.32); I2 =1%
Test for overall effect: Z = 0.75 (P = 0.46)
2 AI versus megestrol acetate
Dombernowsky 1998 23/174 15/189 100.0 % 1.77 [ 0.89, 3.51 ]
Subtotal (95% CI) 174 189 100.0 % 1.77 [ 0.89, 3.51 ]
Total events: 23 (AI), 15 (comparison)
Heterogeneity: not applicable
Test for overall effect: Z = 1.63 (P = 0.10)
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Analysis 5.1. Comparison 5 AI versus different AI, Outcome 1 Overall survival (reported).
Review: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Comparison: 5 AI versus different AI
Outcome: 1 Overall survival (reported)
Study or subgroup log [HR] HR Weight HR
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 letrozole
Gershanovich 1998 -0.4463 (0.1405) 16.3 % 0.64 [ 0.49, 0.84 ]
Goss 2007 -0.0202 (0.0621) 83.7 % 0.98 [ 0.87, 1.11 ]
Subtotal (95% CI) 100.0 % 0.91 [ 0.82, 1.02 ]
Heterogeneity: Chi2 = 7.69, df = 1 (P = 0.01); I2 =87%
Test for overall effect: Z = 1.58 (P = 0.11)
Test for subgroup differences: Not applicable
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Analysis 5.2. Comparison 5 AI versus different AI, Outcome 2 Progession-free survival (reported or
calculated).
Review: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Comparison: 5 AI versus different AI
Outcome: 2 Progession-free survival (reported or calculated)
Study or subgroup log [HR] HR Weight HR
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 letrozole
Gershanovich 1998 -0.3285 (0.1221) 10.1 % 0.72 [ 0.57, 0.91 ]
Goss 2007 0 (0.0409) 89.9 % 1.00 [ 0.92, 1.08 ]
Subtotal (95% CI) 100.0 % 0.97 [ 0.90, 1.04 ]
Heterogeneity: Chi2 = 6.51, df = 1 (P = 0.01); I2 =85%
Test for overall effect: Z = 0.85 (P = 0.39)
Test for subgroup differences: Not applicable
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Analysis 5.3. Comparison 5 AI versus different AI, Outcome 3 Clinical benefit (assessable).
Review: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Comparison: 5 AI versus different AI
Outcome: 3 Clinical benefit (assessable)
Study or subgroup different AI better AI better Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 letrozole
Gershanovich 1998 52/162 67/173 22.3 % 0.75 [ 0.48, 1.17 ]
Goss 2007 224/298 231/297 29.1 % 0.86 [ 0.59, 1.26 ]
Rose 2003 82/304 96/299 35.8 % 0.78 [ 0.55, 1.11 ]
Tominaga 2003 27/77 39/77 12.8 % 0.53 [ 0.28, 1.00 ]
Subtotal (95% CI) 841 846 100.0 % 0.77 [ 0.62, 0.95 ]
Total events: 385 (different AI better), 433 (AI better)
Heterogeneity: Chi2 = 1.71, df = 3 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 2.48 (P = 0.013)
2 anastrozole
Kleeberg 1997 15/31 12/29 10.4 % 1.33 [ 0.48, 3.69 ]
Rose 2003 96/299 82/304 89.6 % 1.28 [ 0.90, 1.82 ]
Subtotal (95% CI) 330 333 100.0 % 1.29 [ 0.92, 1.79 ]
Total events: 111 (different AI better), 94 (AI better)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 1.48 (P = 0.14)
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Analysis 5.4. Comparison 5 AI versus different AI, Outcome 4 Objective response (assessable).
Review: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Comparison: 5 AI versus different AI
Outcome: 4 Objective response (assessable)
Study or subgroup different AI AI Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 letrozole
Gershanovich 1998 22/162 36/173 15.4 % 0.60 [ 0.33, 1.07 ]
Goss 2007 132/298 154/297 43.9 % 0.74 [ 0.53, 1.02 ]
Rose 2003 44/304 68/299 30.0 % 0.57 [ 0.38, 0.87 ]
Tominaga 2003 10/77 24/77 10.7 % 0.33 [ 0.15, 0.75 ]
Subtotal (95% CI) 841 846 100.0 % 0.62 [ 0.50, 0.78 ]
Total events: 208 (different AI), 282 (AI)
Heterogeneity: Chi2 = 3.54, df = 3 (P = 0.32); I2 =15%
Test for overall effect: Z = 4.13 (P = 0.000037)
2 anastrozole
Kleeberg 1997 3/31 5/29 12.2 % 0.51 [ 0.11, 2.38 ]
Rose 2003 68/299 44/304 87.8 % 1.74 [ 1.14, 2.64 ]
Subtotal (95% CI) 330 333 100.0 % 1.59 [ 1.07, 2.37 ]
Total events: 71 (different AI), 49 (AI)
Heterogeneity: Chi2 = 2.26, df = 1 (P = 0.13); I2 =56%
Test for overall effect: Z = 2.27 (P = 0.023)
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Analysis 5.5. Comparison 5 AI versus different AI, Outcome 5 Clinical benefit (randomised).
Review: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Comparison: 5 AI versus different AI
Outcome: 5 Clinical benefit (randomised)
Study or subgroup different AI better AI better Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 letrozole
Gershanovich 1998 52/178 67/185 18.0 % 0.73 [ 0.47, 1.13 ]
Goss 2007 224/434 231/431 43.5 % 0.92 [ 0.71, 1.21 ]
Rose 2003 82/357 96/356 28.7 % 0.81 [ 0.57, 1.13 ]
Tominaga 2003 27/78 39/79 9.8 % 0.54 [ 0.29, 1.03 ]
Subtotal (95% CI) 1047 1051 100.0 % 0.82 [ 0.68, 0.98 ]
Total events: 385 (different AI better), 433 (AI better)
Heterogeneity: Chi2 = 2.64, df = 3 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 2.18 (P = 0.030)
2 anastrozole
Kleeberg 1997 15/31 12/29 9.7 % 1.33 [ 0.48, 3.69 ]
Rose 2003 96/356 82/357 90.3 % 1.24 [ 0.88, 1.74 ]
Subtotal (95% CI) 387 386 100.0 % 1.25 [ 0.90, 1.72 ]
Total events: 111 (different AI better), 94 (AI better)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.34 (P = 0.18)
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Analysis 5.6. Comparison 5 AI versus different AI, Outcome 6 Objective response (randomised).
Review: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Comparison: 5 AI versus different AI
Outcome: 6 Objective response (randomised)
Study or subgroup different AI AI Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 letrozole
Gershanovich 1998 22/178 36/185 14.1 % 0.58 [ 0.33, 1.04 ]
Goss 2007 132/434 154/431 49.1 % 0.79 [ 0.59, 1.04 ]
Rose 2003 44/357 68/356 27.3 % 0.60 [ 0.39, 0.90 ]
Tominaga 2003 10/78 24/79 9.5 % 0.34 [ 0.15, 0.76 ]
Subtotal (95% CI) 1047 1051 100.0 % 0.66 [ 0.54, 0.82 ]
Total events: 208 (different AI), 282 (AI)
Heterogeneity: Chi2 = 4.46, df = 3 (P = 0.22); I2 =33%
Test for overall effect: Z = 3.87 (P = 0.00011)
2 anastrozole
Kleeberg 1997 3/31 5/29 11.4 % 0.51 [ 0.11, 2.38 ]
Rose 2003 68/365 44/357 88.6 % 1.63 [ 1.08, 2.46 ]
Subtotal (95% CI) 396 386 100.0 % 1.50 [ 1.01, 2.23 ]
Total events: 71 (different AI), 49 (AI)
Heterogeneity: Chi2 = 2.03, df = 1 (P = 0.15); I2 =51%
Test for overall effect: Z = 2.02 (P = 0.043)
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Analysis 6.1. Comparison 6 AI as first-line therapy versus any other therapy (tamoxifen), Outcome 1
Overall survival (reported or calculated).
Review: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Comparison: 6 AI as first-line therapy versus any other therapy (tamoxifen)
Outcome: 1 Overall survival (reported or calculated)
Study or subgroup log [HR] HR Weight HR
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 aminoglutethimide as first-line therapy
Gale 1994 0.11 (0.16) 21.4 % 1.12 [ 0.82, 1.53 ]
Subtotal (95% CI) 21.4 % 1.12 [ 0.82, 1.53 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
2 anastrozole as first-line therapy
Bonneterre 2001 -0.0305 (0.0931) 63.2 % 0.97 [ 0.81, 1.16 ]
Subtotal (95% CI) 63.2 % 0.97 [ 0.81, 1.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
3 fadrozole as first-line therapy
Thuerlimann 1996 -0.0943 (0.1887) 15.4 % 0.91 [ 0.63, 1.32 ]
Subtotal (95% CI) 15.4 % 0.91 [ 0.63, 1.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.62)
Total (95% CI) 100.0 % 0.99 [ 0.86, 1.14 ]
Heterogeneity: Chi2 = 0.81, df = 2 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Chi2 = 0.81, df = 2 (P = 0.67), I2 =0.0%
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Analysis 6.2. Comparison 6 AI as first-line therapy versus any other therapy (tamoxifen), Outcome 2
Progression-free survival (reported or calculated).
Review: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Comparison: 6 AI as first-line therapy versus any other therapy (tamoxifen)
Outcome: 2 Progression-free survival (reported or calculated)
Study or subgroup log [HR] HR Weight HR
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 aminoglutethimide
Gale 1994 -0.18 (0.13) 13.6 % 0.84 [ 0.65, 1.08 ]
Subtotal (95% CI) 13.6 % 0.84 [ 0.65, 1.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.38 (P = 0.17)
2 formestane as first-line therapy
Thuerlimann 1997 -0.0726 (0.1631) 8.6 % 0.93 [ 0.68, 1.28 ]
Subtotal (95% CI) 8.6 % 0.93 [ 0.68, 1.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.66)
3 anastrozole as first-line therapy
Bonneterre 2001 -0.1985 (0.0743) 41.6 % 0.82 [ 0.71, 0.95 ]
Subtotal (95% CI) 41.6 % 0.82 [ 0.71, 0.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.67 (P = 0.0075)
4 letrozole as first-line therapy
Mourisden 2001 -0.3567 (0.0797) 36.2 % 0.70 [ 0.60, 0.82 ]
Subtotal (95% CI) 36.2 % 0.70 [ 0.60, 0.82 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.48 (P < 0.00001)
Total (95% CI) 100.0 % 0.78 [ 0.71, 0.86 ]
Heterogeneity: Chi2 = 3.72, df = 3 (P = 0.29); I2 =19%
Test for overall effect: Z = 5.06 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.72, df = 3 (P = 0.29), I2 =19%
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Analysis 6.3. Comparison 6 AI as first-line therapy versus any other therapy (tamoxifen), Outcome 3
Clinical benefit (assessable).
Review: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Comparison: 6 AI as first-line therapy versus any other therapy (tamoxifen)
Outcome: 3 Clinical benefit (assessable)
Study or subgroup tamoxifen AI Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 aminoglutethimide (any dose)
Alonso-Munoz 1988 28/34 25/31 4.2 % 1.12 [ 0.32, 3.92 ]
Gale 1994 71/108 83/108 10.5 % 0.58 [ 0.32, 1.05 ]
Powles 1984 55/99 67/99 10.8 % 0.60 [ 0.33, 1.06 ]
Subtotal (95% CI) 241 238 25.4 % 0.63 [ 0.42, 0.93 ]
Total events: 154 (tamoxifen), 175 (AI)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.92, df = 2 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 2.32 (P = 0.020)
2 formestane 250 mg
Perez Carrion 1994 124/175 111/173 13.0 % 1.36 [ 0.87, 2.13 ]
Subtotal (95% CI) 175 173 13.0 % 1.36 [ 0.87, 2.13 ]
Total events: 124 (tamoxifen), 111 (AI)
Heterogeneity: not applicable
Test for overall effect: Z = 1.33 (P = 0.18)
3 anastrozole 1 mg
Bonneterre 2001 265/510 292/511 16.6 % 0.81 [ 0.63, 1.04 ]
Milla-Santos 2003 65/117 100/121 10.5 % 0.26 [ 0.14, 0.48 ]
Subtotal (95% CI) 627 632 27.1 % 0.48 [ 0.16, 1.44 ]
Total events: 330 (tamoxifen), 392 (AI)
Heterogeneity: Tau2 = 0.58; Chi2 = 11.79, df = 1 (P = 0.00060); I2 =92%
Test for overall effect: Z = 1.31 (P = 0.19)
4 exemestane 25 mg
Paridaens 2003 25/57 35/56 8.3 % 0.47 [ 0.22, 0.99 ]
Subtotal (95% CI) 57 56 8.3 % 0.47 [ 0.22, 0.99 ]
Total events: 25 (tamoxifen), 35 (AI)
Heterogeneity: not applicable
Test for overall effect: Z = 1.97 (P = 0.048)
5 fadrozole 2 mg
Thuerlimann 1996 81/106 77/103 10.0 % 1.09 [ 0.58, 2.06 ]
Subtotal (95% CI) 106 103 10.0 % 1.09 [ 0.58, 2.06 ]
Total events: 81 (tamoxifen), 77 (AI)
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(. . . Continued)
Study or subgroup tamoxifen AI Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
6 letrozole 2.5 mg
Mourisden 2001 173/423 221/421 16.2 % 0.63 [ 0.48, 0.82 ]
Subtotal (95% CI) 423 421 16.2 % 0.63 [ 0.48, 0.82 ]
Total events: 173 (tamoxifen), 221 (AI)
Heterogeneity: not applicable
Test for overall effect: Z = 3.37 (P = 0.00076)
Total (95% CI) 1629 1623 100.0 % 0.69 [ 0.51, 0.92 ]
Total events: 887 (tamoxifen), 1011 (AI)
Heterogeneity: Tau2 = 0.12; Chi2 = 24.90, df = 8 (P = 0.002); I2 =68%
Test for overall effect: Z = 2.52 (P = 0.012)
0.2 0.5 1 2 5
1st-line AI better tamoxifen better
103Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 6.4. Comparison 6 AI as first-line therapy versus any other therapy (tamoxifen), Outcome 4
Objective response (assessable).
Review: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Comparison: 6 AI as first-line therapy versus any other therapy (tamoxifen)
Outcome: 4 Objective response (assessable)
Study or subgroup tamoxifen AI Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 aminoglutethimide (any dose)
Alonso-Munoz 1988 18/34 15/31 5.0 % 1.20 [ 0.45, 3.18 ]
Gale 1994 30/108 49/108 9.3 % 0.46 [ 0.26, 0.82 ]
Powles 1984 34/99 48/99 9.3 % 0.56 [ 0.31, 0.98 ]
Rose 1986 32/94 24/83 8.4 % 1.27 [ 0.67, 2.40 ]
Subtotal (95% CI) 335 321 32.0 % 0.75 [ 0.45, 1.25 ]
Total events: 114 (tamoxifen), 136 (AI)
Heterogeneity: Tau2 = 0.16; Chi2 = 7.18, df = 3 (P = 0.07); I2 =58%
Test for overall effect: Z = 1.12 (P = 0.26)
2 formestane 250 mg
Perez Carrion 1994 65/175 57/173 11.3 % 1.20 [ 0.77, 1.87 ]
Subtotal (95% CI) 175 173 11.3 % 1.20 [ 0.77, 1.87 ]
Total events: 65 (tamoxifen), 57 (AI)
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
3 anastrozole 1 mg
Bonneterre 2001 138/510 148/511 14.0 % 0.91 [ 0.69, 1.20 ]
Milla-Santos 2003 31/117 43/121 9.5 % 0.65 [ 0.38, 1.14 ]
Subtotal (95% CI) 627 632 23.5 % 0.85 [ 0.65, 1.11 ]
Total events: 169 (tamoxifen), 191 (AI)
Heterogeneity: Tau2 = 0.00; Chi2 = 1.10, df = 1 (P = 0.29); I2 =9%
Test for overall effect: Z = 1.22 (P = 0.22)
4 exemestane 25 mg
Paridaens 2003 10/57 25/56 5.9 % 0.26 [ 0.11, 0.62 ]
Subtotal (95% CI) 57 56 5.9 % 0.26 [ 0.11, 0.62 ]
Total events: 10 (tamoxifen), 25 (AI)
Heterogeneity: not applicable
Test for overall effect: Z = 3.03 (P = 0.0025)
5 fadrozole 2 mg
Falkson 1996 17/38 18/36 5.5 % 0.81 [ 0.32, 2.02 ]
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(. . . Continued)
Study or subgroup tamoxifen AI Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Thuerlimann 1996 29/106 21/103 8.3 % 1.47 [ 0.77, 2.79 ]
Subtotal (95% CI) 144 139 13.8 % 1.20 [ 0.69, 2.09 ]
Total events: 46 (tamoxifen), 39 (AI)
Heterogeneity: Tau2 = 0.02; Chi2 = 1.10, df = 1 (P = 0.29); I2 =9%
Test for overall effect: Z = 0.63 (P = 0.53)
6 letrozole 2.5 mg
Mourisden 2001 92/423 137/421 13.4 % 0.58 [ 0.42, 0.78 ]
Subtotal (95% CI) 423 421 13.4 % 0.58 [ 0.42, 0.78 ]
Total events: 92 (tamoxifen), 137 (AI)
Heterogeneity: not applicable
Test for overall effect: Z = 3.51 (P = 0.00045)
Total (95% CI) 1761 1742 100.0 % 0.77 [ 0.59, 1.00 ]
Total events: 496 (tamoxifen), 585 (AI)
Heterogeneity: Tau2 = 0.11; Chi2 = 26.42, df = 10 (P = 0.003); I2 =62%
Test for overall effect: Z = 1.96 (P = 0.050)
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Analysis 6.5. Comparison 6 AI as first-line therapy versus any other therapy (tamoxifen), Outcome 5
Clinical benefit (randomised).
Review: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Comparison: 6 AI as first-line therapy versus any other therapy (tamoxifen)
Outcome: 5 Clinical benefit (randomised)
Study or subgroup tamoxifen AI Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 aminoglutethimide (any dose)
Alonso-Munoz 1988 28/35 25/35 4.7 % 1.60 [ 0.53, 4.84 ]
Gale 1994 71/119 83/122 11.0 % 0.70 [ 0.41, 1.18 ]
Powles 1984 55/111 67/111 10.9 % 0.64 [ 0.38, 1.10 ]
Subtotal (95% CI) 265 268 26.6 % 0.74 [ 0.51, 1.08 ]
Total events: 154 (tamoxifen), 175 (AI)
Heterogeneity: Tau2 = 0.01; Chi2 = 2.17, df = 2 (P = 0.34); I2 =8%
Test for overall effect: Z = 1.58 (P = 0.11)
2 formestane 250 mg
Perez Carrion 1994 124/206 111/203 13.4 % 1.25 [ 0.85, 1.86 ]
Subtotal (95% CI) 206 203 13.4 % 1.25 [ 0.85, 1.86 ]
Total events: 124 (tamoxifen), 111 (AI)
Heterogeneity: not applicable
Test for overall effect: Z = 1.13 (P = 0.26)
3 anastrozole 1 mg
Bonneterre 2001 265/510 292/511 16.0 % 0.81 [ 0.63, 1.04 ]
Milla-Santos 2003 65/117 100/121 9.9 % 0.26 [ 0.14, 0.48 ]
Subtotal (95% CI) 627 632 25.9 % 0.48 [ 0.16, 1.44 ]
Total events: 330 (tamoxifen), 392 (AI)
Heterogeneity: Tau2 = 0.58; Chi2 = 11.79, df = 1 (P = 0.00060); I2 =92%
Test for overall effect: Z = 1.31 (P = 0.19)
4 exemestane 25 mg
Paridaens 2003 25/60 35/62 8.2 % 0.55 [ 0.27, 1.13 ]
Subtotal (95% CI) 60 62 8.2 % 0.55 [ 0.27, 1.13 ]
Total events: 25 (tamoxifen), 35 (AI)
Heterogeneity: not applicable
Test for overall effect: Z = 1.63 (P = 0.10)
5 fadrozole 2 mg
Thuerlimann 1996 81/110 77/111 10.1 % 1.23 [ 0.69, 2.21 ]
Subtotal (95% CI) 110 111 10.1 % 1.23 [ 0.69, 2.21 ]
Total events: 81 (tamoxifen), 77 (AI)
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(. . . Continued)
Study or subgroup tamoxifen AI Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
6 letrozole 2.5 mg
Mourisden 2001 173/454 221/453 15.7 % 0.65 [ 0.50, 0.84 ]
Subtotal (95% CI) 454 453 15.7 % 0.65 [ 0.50, 0.84 ]
Total events: 173 (tamoxifen), 221 (AI)
Heterogeneity: not applicable
Test for overall effect: Z = 3.24 (P = 0.0012)
Total (95% CI) 1722 1729 100.0 % 0.74 [ 0.56, 0.98 ]
Total events: 887 (tamoxifen), 1011 (AI)
Heterogeneity: Tau2 = 0.11; Chi2 = 25.80, df = 8 (P = 0.001); I2 =69%
Test for overall effect: Z = 2.11 (P = 0.035)
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Analysis 6.6. Comparison 6 AI as first-line therapy versus any other therapy (tamoxifen), Outcome 6
Objective response (randomised).
Review: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Comparison: 6 AI as first-line therapy versus any other therapy (tamoxifen)
Outcome: 6 Objective response (randomised)
Study or subgroup tamoxifen AI Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 aminoglutethimide (any dose)
Alonso-Munoz 1988 18/35 15/35 5.2 % 1.41 [ 0.55, 3.62 ]
Gale 1994 30/119 49/122 9.4 % 0.50 [ 0.29, 0.87 ]
Powles 1984 34/111 48/111 9.4 % 0.58 [ 0.33, 1.01 ]
Rose 1986 32/108 24/107 8.5 % 1.46 [ 0.79, 2.69 ]
Subtotal (95% CI) 373 375 32.5 % 0.83 [ 0.48, 1.45 ]
Total events: 114 (tamoxifen), 136 (AI)
Heterogeneity: Tau2 = 0.21; Chi2 = 9.07, df = 3 (P = 0.03); I2 =67%
Test for overall effect: Z = 0.64 (P = 0.52)
2 formestane 250 mg
Perez Carrion 1994 65/206 57/203 11.3 % 1.18 [ 0.77, 1.80 ]
Subtotal (95% CI) 206 203 11.3 % 1.18 [ 0.77, 1.80 ]
Total events: 65 (tamoxifen), 57 (AI)
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
3 anastrozole 1 mg
Bonneterre 2001 138/510 148/511 13.7 % 0.91 [ 0.69, 1.20 ]
Milla-Santos 2003 31/117 43/121 9.3 % 0.65 [ 0.38, 1.14 ]
Subtotal (95% CI) 627 632 23.1 % 0.85 [ 0.65, 1.11 ]
Total events: 169 (tamoxifen), 191 (AI)
Heterogeneity: Tau2 = 0.00; Chi2 = 1.10, df = 1 (P = 0.29); I2 =9%
Test for overall effect: Z = 1.22 (P = 0.22)
4 exemestane 25 mg
Paridaens 2003 10/60 25/62 6.0 % 0.30 [ 0.13, 0.69 ]
Subtotal (95% CI) 60 62 6.0 % 0.30 [ 0.13, 0.69 ]
Total events: 10 (tamoxifen), 25 (AI)
Heterogeneity: not applicable
Test for overall effect: Z = 2.82 (P = 0.0049)
5 fadrozole 2 mg
Falkson 1996 17/40 18/40 5.7 % 0.90 [ 0.37, 2.19 ]
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(. . . Continued)
Study or subgroup tamoxifen AI Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Thuerlimann 1996 29/110 21/111 8.2 % 1.53 [ 0.81, 2.90 ]
Subtotal (95% CI) 150 151 13.9 % 1.28 [ 0.76, 2.15 ]
Total events: 46 (tamoxifen), 39 (AI)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.91, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 0.94 (P = 0.35)
6 letrozole 2.5 mg
Mourisden 2001 92/454 137/453 13.3 % 0.59 [ 0.43, 0.79 ]
Subtotal (95% CI) 454 453 13.3 % 0.59 [ 0.43, 0.79 ]
Total events: 92 (tamoxifen), 137 (AI)
Heterogeneity: not applicable
Test for overall effect: Z = 3.44 (P = 0.00058)
Total (95% CI) 1870 1876 100.0 % 0.81 [ 0.62, 1.05 ]
Total events: 496 (tamoxifen), 585 (AI)
Heterogeneity: Tau2 = 0.11; Chi2 = 27.11, df = 10 (P = 0.003); I2 =63%
Test for overall effect: Z = 1.61 (P = 0.11)
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Analysis 7.1. Comparison 7 AI as second-line therapy versus any other therapy, Outcome 1 Overall survival
(reported or calculated).
Review: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Comparison: 7 AI as second-line therapy versus any other therapy
Outcome: 1 Overall survival (reported or calculated)
Study or subgroup log [HR] HR Weight HR
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 anastrozole as second-line therapy
Buzdar 1996a -0.2485 (0.1277) 53.7 % 0.78 [ 0.61, 1.00 ]
Subtotal (95% CI) 53.7 % 0.78 [ 0.61, 1.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.95 (P = 0.052)
2 letrozole as second-line therapy
Dombernowsky 1998 -0.1985 (0.1375) 46.3 % 0.82 [ 0.63, 1.07 ]
Subtotal (95% CI) 46.3 % 0.82 [ 0.63, 1.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.44 (P = 0.15)
Total (95% CI) 100.0 % 0.80 [ 0.66, 0.96 ]
Heterogeneity: Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 2.41 (P = 0.016)
Test for subgroup differences: Chi2 = 0.07, df = 1 (P = 0.79), I2 =0.0%
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Analysis 7.2. Comparison 7 AI as second-line therapy versus any other therapy, Outcome 2 Progression-free
survival (reported or calculated).
Review: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Comparison: 7 AI as second-line therapy versus any other therapy
Outcome: 2 Progression-free survival (reported or calculated)
Study or subgroup log [HR] HR Weight HR
(SE) IV,Random,95% CI IV,Random,95% CI
1 aminoglutethimide (any dose)
Russell 1997 0.2231 (0.1624) 9.2 % 1.25 [ 0.91, 1.72 ]
Subtotal (95% CI) 9.2 % 1.25 [ 0.91, 1.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
2 formestane 250 mg biweekly
Freue 2000 0.06 (0.08) 14.9 % 1.06 [ 0.91, 1.24 ]
Thuerlimann 1997 -0.0726 (0.1631) 9.2 % 0.93 [ 0.68, 1.28 ]
Subtotal (95% CI) 24.1 % 1.03 [ 0.90, 1.19 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.53, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.48 (P = 0.63)
3 anastrozole 1 mg
Mauriac 2003 0.2927 (0.0739) 15.4 % 1.34 [ 1.16, 1.55 ]
Subtotal (95% CI) 15.4 % 1.34 [ 1.16, 1.55 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.96 (P = 0.000075)
4 exemestane 25 mg
Chia 2008 0.0377 (0.1237) 11.7 % 1.04 [ 0.81, 1.32 ]
Kaufmann 2000 -0.1985 (0.0842) 14.6 % 0.82 [ 0.70, 0.97 ]
Subtotal (95% CI) 26.3 % 0.91 [ 0.72, 1.14 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 2.49, df = 1 (P = 0.11); I2 =60%
Test for overall effect: Z = 0.84 (P = 0.40)
5 letrozole 2.5 mg
Dombernowsky 1998 -0.0202 (0.1236) 11.7 % 0.98 [ 0.77, 1.25 ]
Subtotal (95% CI) 11.7 % 0.98 [ 0.77, 1.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.87)
6 vorozole 2.5 mg
Goss 1999 0.239 (0.1034) 13.2 % 1.27 [ 1.04, 1.56 ]
Subtotal (95% CI) 13.2 % 1.27 [ 1.04, 1.56 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.31 (P = 0.021)
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(. . . Continued)
Study or subgroup log [HR] HR Weight HR
(SE) IV,Random,95% CI IV,Random,95% CI
Total (95% CI) 100.0 % 1.08 [ 0.94, 1.23 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 24.07, df = 7 (P = 0.001); I2 =71%
Test for overall effect: Z = 1.04 (P = 0.30)
0.5 0.7 1 1.5 2
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Analysis 7.3. Comparison 7 AI as second-line therapy versus any other therapy, Outcome 3 Clinical benefit
(assessable).
Review: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Comparison: 7 AI as second-line therapy versus any other therapy
Outcome: 3 Clinical benefit (assessable)
Study or subgroup comparison 2nd line AI Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 aminoglutethimide (any dose)
Canney 1988 61/112 54/106 4.1 % 1.15 [ 0.68, 1.96 ]
Garcia-Giralt 1992 79/112 98/124 4.4 % 0.64 [ 0.35, 1.15 ]
Lundgren 1989 49/90 51/86 3.8 % 0.82 [ 0.45, 1.49 ]
Mercer 1993 13/29 10/27 0.9 % 1.38 [ 0.47, 4.03 ]
Subtotal (95% CI) 343 343 13.2 % 0.90 [ 0.66, 1.23 ]
Total events: 202 (comparison), 213 (2nd line AI)
Heterogeneity: Chi2 = 2.86, df = 3 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.66 (P = 0.51)
2 formestane 250 mg biweekly
Thuerlimann 1997 46/83 56/90 3.9 % 0.75 [ 0.41, 1.39 ]
Subtotal (95% CI) 83 90 3.9 % 0.75 [ 0.41, 1.39 ]
Total events: 46 (comparison), 56 (2nd line AI)
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
3 anastrozole 1mg
Buzdar 1996a 102/253 111/263 10.5 % 0.93 [ 0.65, 1.31 ]
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(. . . Continued)
Study or subgroup comparison 2nd line AI Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mauriac 2003 186/428 173/423 15.8 % 1.11 [ 0.85, 1.46 ]
Subtotal (95% CI) 681 686 26.3 % 1.04 [ 0.84, 1.29 ]
Total events: 288 (comparison), 284 (2nd line AI)
Heterogeneity: Chi2 = 0.65, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.33 (P = 0.74)
4 exemestane 25 mg
Chia 2008 87/270 85/270 9.3 % 1.03 [ 0.72, 1.49 ]
Kaufmann 2000 135/366 133/337 14.1 % 0.90 [ 0.66, 1.22 ]
Subtotal (95% CI) 636 607 23.3 % 0.95 [ 0.75, 1.20 ]
Total events: 222 (comparison), 218 (2nd line AI)
Heterogeneity: Chi2 = 0.35, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.42 (P = 0.67)
5 fadrozole 2 mg
Bezwoda 1998 4/50 5/46 0.8 % 0.71 [ 0.18, 2.84 ]
Buzdar 1996b 65/184 70/195 7.1 % 0.98 [ 0.64, 1.49 ]
Buzdar 1996c 61/148 56/150 5.3 % 1.18 [ 0.74, 1.87 ]
Subtotal (95% CI) 382 391 13.1 % 1.04 [ 0.77, 1.41 ]
Total events: 130 (comparison), 131 (2nd line AI)
Heterogeneity: Chi2 = 0.65, df = 2 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.26 (P = 0.80)
6 letrozole 2.5 mg
Buzdar 2001 47/180 53/182 6.3 % 0.86 [ 0.54, 1.36 ]
Dombernowsky 1998 60/166 60/153 6.4 % 0.88 [ 0.56, 1.38 ]
Schmid 2001 19/60 14/52 1.6 % 1.26 [ 0.55, 2.85 ]
Subtotal (95% CI) 406 387 14.3 % 0.91 [ 0.68, 1.23 ]
Total events: 126 (comparison), 127 (2nd line AI)
Heterogeneity: Chi2 = 0.68, df = 2 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.59 (P = 0.56)
7 vorozole 2.5mg
Goss 1999 71/185 60/190 5.9 % 1.35 [ 0.88, 2.07 ]
Subtotal (95% CI) 185 190 5.9 % 1.35 [ 0.88, 2.07 ]
Total events: 71 (comparison), 60 (2nd line AI)
Heterogeneity: not applicable
Test for overall effect: Z = 1.38 (P = 0.17)
Total (95% CI) 2716 2694 100.0 % 0.99 [ 0.88, 1.11 ]
Total events: 1085 (comparison), 1089 (2nd line AI)
Heterogeneity: Chi2 = 9.02, df = 15 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.19 (P = 0.85)
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Analysis 7.4. Comparison 7 AI as second-line therapy versus any other therapy, Outcome 4 Objective
response (assessable).
Review: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Comparison: 7 AI as second-line therapy versus any other therapy
Outcome: 4 Objective response (assessable)
Study or subgroup comparison 2nd line AI Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 aminoglutethimide (any dose)
Canney 1988 35/112 26/106 4.6 % 1.40 [ 0.77, 2.54 ]
Garcia-Giralt 1992 39/112 48/124 7.4 % 0.85 [ 0.50, 1.44 ]
Lundgren 1989 23/74 26/76 4.4 % 0.87 [ 0.44, 1.72 ]
Mercer 1993 5/29 3/27 0.6 % 1.67 [ 0.36, 7.77 ]
Russell 1997 2/32 10/42 2.0 % 0.21 [ 0.04, 1.05 ]
Subtotal (95% CI) 359 375 19.1 % 0.94 [ 0.68, 1.30 ]
Total events: 104 (comparison), 113 (2nd line AI)
Heterogeneity: Chi2 = 5.75, df = 4 (P = 0.22); I2 =30%
Test for overall effect: Z = 0.35 (P = 0.73)
2 formestane 250 mg biweekly
Freue 2000 55/237 45/242 8.5 % 1.32 [ 0.85, 2.06 ]
Thuerlimann 1997 14/83 15/90 3.0 % 1.01 [ 0.46, 2.25 ]
Subtotal (95% CI) 320 332 11.5 % 1.24 [ 0.84, 1.83 ]
Total events: 69 (comparison), 60 (2nd line AI)
Heterogeneity: Chi2 = 0.32, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.10 (P = 0.27)
3 anastrozole 1 mg
Buzdar 1996a 31/253 33/263 7.1 % 0.97 [ 0.58, 1.64 ]
Mauriac 2003 82/428 70/423 14.2 % 1.20 [ 0.84, 1.70 ]
Subtotal (95% CI) 681 686 21.3 % 1.12 [ 0.84, 1.50 ]
Total events: 113 (comparison), 103 (2nd line AI)
Heterogeneity: Chi2 = 0.41, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.77 (P = 0.44)
4 exemestane 25 mg
Chia 2008 20/270 18/270 4.2 % 1.12 [ 0.58, 2.17 ]
Kaufmann 2000 50/366 55/337 12.3 % 0.81 [ 0.54, 1.23 ]
Subtotal (95% CI) 636 607 16.5 % 0.89 [ 0.63, 1.26 ]
0.1 0.2 0.5 1 2 5 10
2nd line AI better comparison better
(Continued . . . )
114Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup comparison 2nd line AI Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 70 (comparison), 73 (2nd line AI)
Heterogeneity: Chi2 = 0.66, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.66 (P = 0.51)
5 fadrozole 2 mg
Bezwoda 1998 3/50 3/46 0.7 % 0.91 [ 0.18, 4.78 ]
Buzdar 1996b 30/184 22/195 4.5 % 1.53 [ 0.85, 2.77 ]
Buzdar 1996c 17/148 20/150 4.4 % 0.84 [ 0.42, 1.68 ]
Subtotal (95% CI) 382 391 9.6 % 1.17 [ 0.76, 1.80 ]
Total events: 50 (comparison), 45 (2nd line AI)
Heterogeneity: Chi2 = 1.74, df = 2 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
6 letrozole 2.5 mg
Buzdar 2001 30/180 32/182 6.6 % 0.94 [ 0.54, 1.62 ]
Dombernowsky 1998 31/166 41/153 8.7 % 0.63 [ 0.37, 1.07 ]
Schmid 2001 9/60 10/52 2.3 % 0.74 [ 0.28, 1.99 ]
Subtotal (95% CI) 406 387 17.5 % 0.76 [ 0.53, 1.08 ]
Total events: 70 (comparison), 83 (2nd line AI)
Heterogeneity: Chi2 = 1.07, df = 2 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 1.53 (P = 0.13)
7 vorozole 2.5 mg
Goss 1999 14/185 20/190 4.5 % 0.70 [ 0.34, 1.42 ]
Subtotal (95% CI) 185 190 4.5 % 0.70 [ 0.34, 1.42 ]
Total events: 14 (comparison), 20 (2nd line AI)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
Total (95% CI) 2969 2968 100.0 % 0.98 [ 0.86, 1.13 ]
Total events: 490 (comparison), 497 (2nd line AI)
Heterogeneity: Chi2 = 16.00, df = 17 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.21 (P = 0.83)
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Analysis 7.5. Comparison 7 AI as second-line therapy versus any other therapy, Outcome 5 Clinical benefit
(randomised).
Review: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Comparison: 7 AI as second-line therapy versus any other therapy
Outcome: 5 Clinical benefit (randomised)
Study or subgroup comparison 2nd line AI Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 aminoglutethimide (any dose)
Canney 1988 61/112 54/106 3.5 % 1.15 [ 0.68, 1.96 ]
Garcia-Giralt 1992 231/431 224/434 14.3 % 1.08 [ 0.83, 1.41 ]
Lundgren 1989 49/90 51/86 3.3 % 0.82 [ 0.45, 1.49 ]
Mercer 1993 13/33 10/28 0.9 % 1.17 [ 0.41, 3.32 ]
Subtotal (95% CI) 666 654 22.0 % 1.06 [ 0.85, 1.31 ]
Total events: 354 (comparison), 339 (2nd line AI)
Heterogeneity: Chi2 = 0.86, df = 3 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.51 (P = 0.61)
2 formestane 250 mg biweekly
Thuerlimann 1997 46/86 56/91 3.5 % 0.72 [ 0.40, 1.31 ]
Subtotal (95% CI) 86 91 3.5 % 0.72 [ 0.40, 1.31 ]
Total events: 46 (comparison), 56 (2nd line AI)
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
3 anastrozole 1 mg
Buzdar 1996a 102/253 111/263 9.0 % 0.93 [ 0.65, 1.31 ]
Mauriac 2003 186/428 173/423 13.6 % 1.11 [ 0.85, 1.46 ]
Subtotal (95% CI) 681 686 22.6 % 1.04 [ 0.84, 1.29 ]
Total events: 288 (comparison), 284 (2nd line AI)
Heterogeneity: Chi2 = 0.65, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.33 (P = 0.74)
4 exemestane 25 mg
Chia 2008 87/351 85/342 9.0 % 1.00 [ 0.71, 1.41 ]
Kaufmann 2000 135/403 133/366 12.8 % 0.88 [ 0.66, 1.19 ]
Subtotal (95% CI) 754 708 21.8 % 0.93 [ 0.74, 1.16 ]
Total events: 222 (comparison), 218 (2nd line AI)
Heterogeneity: Chi2 = 0.27, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
5 fadrozole 2 mg
Bezwoda 1998 4/50 5/46 0.7 % 0.71 [ 0.18, 2.84 ]
0.2 0.5 1 2 5
2nd-line AI better comparison better
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(. . . Continued)
Study or subgroup comparison 2nd line AI Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Buzdar 1996b 65/184 70/196 6.1 % 0.98 [ 0.65, 1.50 ]
Buzdar 1996c 61/151 56/152 4.6 % 1.16 [ 0.73, 1.85 ]
Subtotal (95% CI) 385 394 11.3 % 1.04 [ 0.77, 1.41 ]
Total events: 130 (comparison), 131 (2nd line AI)
Heterogeneity: Chi2 = 0.58, df = 2 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.25 (P = 0.80)
6 letrozole 2.5 mg
Buzdar 2001 47/201 53/199 5.6 % 0.84 [ 0.53, 1.32 ]
Dombernowsky 1998 60/189 60/174 5.9 % 0.88 [ 0.57, 1.37 ]
Schmid 2001 19/60 14/52 1.4 % 1.26 [ 0.55, 2.85 ]
Subtotal (95% CI) 450 425 13.0 % 0.91 [ 0.68, 1.21 ]
Total events: 126 (comparison), 127 (2nd line AI)
Heterogeneity: Chi2 = 0.73, df = 2 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.66 (P = 0.51)
7 vorozole 2.5mg
Goss 1999 71/227 60/225 5.7 % 1.25 [ 0.83, 1.88 ]
Subtotal (95% CI) 227 225 5.7 % 1.25 [ 0.83, 1.88 ]
Total events: 71 (comparison), 60 (2nd line AI)
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
Total (95% CI) 3249 3183 100.0 % 1.00 [ 0.90, 1.11 ]
Total events: 1237 (comparison), 1215 (2nd line AI)
Heterogeneity: Chi2 = 6.71, df = 15 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
0.2 0.5 1 2 5
2nd-line AI better comparison better
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Analysis 7.6. Comparison 7 AI as second-line therapy versus any other therapy, Outcome 6 Objective
response (randomised).
Review: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Comparison: 7 AI as second-line therapy versus any other therapy
Outcome: 6 Objective response (randomised)
Study or subgroup comparison 2nd line AI Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 aminoglutethimide (any dose)
Canney 1988 35/112 26/106 4.0 % 1.40 [ 0.77, 2.54 ]
Garcia-Giralt 1992 154/431 132/434 18.3 % 1.27 [ 0.96, 1.69 ]
Lundgren 1989 23/90 26/86 4.3 % 0.79 [ 0.41, 1.53 ]
Mercer 1993 5/33 3/28 0.6 % 1.49 [ 0.32, 6.87 ]
Russell 1997 2/75 10/80 2.0 % 0.19 [ 0.04, 0.91 ]
Subtotal (95% CI) 741 734 29.1 % 1.15 [ 0.91, 1.45 ]
Total events: 219 (comparison), 197 (2nd line AI)
Heterogeneity: Chi2 = 7.34, df = 4 (P = 0.12); I2 =46%
Test for overall effect: Z = 1.17 (P = 0.24)
2 formestane 250 mg biweekly
Freue 2000 55/271 45/276 7.7 % 1.31 [ 0.85, 2.02 ]
Thuerlimann 1997 14/86 15/91 2.6 % 0.99 [ 0.44, 2.18 ]
Subtotal (95% CI) 357 367 10.3 % 1.22 [ 0.84, 1.79 ]
Total events: 69 (comparison), 60 (2nd line AI)
Heterogeneity: Chi2 = 0.37, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.04 (P = 0.30)
3 anastrozole 1 mg
Buzdar 1996a 31/253 33/263 6.1 % 0.97 [ 0.58, 1.64 ]
Mauriac 2003 82/428 70/423 12.3 % 1.20 [ 0.84, 1.70 ]
Subtotal (95% CI) 681 686 18.4 % 1.12 [ 0.84, 1.50 ]
Total events: 113 (comparison), 103 (2nd line AI)
Heterogeneity: Chi2 = 0.41, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.77 (P = 0.44)
4 exemestane 25 mg
Chia 2008 20/351 18/342 3.7 % 1.09 [ 0.56, 2.09 ]
Kaufmann 2000 50/403 55/366 10.9 % 0.80 [ 0.53, 1.21 ]
Subtotal (95% CI) 754 708 14.6 % 0.87 [ 0.62, 1.24 ]
Total events: 70 (comparison), 73 (2nd line AI)
Heterogeneity: Chi2 = 0.60, df = 1 (P = 0.44); I2 =0.0%
0.1 0.2 0.5 1 2 5 10
2nd line AI better comparison better
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(. . . Continued)
Study or subgroup comparison 2nd line AI Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 0.76 (P = 0.45)
5 fadrozole 2 mg
Bezwoda 1998 3/50 3/46 0.6 % 0.91 [ 0.18, 4.78 ]
Buzdar 1996b 30/184 22/196 3.9 % 1.54 [ 0.85, 2.78 ]
Buzdar 1996c 17/151 20/152 3.8 % 0.84 [ 0.42, 1.67 ]
Subtotal (95% CI) 385 394 8.3 % 1.17 [ 0.76, 1.80 ]
Total events: 50 (comparison), 45 (2nd line AI)
Heterogeneity: Chi2 = 1.82, df = 2 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
6 letrozole 2.5 mg
Buzdar 2001 30/180 32/199 5.5 % 1.04 [ 0.61, 1.80 ]
Dombernowsky 1998 31/189 41/174 7.7 % 0.64 [ 0.38, 1.07 ]
Schmid 2001 9/60 10/52 2.0 % 0.74 [ 0.28, 1.99 ]
Subtotal (95% CI) 429 425 15.1 % 0.80 [ 0.56, 1.13 ]
Total events: 70 (comparison), 83 (2nd line AI)
Heterogeneity: Chi2 = 1.68, df = 2 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 1.27 (P = 0.21)
7 vorozole 2.5 mg
Goss 1999 14/227 20/225 4.1 % 0.67 [ 0.33, 1.37 ]
Subtotal (95% CI) 227 225 4.1 % 0.67 [ 0.33, 1.37 ]
Total events: 14 (comparison), 20 (2nd line AI)
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.28)
Total (95% CI) 3574 3539 100.0 % 1.04 [ 0.92, 1.18 ]
Total events: 605 (comparison), 581 (2nd line AI)
Heterogeneity: Chi2 = 19.00, df = 17 (P = 0.33); I2 =11%
Test for overall effect: Z = 0.61 (P = 0.54)
0.1 0.2 0.5 1 2 5 10
2nd line AI better comparison better
A D D I T I O N A L T A B L E S
Table 1. Aromatase inhibitors - description
Generic Name Trade Name Generation Doses used
aminoglutethimide First 125 mg, 250 mg, 500 mg, 750 mg, 1000 mg
anastrozole Arimidex Third, non-steroidal 1 mg, 10 mg
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Table 1. Aromatase inhibitors - description (Continued)
atamestane Third, steroidal 500mg
exemestane Aromasin Third, steroidal 25 mg
fadrozole CGS16949A Third, non-steroidal 2 mg
formestane Lentaron Second 250 mg im
letrozole Femara Third, non-steroidal 0.5 mg, 2 mg, 2.5 mg, 10 mg
vorozole Third, non-steroidal 2.5 mg
A P P E N D I C E S
Appendix 1. The Cochrane Central Register of Controlled Trials (CENTRAL) Issue 2, 2008
Search terms “aromatase inhibitor” AND “randomised trial” AND “breast cancer ” AND (advanced OR metastatic)
WH A T ’ S N E W
Last assessed as up-to-date: 29 June 2008.
Date Event Description
6 August 2009 New citation required but conclusions have not changed Update for Issue 4, 2009
6 August 2009 New search has been performed New search and addition of 7 trials
H I S T O R Y
Protocol first published: Issue 4, 2001
Review first published: Issue 1, 2007
120Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Date Event Description
5 August 2009 Amended reference added
8 July 2009 Amended edited to address additional reviewers’ comments
29 June 2009 Amended edited to address reviewers’ comments
3 February 2009 Amended Feedback from group incorporated
27 November 2008 New search has been performed Search run by BCG on 2 November 2007. Authors
updated search to 30 June 2008. Additional studies
identified and data updated
5 September 2008 Amended Converted to new review format.
13 August 2008 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
Judith Bliss wrote the original protocol, initiated the review with Lorna Gibson and reviewed the review.
Lorna Gibson worked with the Cochrane Breast Group to identify the initial list of references; she then worked through the list to
identify eligible trials. Lorna carried out the first independent data extraction from the eligible trials and was a main contributor to the
review and analysis, and the update.
Claire Dawson carried out a second independent extraction of data from the eligible trials and contributed to the original review.
David Lawrence carried out an independent check of the data extraction for accuracy and consistency and was a main contributor to
the original review analysis, and the update.
D E C L A R A T I O N S O F I N T E R E S T
One of the authors (JMB) is a member of the management group and grant holder for the Intergroup Exemestane Study. This is funded
by Pfizer, the producers of the aromatase inhibitor exemestane.
S O U R C E S O F S U P P O R T
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Internal sources
• Cancer Research UK, UK.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Many of the data required to carry out analyses of prospectively identified subgroups, as set out in the review protocol, were not
available. We could not, therefore, identify specific subgroups of women who may benefit from AI use.
N O T E S
This updated review includes the following additional seven trials to the 30 in the original publication: Chia 2008; Gale 1994;
Garcia-Giralt 1992; Goss 2007; Lundgren 1989; Samonis 1994. There were also two papers by Mourisden and colleagues (Mourisden
2004; Mourisden 2007) which contributed follow-up information.
The update demonstrated a survival benefit of 10% with the use of AIs for the treatment of advanced (metastatic) breast cancer,
compared to 11% in the original review.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Postmenopause; Antineoplastic Agents, Hormonal [∗therapeutic use]; Aromatase Inhibitors [∗therapeutic use]; Breast Neoplasms
[∗drug therapy; mortality]; Neoplasms, Hormone-Dependent [∗drug therapy]; Randomized Controlled Trials as Topic
MeSH check words
Female; Humans
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